lineage,string,ID
B.1.351,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccines.",PMC8725896
B.1.427,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccines.",PMC8725896
P.1,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccines.",PMC8725896
B.1.526,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccines.",PMC8725896
B.1.1.7,"The SARS-CoV-2 viruses USA-WA1/2020 (WA1), hC0V-19/USA/CACDC_5574/2020 (B.1.1.7), hCoV-19/South Africa/KRISP-K005325/2020 (B.1.351), hCoV-19/Japan/TY7-503/2021 (P.1), and hCoV-19/USA/NY-NP-DOH1/2021 (B.1.526) were obtained from BEI Resources (NIAID, NIH).",PMC8725896
R.1,"Here we assessed 2–36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484 K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PMC8725896
B.1.617.1,"Here we assessed 2–36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484 K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PMC8725896
B.1.525,"Here we assessed 2–36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484 K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PMC8725896
B.1.1.1,"Here we assessed 2–36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484 K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PMC8725896
B.1.617.2,"Here we assessed 2–36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484 K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PMC8725896
B.1.1.529,"Omicron (B.1.1.529) and sub lineages, now > 99.3% of new sequences in Europe (EpiCov, GISAID; 17th May 2022) have a single C > T mismatch in the 5’ end of the Charité-E forward primer binding region, this has not been observed to affect assay performance.",PMC9261881
B.1.1.529,"Correlation analyses between in vitro neutralization activity and in vivo reductions in lung infection suggest differing mechanisms of action for S309 and AZD7442, which we establish using genetic mAb variants and in vitro and in vivo assays..

We analyzed the substitutions in the RBDs of BA.1 (B.1.1.529), BA.1.1 (B.1.1.529 R346K), and BA.2 strains (Fig.",PMC9250508
B.1.351,"To corroborate these findings, we treated hFcγR transgenic C57BL/6 mice21 (hFcγR Tg) with a single 3 mg/kg dose of S309-LS or S309-GRLR mAbs one day prior to inoculation with a SARS-CoV-2 Beta (B.1.351) isolate; we used the Beta isolate for these studies because Omicron strains replicate poorly in conventional C57BL/6 mice lacking expression of hACE213.",PMC9250508
B.1.1.529,"Worldwide, the dominant SARS-CoV-2 variant of concern (VOC) is Omicron (phylogenetic assignment of named global outbreak (Pango) lineage designation B.1.1.529), and its virological characteristics, such as transmissibility, pathogenicity, and resistance to both vaccine- and infection-induced immunity as well as antiviral drugs, are an urgent public health concern [1,2].",PMC9266794
B.1,"In particular, considering sera from convalescent patients infected during the first (February to May 2020) and second (December 2020 to February 2021) waves, the neutralizations of BA.1 and BA.3 were at least 32 times lower (BA.1 p = 0.0020; BA.3 p = 0.0020) in comparison with the neutralization of B.1 (which was quite similar to the original wild-type strain) [23].",PMC9266794
P.1,"Of 34 sequence-verified patient samples collected in
early, mid, and late 2021 at the UCI Medical Center in Orange, California, REVEALR
identified the correct variant [Wuhan-Hu-1, alpha (B.1.1.7), gamma (P.1), epsilon
(B.1.427/9), delta (B.1.617.2), and omicron (B.1.1.529)] with 100% accuracy.",PMC9236216
B.1.617.2,"Of 34 sequence-verified patient samples collected in
early, mid, and late 2021 at the UCI Medical Center in Orange, California, REVEALR
identified the correct variant [Wuhan-Hu-1, alpha (B.1.1.7), gamma (P.1), epsilon
(B.1.427/9), delta (B.1.617.2), and omicron (B.1.1.529)] with 100% accuracy.",PMC9236216
B.1.1.529,"Of 34 sequence-verified patient samples collected in
early, mid, and late 2021 at the UCI Medical Center in Orange, California, REVEALR
identified the correct variant [Wuhan-Hu-1, alpha (B.1.1.7), gamma (P.1), epsilon
(B.1.427/9), delta (B.1.617.2), and omicron (B.1.1.529)] with 100% accuracy.",PMC9236216
B.1.1.7,"Of 34 sequence-verified patient samples collected in
early, mid, and late 2021 at the UCI Medical Center in Orange, California, REVEALR
identified the correct variant [Wuhan-Hu-1, alpha (B.1.1.7), gamma (P.1), epsilon
(B.1.427/9), delta (B.1.617.2), and omicron (B.1.1.529)] with 100% accuracy.",PMC9236216
B.1.427,"Of 34 sequence-verified patient samples collected in
early, mid, and late 2021 at the UCI Medical Center in Orange, California, REVEALR
identified the correct variant [Wuhan-Hu-1, alpha (B.1.1.7), gamma (P.1), epsilon
(B.1.427/9), delta (B.1.617.2), and omicron (B.1.1.529)] with 100% accuracy.",PMC9236216
B.1.351,"The
five most promising sensors (Figure 4a) are
capable of distinguishing the A570D mutation observed in the alpha (B.1.1.7) variant, the
K417N mutation observed in the beta (B.1.351) variant, the K417T mutation observed in the
gamma (P.1) variant, the L452R mutation observed in the epsilon (B.1.427/9) and delta
(B.1.617.2) variants, and the T547K mutation observed in the omicron (B.1.1.529) variant.",PMC9236216
B.1.1.7,The Alpha (B.1.1.7) variant was first discovered in United Kingdom from a sample obtained in September 2020 [60].,PMC9225183
B.1.351,"The Beta (B.1.351) variant emerged in South Africa in October 2020, being the most representative variant in this country until the onset of Omicron, and extended to 115 countries [79].",PMC9225183
B.1.1.28,"Currently, similar to Alpha and Gamma variants, the dissemination of this strain has slowed, being now considered a de-escalated variant..

Gamma (P.1) variant was detected in Japan in December 2020, although it first emerged in Brazil, evolving from a local B.1.1.28 clade in late November 2020 and replacing the parental lineage in less than 2 months, especially during the second wave [92].",PMC9225183
P.1,"Currently, similar to Alpha and Gamma variants, the dissemination of this strain has slowed, being now considered a de-escalated variant..

Gamma (P.1) variant was detected in Japan in December 2020, although it first emerged in Brazil, evolving from a local B.1.1.28 clade in late November 2020 and replacing the parental lineage in less than 2 months, especially during the second wave [92].",PMC9225183
B.1.617.1,"However, it seems that in general terms, mRNA-based vaccines, AZD1222, and CoronaVac are effective in preventing symptomatic COVID-19 and severe infections against Alpha, Beta, Gamma or Delta variants [98]..

SARS-CoV-2 Delta variant (B.1.617.2) was first reported in India on December 2020, competing with the pre-existing B.1.617.1 (Kappa) and B.1.1.7 (Alpha) variants [99].",PMC9225183
B.1.617.2,"However, it seems that in general terms, mRNA-based vaccines, AZD1222, and CoronaVac are effective in preventing symptomatic COVID-19 and severe infections against Alpha, Beta, Gamma or Delta variants [98]..

SARS-CoV-2 Delta variant (B.1.617.2) was first reported in India on December 2020, competing with the pre-existing B.1.617.1 (Kappa) and B.1.1.7 (Alpha) variants [99].",PMC9225183
B.1.1.529,"The Omicron variant (B.1.1.529) was first identified in Botswana in November 2021, and it was first reported to the WHO on November 24, upon which it was classified as VOC two days later [119].",PMC9225183
B.1.1.7,"The Alpha strain (B.1.1.7) was first detected in the United Kingdom in November of 2020, and infections spiked in December of that year [93].",PMC9230982
B.1.351,The variant formerly known as the ‘South Africa variant’ is now known as the Beta variant (B.1.351) or 20H/501Y.V2 in the Nextstrain database and GH/501Y.V2 in the GISAID database [94].,PMC9230982
P.1,"For Pfizer, Moderna, and AstraZeneca vaccinations, neutralization was projected to be reduced by 5- to 10-fold, whereas Johnson & Johnson vaccine neutralization was reduced by more than 10-fold..

Gamma (P.1) is another VOC, and it is defined as B.1.1.28.1.",PMC9230982
B.1.617.2,"The Delta variant (B.1.617.2) was detected for the first time in India in October 2020, and by December 2021, it had become the widely dominant variant, remaining so until January 2022 [219].",PMC9230982
B.1.617,"Two mutations in the receptor-binding domain of B.1.617 (Delta), which interacts with the ACE2 receptor and is the primary target of neutralizing antibodies, are present in the spike protein of B.1.617 (Delta).",PMC9230982
B.1.1.529,"The World Health Organization (WHO) classified Omicron (B.1.1.529) as the fifth SARS-CoV-2 VOC on 26 November 2021 [282,283].",PMC9230982
B.1,"(2021) found that in comparison to the wild-type (B.1) strain, the Delta variant affected a higher proportion of younger age groups, particularly those younger than 20 years (0–9 years: 4.47% vs. 2.3%, 10–19 year: 9% vs. 7%) [405]..",PMC9230982
B.1.1.529,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron B.1.1.529 (or Nextstrain 21M) variant, first detected in November 2021, includes several sub-lineages, including BA.1 (B.1.1.529.1 or Nextstrain clade 21K), BA.2 (B.1.1.529.2 or Nextstrain clade 21L), and BA.3 (B.1.1.529.3 or Nextstrain clade 21M) (Figure 1
; Data S1; Hadfield et al., 2018; Sagulenko et al., 2018).",PMC9174147
B.1.1.7,"Notably, the BA.2 S protein NTD lacks the H69-V70 deletion (ΔH69-V70) that is present in BA.1, as well as in the Alpha (B.1.1.7) and a mink-associated (ΔFV) variant (Gobeil et al., 2021b; Meng et al., 2021).",PMC9174147
B.1,"Further mutational studies and careful evaluation of point mutants will be required to clarify the contribution of each substitution on the observed differences in the BA.2 S architecture..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesACE2(Henderson et al., 2020)N/ACR3022(Henderson et al., 2020)N/A2G12(Williams et al., 2021)N/AGoat anti-rabbit-HRPAbcamab97080Goat anti-human-HRPJackson ImmunoResearch Laboratories109-035-098Mouse anti-monkey IgG HRPSouthern BiotechCat #:4700-05; RRID:AB_2796069DH1050.1(Li et al., 2021)N/ADH1052(Li et al., 2021)N/AS309(Pinto et al., 2020)N/ADH1041(Li et al., 2021)N/ADH1042(Li et al., 2021)N/ADH1047(Li et al., 2021)N/AS2X259(Totorici et al., 2021)N/ADH1044(Li et al., 2021)N/ADH1193(Li et al., 2021)N/ADH1058(Li et al., 2021)N/ABacterial and virus strainsSpike-pseudotyped virus D614G (B.1)David Montefiori & Xiaoying Shen, DukeSpike-pseudotyped virus Omicron (B.1.1.529.1)David Montefiori & Xiaoying Shen, DukeSpike-pseudotyped virus Omicron (B.1.1.529.2)David Montefiori & Xiaoying Shen, DukeSpike-pseudotyped virus Omicron (B.1.1.529.3)David Montefiori & Xiaoying Shen, DukeChemicals, peptides, and recombinant proteinsFreeStyle 293 Expression MediumGIBCO12,338,018Expi293 Expression MediumGIBCOA1435101ExpiFectamine 293 Transfection KitGIBCOA14524Hyclone SFM4HEK293CytivaSH30521.02Opti-MEM IGIBCO31,985-070Turbo293Speed BioSystemsPXX100210x Buffer EIBA2-100010x Buffer RIBA2-100210x Buffer WIBA2-1003Strep-Tactin resinIBA2-12018% GlutaraldehydeElectron Microscopy Sciences16,019300mesh Cu carbon coatedElectron Microscopy SciencesCF300-CuUranyl formateElectron Microscopy Sciences22,450S-888Quantifoil R 1.2/1.3 300 meshElectron Microscopy SciencesQ350CR-14StreptavidinThermo Fisher ScientificS-888Streptavidin-HRPThermo ScientificRef #21132D-mannoseSigmaCAS #:3458-28-4Tween 20SigmaP7949Phosphate Buffered Saline (25x) pH 7.6Cat No:PBS-20000Sodium BicarbonateSigmaS6297Sodium AzideSigmaS8032Hydrochloric AcidFischer ScientificA142-212Whey ProteinBipro USAUnflavored WheyGoat SerumInvitrogen16,210-072SureBlue Reserve TMBKPL53-00-03BSASigmaA3059HBS-EP + buffer 10xCytivaBR100669Critical commercial assaysSuperose 6 Increase 10/300 GLCytiva29,091,596NuPage 4-12%InvitrogenNP0321TMB substrateSera Care Life Sciences5120-0083Luciferase Cell Culture Lysis 5x ReagentPromegaCat# E1531Bright-Glo Luciferase Assay SystemPromegaCat# #2650Series S CM5 Sensor chipCytiva29,104,988Series S SA sensor chipCytivaBR100398Human Antibody Capture kitCytivaBR100839Deposited dataSARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyPDB 7UB0; EMDB- 26,433SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyPDB 7UB5; EMD- 26435SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyPDB 7UB6; EMD- 26436SARS-CoV-2 Omicron-BA.2 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyEMD- 26644SARS-CoV-2 Omicron-BA.2 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyEMD- 26647SARS-CoV-2 Omicron-BA.2 1.5-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyEMD-26643Experimental models: Cell linesFreestyle 293-F cellsGIBCOR79007Expi293F cellsGIBCOA14527293T/ACE2 cellsDrs.",PMC9174147
B.1.91,"More cases soon followed: e.g., co-infection by B.1.1.248 (either as major or minor haplotype) and B.1.1.33 or B.1.91, respectively [44], or co-infection between B.1.1.7 and B.1.351 [45] or GH and GR [46].",PMC9228924
B.1.1.248,"More cases soon followed: e.g., co-infection by B.1.1.248 (either as major or minor haplotype) and B.1.1.33 or B.1.91, respectively [44], or co-infection between B.1.1.7 and B.1.351 [45] or GH and GR [46].",PMC9228924
B.1.351,"More cases soon followed: e.g., co-infection by B.1.1.248 (either as major or minor haplotype) and B.1.1.33 or B.1.91, respectively [44], or co-infection between B.1.1.7 and B.1.351 [45] or GH and GR [46].",PMC9228924
B.1.1.7,"More cases soon followed: e.g., co-infection by B.1.1.248 (either as major or minor haplotype) and B.1.1.33 or B.1.91, respectively [44], or co-infection between B.1.1.7 and B.1.351 [45] or GH and GR [46].",PMC9228924
B.1.1.33,"More cases soon followed: e.g., co-infection by B.1.1.248 (either as major or minor haplotype) and B.1.1.33 or B.1.91, respectively [44], or co-infection between B.1.1.7 and B.1.351 [45] or GH and GR [46].",PMC9228924
B.1.160,"Many more cases are likely to have occurred between non-VOCs in a pre-VOC era or within individual hosts, such as a recombinant between B.1.160 and Alpha variants in a lymphoma patient chronically infected for 14 months [70]: nevertheless, those recombinant have been not fit enough to spread and outcompete the dominant strain of the moment..

Recombination has been proposed as a mechanism for the generation of B.1.1.7 (Alpha VOC) [71].",PMC9228924
B.1.221.1,"Accordingly, further recombination has been detected among B.1.1.7 and other strains (B.1.36.17, B.1.36.28, B.1.177, B.1.177.9, B.1.177.16, and B.1.221.1): interestingly, in six of eight instances (and all four of the transmitting groups, including one transmission cluster of 45 sequenced cases over 2 months), the mosaic viruses contain a Spike gene from the B.1.1.7 lineage, and in four instances, there is a proposed recombination breakpoint at or near the 5′ end of the spike gene [72]..

As soon as the possibility of recombination emerged, nomenclature systems started considering how to name these sublineages.",PMC9228924
B.1.36.28,"Accordingly, further recombination has been detected among B.1.1.7 and other strains (B.1.36.17, B.1.36.28, B.1.177, B.1.177.9, B.1.177.16, and B.1.221.1): interestingly, in six of eight instances (and all four of the transmitting groups, including one transmission cluster of 45 sequenced cases over 2 months), the mosaic viruses contain a Spike gene from the B.1.1.7 lineage, and in four instances, there is a proposed recombination breakpoint at or near the 5′ end of the spike gene [72]..

As soon as the possibility of recombination emerged, nomenclature systems started considering how to name these sublineages.",PMC9228924
B.1.36.17,"Accordingly, further recombination has been detected among B.1.1.7 and other strains (B.1.36.17, B.1.36.28, B.1.177, B.1.177.9, B.1.177.16, and B.1.221.1): interestingly, in six of eight instances (and all four of the transmitting groups, including one transmission cluster of 45 sequenced cases over 2 months), the mosaic viruses contain a Spike gene from the B.1.1.7 lineage, and in four instances, there is a proposed recombination breakpoint at or near the 5′ end of the spike gene [72]..

As soon as the possibility of recombination emerged, nomenclature systems started considering how to name these sublineages.",PMC9228924
B.1.177.16,"Accordingly, further recombination has been detected among B.1.1.7 and other strains (B.1.36.17, B.1.36.28, B.1.177, B.1.177.9, B.1.177.16, and B.1.221.1): interestingly, in six of eight instances (and all four of the transmitting groups, including one transmission cluster of 45 sequenced cases over 2 months), the mosaic viruses contain a Spike gene from the B.1.1.7 lineage, and in four instances, there is a proposed recombination breakpoint at or near the 5′ end of the spike gene [72]..

As soon as the possibility of recombination emerged, nomenclature systems started considering how to name these sublineages.",PMC9228924
B.1.177,"Accordingly, further recombination has been detected among B.1.1.7 and other strains (B.1.36.17, B.1.36.28, B.1.177, B.1.177.9, B.1.177.16, and B.1.221.1): interestingly, in six of eight instances (and all four of the transmitting groups, including one transmission cluster of 45 sequenced cases over 2 months), the mosaic viruses contain a Spike gene from the B.1.1.7 lineage, and in four instances, there is a proposed recombination breakpoint at or near the 5′ end of the spike gene [72]..

As soon as the possibility of recombination emerged, nomenclature systems started considering how to name these sublineages.",PMC9228924
B.1.177.9,"Accordingly, further recombination has been detected among B.1.1.7 and other strains (B.1.36.17, B.1.36.28, B.1.177, B.1.177.9, B.1.177.16, and B.1.221.1): interestingly, in six of eight instances (and all four of the transmitting groups, including one transmission cluster of 45 sequenced cases over 2 months), the mosaic viruses contain a Spike gene from the B.1.1.7 lineage, and in four instances, there is a proposed recombination breakpoint at or near the 5′ end of the spike gene [72]..

As soon as the possibility of recombination emerged, nomenclature systems started considering how to name these sublineages.",PMC9228924
P.1,"These variants emerged in the fall of 2020 and were reported by the United Kingdom (B.1.1.7, WHO designation Alpha, GISAID Clade GRY), South Africa (B.1.351), and Brazil (P.1, WHO designation Gamma) (CDC, 2021a).",PMC9207459
B.1.351,"These variants emerged in the fall of 2020 and were reported by the United Kingdom (B.1.1.7, WHO designation Alpha, GISAID Clade GRY), South Africa (B.1.351), and Brazil (P.1, WHO designation Gamma) (CDC, 2021a).",PMC9207459
B.1.1.7,"These variants emerged in the fall of 2020 and were reported by the United Kingdom (B.1.1.7, WHO designation Alpha, GISAID Clade GRY), South Africa (B.1.351), and Brazil (P.1, WHO designation Gamma) (CDC, 2021a).",PMC9207459
B.1.617.2,"Skipping a year forward, and there was the emergence and eventual global dominance of the WHO label Delta variant (B.1.617.2, GISAID clade GK), that carried 15 substitutions or deletions in the Spike protein including the aforementioned D614G (CDC, 2021b).",PMC9207459
B.1.1.529,"This new variant was designated as the Omicron variant of concern by the WHO (B.1.1.529, GISAID clade GRA) and while vaccines are still considered to be effective in preventing severe illness and hospitalizations, break-through infections are observed (CDC, 2021c)..",PMC9207459
B.1.640,"Similarly, VariantSpark flagged C27513T SNV, which WHO started monitoring as B.1.640 originating in Republic of Congo..",PMC9162986
P.1,"Since December 2020, the SARS-CoV-2 has emerged five quickly spreading strains, designated variants of concern (VOCs), including the Alpha (B.1.1.7) variant, the Beta (B.1.351) variant, the Gamma (P.1) variant, the Delta (B.1.617.2) variant and the Omicron (B.1.1.529) variant.",PMC9163346
B.1.617.2,"Since December 2020, the SARS-CoV-2 has emerged five quickly spreading strains, designated variants of concern (VOCs), including the Alpha (B.1.1.7) variant, the Beta (B.1.351) variant, the Gamma (P.1) variant, the Delta (B.1.617.2) variant and the Omicron (B.1.1.529) variant.",PMC9163346
B.1.1.529,"Since December 2020, the SARS-CoV-2 has emerged five quickly spreading strains, designated variants of concern (VOCs), including the Alpha (B.1.1.7) variant, the Beta (B.1.351) variant, the Gamma (P.1) variant, the Delta (B.1.617.2) variant and the Omicron (B.1.1.529) variant.",PMC9163346
B.1.351,"Since December 2020, the SARS-CoV-2 has emerged five quickly spreading strains, designated variants of concern (VOCs), including the Alpha (B.1.1.7) variant, the Beta (B.1.351) variant, the Gamma (P.1) variant, the Delta (B.1.617.2) variant and the Omicron (B.1.1.529) variant.",PMC9163346
B.1.1.7,"Since December 2020, the SARS-CoV-2 has emerged five quickly spreading strains, designated variants of concern (VOCs), including the Alpha (B.1.1.7) variant, the Beta (B.1.351) variant, the Gamma (P.1) variant, the Delta (B.1.617.2) variant and the Omicron (B.1.1.529) variant.",PMC9163346
B.1.617,"The B.1.617 variant first emerged in the state of Maharastra in India in late 2020 (20, 30–33).",PMC9163346
B.1.617.3,"The B.1.617 variant contains three main subtypes, known as B.1.617.1 (the original B.1.617), B.1.617.2 and B.1.617.3 carrying diverse spike mutations in the NTD and the RBD which may increase their immune evasion potential (20, 33).",PMC9163346
B.1.617.1,"The B.1.617 variant contains three main subtypes, known as B.1.617.1 (the original B.1.617), B.1.617.2 and B.1.617.3 carrying diverse spike mutations in the NTD and the RBD which may increase their immune evasion potential (20, 33).",PMC9163346
B.1.258,"Fallowing the emergence of D614G mutation, the B.1.258 variant with N439K mutation in the RBM emerged and spread in European countries (58).",PMC9163346
B.1.1.298,"The B.1.1.298 lineage containing Y453F mutation within the RBM has been identified in Denmark, that enhances ACE2-binding affinity (56).",PMC9163346
B.1.427,"Recently, Alpha variant with E484K in the United Kingdom and the US-Epsilon (B.1.427/29) variants have been reported as VOCs (6, 25).",PMC9163346
B.1.526,"The new SARS-CoV-2 variant, known as B.1.526 was detected by Columbia University (23, 69).",PMC9163346
B.1.618,"In the same period, the B.1.618 strain has been dominant strain in West Bengal (31).",PMC9163346
B.1.135,"Local refinement of Omi-38 with B.1.135 was performed also using cryoSPARC upon this particle set from which the areas outside of the area of interest (two upwards conformation RBDs in closeness, proximity to each other and associated fabs) was subtracted.",PMC9120130
B.1.617.2,"We acknowledge rapid sharing of Victoria, B.1.1.7, and B.1.351 isolated by scientists in the National Infection Service at PHE Porton Down, and B.1.617.2 virus was kindly provided by Wendy Barclay and Thushan De-Silva.",PMC9120130
B.1.351,"We acknowledge rapid sharing of Victoria, B.1.1.7, and B.1.351 isolated by scientists in the National Infection Service at PHE Porton Down, and B.1.617.2 virus was kindly provided by Wendy Barclay and Thushan De-Silva.",PMC9120130
B.1.1.7,"We acknowledge rapid sharing of Victoria, B.1.1.7, and B.1.351 isolated by scientists in the National Infection Service at PHE Porton Down, and B.1.617.2 virus was kindly provided by Wendy Barclay and Thushan De-Silva.",PMC9120130
P.1,"We thank The Secretariat of National Surveillance, Ministry of Health Brazil for assistance in obtaining P.1 samples.",PMC9120130
B.1.1.7,"Amino acid changes in the B.1.1.7 protein improve both the accessibility of RBD and the affinity for ACE2, which might be one of the causes for the increased transmission (Cai et al., 2021).",PMC9134119
B.1.1.54,"In comparison with the previous three largest lineages (B.1.1.54, B.1.1.56, and C.1) circulating in South Africa, B.1.351 shows remarkable hypermutation including nonsynonymous mutations that result in amino acid changes (Tegally et al., 2021).",PMC9134119
B.1.1.56,"In comparison with the previous three largest lineages (B.1.1.54, B.1.1.56, and C.1) circulating in South Africa, B.1.351 shows remarkable hypermutation including nonsynonymous mutations that result in amino acid changes (Tegally et al., 2021).",PMC9134119
C.1,"In comparison with the previous three largest lineages (B.1.1.54, B.1.1.56, and C.1) circulating in South Africa, B.1.351 shows remarkable hypermutation including nonsynonymous mutations that result in amino acid changes (Tegally et al., 2021).",PMC9134119
B.1.351,"In comparison with the previous three largest lineages (B.1.1.54, B.1.1.56, and C.1) circulating in South Africa, B.1.351 shows remarkable hypermutation including nonsynonymous mutations that result in amino acid changes (Tegally et al., 2021).",PMC9134119
B.1.617.2,"The fourth variant of concern, delta variant is also known as the B.1.617.2 was initially identified in December 2020 in India and was responsible for the deadly second wave of COVID-19 infections in April 2021 in India (Cascella et al., 2021).",PMC9134119
P.3,"In the early stages, VOI consisted of eight variants, including Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621) (Cascella et al., 2021).",PMC9134119
B.1.429,"In the early stages, VOI consisted of eight variants, including Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621) (Cascella et al., 2021).",PMC9134119
B.1.525,"In the early stages, VOI consisted of eight variants, including Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621) (Cascella et al., 2021).",PMC9134119
B.1.617.1,"In the early stages, VOI consisted of eight variants, including Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621) (Cascella et al., 2021).",PMC9134119
C.37,"In the early stages, VOI consisted of eight variants, including Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621) (Cascella et al., 2021).",PMC9134119
B.1.621,"In the early stages, VOI consisted of eight variants, including Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621) (Cascella et al., 2021).",PMC9134119
B.1.526,"In the early stages, VOI consisted of eight variants, including Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621) (Cascella et al., 2021).",PMC9134119
P.2,"In the early stages, VOI consisted of eight variants, including Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621) (Cascella et al., 2021).",PMC9134119
B.1.427,"In the early stages, VOI consisted of eight variants, including Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621) (Cascella et al., 2021).",PMC9134119
B.1.1.318,"The currently designated VUM mainly includes B.1.1.318, C.1.2, and B.1.640..",PMC9134119
C.1.2,"The currently designated VUM mainly includes B.1.1.318, C.1.2, and B.1.640..",PMC9134119
B.3,Phylogenetic analyses of these sequences revealed mainly two circulating strains with 74 samples assigned to lineage B.3 and 6 samples assigned to lineage B.1.,PMC9088089
A.1,identified six lineages derived from lineage A (denoted A.1-A.6) and two descendant sub-lineages of A.1 (A.1.1 and A.3).,PMC9088089
A.3,identified six lineages derived from lineage A (denoted A.1-A.6) and two descendant sub-lineages of A.1 (A.1.1 and A.3).,PMC9088089
B.1,"They also described 16 lineages, which were directly derived from lineage B. Lineage B.1 is the predominant lineage globally and it has been divided into more than 70 sub-lineages.",PMC9088089
B.4,"Multiple lineage introductions were noted during the initial phase of the pandemic, including B.4, B.1.1, B.1.428.2, B.1.540 and B.1.1.189.",PMC9085353
B.1.1,"Multiple lineage introductions were noted during the initial phase of the pandemic, including B.4, B.1.1, B.1.428.2, B.1.540 and B.1.1.189.",PMC9085353
B.1.540,"Multiple lineage introductions were noted during the initial phase of the pandemic, including B.4, B.1.1, B.1.428.2, B.1.540 and B.1.1.189.",PMC9085353
B.1.428.2,"Multiple lineage introductions were noted during the initial phase of the pandemic, including B.4, B.1.1, B.1.428.2, B.1.540 and B.1.1.189.",PMC9085353
B.1.1.7,The Alpha variant (B.1.1.7 lineage) was identified in February 2021 and firstly observed in the center of our country.,PMC9085353
B.1.617.2,"Epidemiological and phylogenetic studies revealed that the significant increase in the rate of infection and/or death was correlated with the emergence of fourVariant of Concern (VOC) belonging to B.1.1.7, B.1.351, B.1.617.2 and B.1.1.28 lineages.",PMC9085353
B.1.1.28,"Epidemiological and phylogenetic studies revealed that the significant increase in the rate of infection and/or death was correlated with the emergence of fourVariant of Concern (VOC) belonging to B.1.1.7, B.1.351, B.1.617.2 and B.1.1.28 lineages.",PMC9085353
B.1.351,"Epidemiological and phylogenetic studies revealed that the significant increase in the rate of infection and/or death was correlated with the emergence of fourVariant of Concern (VOC) belonging to B.1.1.7, B.1.351, B.1.617.2 and B.1.1.28 lineages.",PMC9085353
A.2,"A.1, A.2, A.3, …) and sub sub-lineages (e.g.",PMC9085353
A.3,"A.1, A.2, A.3, …) and sub sub-lineages (e.g.",PMC9085353
B.1.1.189,"B.4, B.1.1.189 and B.1.540 were identified in tow patient each one (n = 2; 3.4%).",PMC9085353
B.1.177.6,"B.55, B.1.9, B.1.177.6, B.1.333, B.1.356 and B.1.597 lineages were identified in one patient each (Fig.",PMC9085353
B.1.9,"B.55, B.1.9, B.1.177.6, B.1.333, B.1.356 and B.1.597 lineages were identified in one patient each (Fig.",PMC9085353
B.1.333,"B.55, B.1.9, B.1.177.6, B.1.333, B.1.356 and B.1.597 lineages were identified in one patient each (Fig.",PMC9085353
B.1.356,"B.55, B.1.9, B.1.177.6, B.1.333, B.1.356 and B.1.597 lineages were identified in one patient each (Fig.",PMC9085353
B.1.597,"B.55, B.1.9, B.1.177.6, B.1.333, B.1.356 and B.1.597 lineages were identified in one patient each (Fig.",PMC9085353
A.27,A local cluster of the A.27 lineage was detected in Zaghouan and Sousse (Supplementary data Fig.,PMC9085353
B.1,"Indeed, among the 14 different lineages generated in this study six were identified during the early phase including B.1, B.1.1, B.1.1.189, B.1.428.2, B.1.597 and B4.",PMC9085353
B.1.160,"As the majority of European countries B.1.160, B.1.177 and B.1.1.7 were the predominant lineages during the second and the third waives (Hodcroft et al., 2021)..

Our data revealed a clear difference between the North of the country (Tunis, Nabeul, Ben Arous and Ariana) where diverse lineages circulated and the South (Gafsa, Djerba, Sidi Bouzid) where only one lineage was exclusively present.",PMC9085353
B.1.177,"As the majority of European countries B.1.160, B.1.177 and B.1.1.7 were the predominant lineages during the second and the third waives (Hodcroft et al., 2021)..

Our data revealed a clear difference between the North of the country (Tunis, Nabeul, Ben Arous and Ariana) where diverse lineages circulated and the South (Gafsa, Djerba, Sidi Bouzid) where only one lineage was exclusively present.",PMC9085353
B.1,"The neutralizing capacity was measured at one, three, and six-months post-vaccination by plaque reduction neutralization assay using SARS-CoV-2 B.1 (D614G) and the Gamma, Alpha, Delta, and Mu variants.",PMC9108166
B.1.117,"The lineages assessed were B.1 (D614G) (hCoV-19/Colombia/ANTUdeA-200325-01/2020 ID accession: EPI_ISL_536399), variants of concern (VOC) Gamma (P.1) (hCoV-19/Colombia/ANT-UdeA-21002835v/2021 ID accession: EPI_ISL_4926393), Alpha (B.1.117) (hCoV-19/Colombia/ANT-UdeA-21001965v/2021 ID accession: and Delta (B.1.617.2) (hCoV-19/Colombia/ANT-UdeA-36211/2021 ID accession: EPI_ISL_5103929), and the variant of interest (VOI) Mu (B.1.621) (hCoV-19/Colombia/ANT-UdeA-21002149/2021 ID accession: EPI_ISL_4005445).",PMC9108166
P.1,"The lineages assessed were B.1 (D614G) (hCoV-19/Colombia/ANTUdeA-200325-01/2020 ID accession: EPI_ISL_536399), variants of concern (VOC) Gamma (P.1) (hCoV-19/Colombia/ANT-UdeA-21002835v/2021 ID accession: EPI_ISL_4926393), Alpha (B.1.117) (hCoV-19/Colombia/ANT-UdeA-21001965v/2021 ID accession: and Delta (B.1.617.2) (hCoV-19/Colombia/ANT-UdeA-36211/2021 ID accession: EPI_ISL_5103929), and the variant of interest (VOI) Mu (B.1.621) (hCoV-19/Colombia/ANT-UdeA-21002149/2021 ID accession: EPI_ISL_4005445).",PMC9108166
B.1.617.2,"The lineages assessed were B.1 (D614G) (hCoV-19/Colombia/ANTUdeA-200325-01/2020 ID accession: EPI_ISL_536399), variants of concern (VOC) Gamma (P.1) (hCoV-19/Colombia/ANT-UdeA-21002835v/2021 ID accession: EPI_ISL_4926393), Alpha (B.1.117) (hCoV-19/Colombia/ANT-UdeA-21001965v/2021 ID accession: and Delta (B.1.617.2) (hCoV-19/Colombia/ANT-UdeA-36211/2021 ID accession: EPI_ISL_5103929), and the variant of interest (VOI) Mu (B.1.621) (hCoV-19/Colombia/ANT-UdeA-21002149/2021 ID accession: EPI_ISL_4005445).",PMC9108166
B.1.621,"The lineages assessed were B.1 (D614G) (hCoV-19/Colombia/ANTUdeA-200325-01/2020 ID accession: EPI_ISL_536399), variants of concern (VOC) Gamma (P.1) (hCoV-19/Colombia/ANT-UdeA-21002835v/2021 ID accession: EPI_ISL_4926393), Alpha (B.1.117) (hCoV-19/Colombia/ANT-UdeA-21001965v/2021 ID accession: and Delta (B.1.617.2) (hCoV-19/Colombia/ANT-UdeA-36211/2021 ID accession: EPI_ISL_5103929), and the variant of interest (VOI) Mu (B.1.621) (hCoV-19/Colombia/ANT-UdeA-21002149/2021 ID accession: EPI_ISL_4005445).",PMC9108166
B.1.111,"found that serum neutralizing activity from individuals vaccinated with BNT162b2 decreased by 75.7- and 17.7-fold against Mu, with respect to B.1.111 lineage and Gamma variant, respectively (26).",PMC9108166
C.1.2,"reported that Mu and C.1.2 variants were more resistant to neutralization by BNT162b2 vaccination (6.8- and 7.3-fold decrease in titer, respectively, compared with D614G strain) (27).",PMC9108166
B.1.351,"The B.1.351 variant has mutations in the spike protein including L18F*, D80A, D215G, Δ241-243 and R246I* in the NTD, K417N, E484K, and N501Y in the RBD, and D614 and A701V in the S1/S2 region (Fig.",PMC9043892
B.1,"Importantly, the nasopharyngeal viral load for Delta appears similar for vaccinated and unvaccinated individuals, as well as asymptomatic individuals irrespective of vaccination status [54, 55], which explains why vaccinated and/or asymptomatic individuals may still infect others at high R0 numbers..

Additionally, B.1.617.1, a variant closely related to the Delta variant, was shown to be more pathogenic in hamsters than the B.1 variant [56].",PMC9043892
B.1.617.1,"Importantly, the nasopharyngeal viral load for Delta appears similar for vaccinated and unvaccinated individuals, as well as asymptomatic individuals irrespective of vaccination status [54, 55], which explains why vaccinated and/or asymptomatic individuals may still infect others at high R0 numbers..

Additionally, B.1.617.1, a variant closely related to the Delta variant, was shown to be more pathogenic in hamsters than the B.1 variant [56].",PMC9043892
B.1.1.529,It was given the PANGO lineage designation B.1.1.529 on 24 November 2021 and then designated as a VOC on 26 November 2021.,PMC9043892
P.3,"Moreover, variants carrying the now ubiquitous E484K mutation (including all Beta, Gamma, Eta, P.2, P.3, Mu, and C.1.2 variants, as well as some Alpha and Iota variants; see Fig.",PMC9043892
C.1.2,"Moreover, variants carrying the now ubiquitous E484K mutation (including all Beta, Gamma, Eta, P.2, P.3, Mu, and C.1.2 variants, as well as some Alpha and Iota variants; see Fig.",PMC9043892
P.2,"Moreover, variants carrying the now ubiquitous E484K mutation (including all Beta, Gamma, Eta, P.2, P.3, Mu, and C.1.2 variants, as well as some Alpha and Iota variants; see Fig.",PMC9043892
B.1.1.7,"These polyclonal antibodies, which were found to be effective against the Alpha (B.1.1.7, UK) and Beta (B.1.351, South Africa) variants even though the swine were immunized with the “wildtype” Wuhan-D614G spike protein [190], are currently being evaluated in the POLYCOR Phase II clinical trial [191].",PMC9043892
B.1.1.28,"This ultimately led the FDA to revoke EUA on 16 April 2021 for use of bamlanivimab as a single agent, which resulted in bamlanivimab no longer being developed as a single agent for treatment of COVID-19.Table 6Neutralization of SARS-CoV-2 wild-type virus and variants by selected monoclonal antibodiesaAntibodyEpitope groupNeutralization (IC50 in ng/mL in pseudovirus assays) against SARS-CoV-2 variantsReferencesbWild-typeWT-D614GAlpha(B.1.1.7)Beta(B.1.351)Gamma(P.1, B.1.1.28)Delta b(B.1.617.2)Epsilon(B.1.427/B.1.429)Omicron(B.1.1.529.1; BA.1) bBamlanivimab (LY3819253; LY-CoV555)RBD-26–123–54–9> 10,000c> 10,0008311–> 10,000> 10,000> 10,000[80, 386, 391, 405]Etesevimab (LY-CoV016, CB6)RBD-126–3531–5222–3225> 10,000> 10,00012–1523–547600
– > 10,000[386, 391, 405]Bamlanivimab plus EtesevimabRBD-2/RBD-1ND911> 10,000> 10,000ND63> 10,000[391]Casirivimab (REGN10933)RBD-24–435–77–133284–> 10,0001046–61773–74–9> 10,000[80, 386, 391, 405]Imdevimab (REGN10987)RBD-5A32–7112–207–284–244–1317–45575–114> 10,000[80, 386, 391, 405]REGEN-COV™ (Casirivimab plus Imdevimab)RBD-2/RBD-5AND538754> 10,000[80, 386, 391]Cilgavimab (AZD1061; COV2-2130)RBD-42–132–261–123–192–144–80552178–5850[80, 386, 391, 405–407]Tixagevimab (AZD8895;COV2-2196)RBD-21–51–42–114–462–462–311270–1150[80, 386, 391, 405–407]Cilgavimab plus TixagevimabRBD-4/RBD-2944–711–126–7ND551–418[80, 386, 405]Bebtelovimab(LY-CoV1404)RBD-5A332–312–41–12ND1–45[214, 405]Amubarvimab (BRII-196)RBD-1305331304142ND7258[407]Romlusevimab (BRII-198)RBD-5BND~ 180~ 45–70~ 580~ 320~ 1600~ 43082[382, 408]ABBV-2B04UNKND11> 10,000> 10,000ND3ND[386]ABBV-47D11RBD-5BND319305240277ND456ND[386]ABBV-2B04 plus 47D11UNK/RBD-5BND32431384ND4ND[386]BMS C144RBD-2ND4–56> 10,000> 10,0005ND> 10,000[405]BMS C135RBD-5BND11–1714341525ND5850[405]SARS2-38Likely RBD-5A2234241ND[409]Sotrovimab(GSK4182136, VIR-7831)RBD-5B1005880506642ND180–340[80, 407]S309 (precursor to Sotrovimab)RBD-5B4015678–20982–987611320256–281[80, 386, 405]B1-182.1RBD-231<11<122281[391, 405]S2E12RBD-225211022238[386, 405]S309/S2E12 combinedRBD-5B/RBD-2––78153ND5ND[386]IGM-6268 (as an IgM)RBD-26ND313123NDND230[245, 410]Regkirona (Regdanvimab; CT-P59)RBD-2<1–102–102–666–33013–4015–1,237366> 10,000[405, 406, 411, 412]ADG20RBD-5Ad1–452–65–163–91–811100–2037[80, 220, 405]MW05RBD-430NDCa.",PMC9043892
P.1,"This ultimately led the FDA to revoke EUA on 16 April 2021 for use of bamlanivimab as a single agent, which resulted in bamlanivimab no longer being developed as a single agent for treatment of COVID-19.Table 6Neutralization of SARS-CoV-2 wild-type virus and variants by selected monoclonal antibodiesaAntibodyEpitope groupNeutralization (IC50 in ng/mL in pseudovirus assays) against SARS-CoV-2 variantsReferencesbWild-typeWT-D614GAlpha(B.1.1.7)Beta(B.1.351)Gamma(P.1, B.1.1.28)Delta b(B.1.617.2)Epsilon(B.1.427/B.1.429)Omicron(B.1.1.529.1; BA.1) bBamlanivimab (LY3819253; LY-CoV555)RBD-26–123–54–9> 10,000c> 10,0008311–> 10,000> 10,000> 10,000[80, 386, 391, 405]Etesevimab (LY-CoV016, CB6)RBD-126–3531–5222–3225> 10,000> 10,00012–1523–547600
– > 10,000[386, 391, 405]Bamlanivimab plus EtesevimabRBD-2/RBD-1ND911> 10,000> 10,000ND63> 10,000[391]Casirivimab (REGN10933)RBD-24–435–77–133284–> 10,0001046–61773–74–9> 10,000[80, 386, 391, 405]Imdevimab (REGN10987)RBD-5A32–7112–207–284–244–1317–45575–114> 10,000[80, 386, 391, 405]REGEN-COV™ (Casirivimab plus Imdevimab)RBD-2/RBD-5AND538754> 10,000[80, 386, 391]Cilgavimab (AZD1061; COV2-2130)RBD-42–132–261–123–192–144–80552178–5850[80, 386, 391, 405–407]Tixagevimab (AZD8895;COV2-2196)RBD-21–51–42–114–462–462–311270–1150[80, 386, 391, 405–407]Cilgavimab plus TixagevimabRBD-4/RBD-2944–711–126–7ND551–418[80, 386, 405]Bebtelovimab(LY-CoV1404)RBD-5A332–312–41–12ND1–45[214, 405]Amubarvimab (BRII-196)RBD-1305331304142ND7258[407]Romlusevimab (BRII-198)RBD-5BND~ 180~ 45–70~ 580~ 320~ 1600~ 43082[382, 408]ABBV-2B04UNKND11> 10,000> 10,000ND3ND[386]ABBV-47D11RBD-5BND319305240277ND456ND[386]ABBV-2B04 plus 47D11UNK/RBD-5BND32431384ND4ND[386]BMS C144RBD-2ND4–56> 10,000> 10,0005ND> 10,000[405]BMS C135RBD-5BND11–1714341525ND5850[405]SARS2-38Likely RBD-5A2234241ND[409]Sotrovimab(GSK4182136, VIR-7831)RBD-5B1005880506642ND180–340[80, 407]S309 (precursor to Sotrovimab)RBD-5B4015678–20982–987611320256–281[80, 386, 405]B1-182.1RBD-231<11<122281[391, 405]S2E12RBD-225211022238[386, 405]S309/S2E12 combinedRBD-5B/RBD-2––78153ND5ND[386]IGM-6268 (as an IgM)RBD-26ND313123NDND230[245, 410]Regkirona (Regdanvimab; CT-P59)RBD-2<1–102–102–666–33013–4015–1,237366> 10,000[405, 406, 411, 412]ADG20RBD-5Ad1–452–65–163–91–811100–2037[80, 220, 405]MW05RBD-430NDCa.",PMC9043892
B.1.617.2,"This ultimately led the FDA to revoke EUA on 16 April 2021 for use of bamlanivimab as a single agent, which resulted in bamlanivimab no longer being developed as a single agent for treatment of COVID-19.Table 6Neutralization of SARS-CoV-2 wild-type virus and variants by selected monoclonal antibodiesaAntibodyEpitope groupNeutralization (IC50 in ng/mL in pseudovirus assays) against SARS-CoV-2 variantsReferencesbWild-typeWT-D614GAlpha(B.1.1.7)Beta(B.1.351)Gamma(P.1, B.1.1.28)Delta b(B.1.617.2)Epsilon(B.1.427/B.1.429)Omicron(B.1.1.529.1; BA.1) bBamlanivimab (LY3819253; LY-CoV555)RBD-26–123–54–9> 10,000c> 10,0008311–> 10,000> 10,000> 10,000[80, 386, 391, 405]Etesevimab (LY-CoV016, CB6)RBD-126–3531–5222–3225> 10,000> 10,00012–1523–547600
– > 10,000[386, 391, 405]Bamlanivimab plus EtesevimabRBD-2/RBD-1ND911> 10,000> 10,000ND63> 10,000[391]Casirivimab (REGN10933)RBD-24–435–77–133284–> 10,0001046–61773–74–9> 10,000[80, 386, 391, 405]Imdevimab (REGN10987)RBD-5A32–7112–207–284–244–1317–45575–114> 10,000[80, 386, 391, 405]REGEN-COV™ (Casirivimab plus Imdevimab)RBD-2/RBD-5AND538754> 10,000[80, 386, 391]Cilgavimab (AZD1061; COV2-2130)RBD-42–132–261–123–192–144–80552178–5850[80, 386, 391, 405–407]Tixagevimab (AZD8895;COV2-2196)RBD-21–51–42–114–462–462–311270–1150[80, 386, 391, 405–407]Cilgavimab plus TixagevimabRBD-4/RBD-2944–711–126–7ND551–418[80, 386, 405]Bebtelovimab(LY-CoV1404)RBD-5A332–312–41–12ND1–45[214, 405]Amubarvimab (BRII-196)RBD-1305331304142ND7258[407]Romlusevimab (BRII-198)RBD-5BND~ 180~ 45–70~ 580~ 320~ 1600~ 43082[382, 408]ABBV-2B04UNKND11> 10,000> 10,000ND3ND[386]ABBV-47D11RBD-5BND319305240277ND456ND[386]ABBV-2B04 plus 47D11UNK/RBD-5BND32431384ND4ND[386]BMS C144RBD-2ND4–56> 10,000> 10,0005ND> 10,000[405]BMS C135RBD-5BND11–1714341525ND5850[405]SARS2-38Likely RBD-5A2234241ND[409]Sotrovimab(GSK4182136, VIR-7831)RBD-5B1005880506642ND180–340[80, 407]S309 (precursor to Sotrovimab)RBD-5B4015678–20982–987611320256–281[80, 386, 405]B1-182.1RBD-231<11<122281[391, 405]S2E12RBD-225211022238[386, 405]S309/S2E12 combinedRBD-5B/RBD-2––78153ND5ND[386]IGM-6268 (as an IgM)RBD-26ND313123NDND230[245, 410]Regkirona (Regdanvimab; CT-P59)RBD-2<1–102–102–666–33013–4015–1,237366> 10,000[405, 406, 411, 412]ADG20RBD-5Ad1–452–65–163–91–811100–2037[80, 220, 405]MW05RBD-430NDCa.",PMC9043892
B.1.427,"This ultimately led the FDA to revoke EUA on 16 April 2021 for use of bamlanivimab as a single agent, which resulted in bamlanivimab no longer being developed as a single agent for treatment of COVID-19.Table 6Neutralization of SARS-CoV-2 wild-type virus and variants by selected monoclonal antibodiesaAntibodyEpitope groupNeutralization (IC50 in ng/mL in pseudovirus assays) against SARS-CoV-2 variantsReferencesbWild-typeWT-D614GAlpha(B.1.1.7)Beta(B.1.351)Gamma(P.1, B.1.1.28)Delta b(B.1.617.2)Epsilon(B.1.427/B.1.429)Omicron(B.1.1.529.1; BA.1) bBamlanivimab (LY3819253; LY-CoV555)RBD-26–123–54–9> 10,000c> 10,0008311–> 10,000> 10,000> 10,000[80, 386, 391, 405]Etesevimab (LY-CoV016, CB6)RBD-126–3531–5222–3225> 10,000> 10,00012–1523–547600
– > 10,000[386, 391, 405]Bamlanivimab plus EtesevimabRBD-2/RBD-1ND911> 10,000> 10,000ND63> 10,000[391]Casirivimab (REGN10933)RBD-24–435–77–133284–> 10,0001046–61773–74–9> 10,000[80, 386, 391, 405]Imdevimab (REGN10987)RBD-5A32–7112–207–284–244–1317–45575–114> 10,000[80, 386, 391, 405]REGEN-COV™ (Casirivimab plus Imdevimab)RBD-2/RBD-5AND538754> 10,000[80, 386, 391]Cilgavimab (AZD1061; COV2-2130)RBD-42–132–261–123–192–144–80552178–5850[80, 386, 391, 405–407]Tixagevimab (AZD8895;COV2-2196)RBD-21–51–42–114–462–462–311270–1150[80, 386, 391, 405–407]Cilgavimab plus TixagevimabRBD-4/RBD-2944–711–126–7ND551–418[80, 386, 405]Bebtelovimab(LY-CoV1404)RBD-5A332–312–41–12ND1–45[214, 405]Amubarvimab (BRII-196)RBD-1305331304142ND7258[407]Romlusevimab (BRII-198)RBD-5BND~ 180~ 45–70~ 580~ 320~ 1600~ 43082[382, 408]ABBV-2B04UNKND11> 10,000> 10,000ND3ND[386]ABBV-47D11RBD-5BND319305240277ND456ND[386]ABBV-2B04 plus 47D11UNK/RBD-5BND32431384ND4ND[386]BMS C144RBD-2ND4–56> 10,000> 10,0005ND> 10,000[405]BMS C135RBD-5BND11–1714341525ND5850[405]SARS2-38Likely RBD-5A2234241ND[409]Sotrovimab(GSK4182136, VIR-7831)RBD-5B1005880506642ND180–340[80, 407]S309 (precursor to Sotrovimab)RBD-5B4015678–20982–987611320256–281[80, 386, 405]B1-182.1RBD-231<11<122281[391, 405]S2E12RBD-225211022238[386, 405]S309/S2E12 combinedRBD-5B/RBD-2––78153ND5ND[386]IGM-6268 (as an IgM)RBD-26ND313123NDND230[245, 410]Regkirona (Regdanvimab; CT-P59)RBD-2<1–102–102–666–33013–4015–1,237366> 10,000[405, 406, 411, 412]ADG20RBD-5Ad1–452–65–163–91–811100–2037[80, 220, 405]MW05RBD-430NDCa.",PMC9043892
B.1.429,"Similarly, the NTD-targeting nAb, 4-8, a representative example of a family of NTD-binding antagonist antibodies (including 4A8, 1-87, 2-17, 2-51, 4-18, 5-24, FC05, S2L28, S2M28, S2X333, and DH1050.1) targeting the supersite, loses virtually all of its activity against variants Alpha (B.1.1.7), Beta (B.1.351), and Epsilon (B.1.429) [172].",PMC9043892
B.1.526,"Importantly, NTD-binding nAb 5–7 has at least partial efficacy against Alpha (B.1.1.7), Beta (B.1.351), and Iota (B.1.526) variants [449].",PMC9043892
B.1.351,"LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2.",PMC9035363
B.1.1.7,"LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2.",PMC9035363
P.1,"In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant.",PMC9035363
B.1.617.2,"In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant.",PMC9035363
B.1.1.529,"In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant.",PMC9035363
B.1.526,"In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant.",PMC9035363
B.1.427,"In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant.",PMC9035363
B.1.429,"Variants such as B.1.1.529, BA.2, B.1.1.7, B.1.351, P.1, B.1.526, B.1.427, and B.1.429 affect the in vitro binding of antibodies being tested clinically or of those already authorized for emergency use to varying degrees (Kuzmina et al., 2021; Liu et al., 2021; Rees-Spear et al., 2021; Iketani et al., 2022).",PMC9035363
B.1.426,"LY-CoV1404 binds to or neutralizes variants, including B.1.1.529 (Omicron) and those first identified in India (B.1.617.1, B.1.617.2, and B.1.617.3), the United Kingdom (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.426 and B.1.429), and New York (B.1.526).",PMC9035363
B.1.617.1,"LY-CoV1404 binds to or neutralizes variants, including B.1.1.529 (Omicron) and those first identified in India (B.1.617.1, B.1.617.2, and B.1.617.3), the United Kingdom (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.426 and B.1.429), and New York (B.1.526).",PMC9035363
B.1.617.3,"LY-CoV1404 binds to or neutralizes variants, including B.1.1.529 (Omicron) and those first identified in India (B.1.617.1, B.1.617.2, and B.1.617.3), the United Kingdom (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.426 and B.1.429), and New York (B.1.526).",PMC9035363
P.1,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
B.1.617.2,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
B.1.351,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
B.1.1.7,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
B.1.617,"With the progression of pandemic, SARS-CoV-2 acquired additional mutations in S protein on the background of D614G mutation in different geographical regions and classified as B.1.1.7or Alpha, B.1.351or Beta, P.1 or Gamma and B.1.617 or Delta variant.",PMC9009757
P.1,"With the progression of pandemic, SARS-CoV-2 acquired additional mutations in S protein on the background of D614G mutation in different geographical regions and classified as B.1.1.7or Alpha, B.1.351or Beta, P.1 or Gamma and B.1.617 or Delta variant.",PMC9009757
B.1.351,"Due to their higher transmissibility, mortality, and immune-escape properties, these variants are known as the variant of concerns (VOCs, Table 1).Table 1SARS-CoV-2 variants of concerns: defining mutations in the spike protein.VOCCountry of OriginCharacteristic Spike mutationsBiological relevanceAlpha (B.1.1.7)Englanddel69/70, del144/145, N501Y, A570D, D614G, P681H, T716IS982A, D1118HIncreased transmissibility, hospitalization risk, and minimal effect on vaccine efficacyBeta (B.1.351)South AfricaD80 A, D215G, 241/243del, K417N, E484K, N501Y, D614G, A701VIncreased transmissibility, hospitalization risk, mortality, immune escape property and might affect the vaccine efficacyGamma (P.1)BrazilL18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176FIncreased transmissibility, hospitalization risk, and minimal effect on vaccine efficacyDelta (B.1.617.2)IndiaT19R, G142D, L452R, T478K, D614G, P681R, D950N, del157/158Increased transmissibility, hospitalization risk, mortality, immune escape property and might affect the vaccine efficacy.",PMC9009757
B.1.617.2,"Due to their higher transmissibility, mortality, and immune-escape properties, these variants are known as the variant of concerns (VOCs, Table 1).Table 1SARS-CoV-2 variants of concerns: defining mutations in the spike protein.VOCCountry of OriginCharacteristic Spike mutationsBiological relevanceAlpha (B.1.1.7)Englanddel69/70, del144/145, N501Y, A570D, D614G, P681H, T716IS982A, D1118HIncreased transmissibility, hospitalization risk, and minimal effect on vaccine efficacyBeta (B.1.351)South AfricaD80 A, D215G, 241/243del, K417N, E484K, N501Y, D614G, A701VIncreased transmissibility, hospitalization risk, mortality, immune escape property and might affect the vaccine efficacyGamma (P.1)BrazilL18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176FIncreased transmissibility, hospitalization risk, and minimal effect on vaccine efficacyDelta (B.1.617.2)IndiaT19R, G142D, L452R, T478K, D614G, P681R, D950N, del157/158Increased transmissibility, hospitalization risk, mortality, immune escape property and might affect the vaccine efficacy.",PMC9009757
B.1.1.7,"Due to their higher transmissibility, mortality, and immune-escape properties, these variants are known as the variant of concerns (VOCs, Table 1).Table 1SARS-CoV-2 variants of concerns: defining mutations in the spike protein.VOCCountry of OriginCharacteristic Spike mutationsBiological relevanceAlpha (B.1.1.7)Englanddel69/70, del144/145, N501Y, A570D, D614G, P681H, T716IS982A, D1118HIncreased transmissibility, hospitalization risk, and minimal effect on vaccine efficacyBeta (B.1.351)South AfricaD80 A, D215G, 241/243del, K417N, E484K, N501Y, D614G, A701VIncreased transmissibility, hospitalization risk, mortality, immune escape property and might affect the vaccine efficacyGamma (P.1)BrazilL18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176FIncreased transmissibility, hospitalization risk, and minimal effect on vaccine efficacyDelta (B.1.617.2)IndiaT19R, G142D, L452R, T478K, D614G, P681R, D950N, del157/158Increased transmissibility, hospitalization risk, mortality, immune escape property and might affect the vaccine efficacy.",PMC9009757
B.1.617.3,"It consists of three sub-lineages: B.1.617.1, B.1.617.2, and B.1.617.3, of which the B.1.617.1 and B.1.617.2 were first detected in India in December 2020, whereas the B.1.617.3 sub-lineage was first reported in India in February 202116.",PMC9009757
B.1.617.1,"It consists of three sub-lineages: B.1.617.1, B.1.617.2, and B.1.617.3, of which the B.1.617.1 and B.1.617.2 were first detected in India in December 2020, whereas the B.1.617.3 sub-lineage was first reported in India in February 202116.",PMC9009757
B.1.351,"Lower than expected inhibitory activity of antibodies was reported against viruses with E484K Spike mutation, including B.1.1.7 (UK), P.1 (Brazil), B.1.351 (South African), and new Omicron variant (B.1.1.529) with E484A mutation.",PMC9111059
B.1.1.529,"Lower than expected inhibitory activity of antibodies was reported against viruses with E484K Spike mutation, including B.1.1.7 (UK), P.1 (Brazil), B.1.351 (South African), and new Omicron variant (B.1.1.529) with E484A mutation.",PMC9111059
P.1,"Lower than expected inhibitory activity of antibodies was reported against viruses with E484K Spike mutation, including B.1.1.7 (UK), P.1 (Brazil), B.1.351 (South African), and new Omicron variant (B.1.1.529) with E484A mutation.",PMC9111059
B.1.1.7,"Lower than expected inhibitory activity of antibodies was reported against viruses with E484K Spike mutation, including B.1.1.7 (UK), P.1 (Brazil), B.1.351 (South African), and new Omicron variant (B.1.1.529) with E484A mutation.",PMC9111059
B.1.617.2,"In this review, we assess the reported mutation‐acquiring potential of coronaviruses and compare efficacies of current COVID‐19 vaccines against ‘parent’ and ‘mutant’ strains of SARS‐CoV‐2 (Kappa (B.1.617.1), Delta (B.1.617.2), and Omicron (B.1.1.529))..




Beeraka
NM
, 
Sukocheva
OA
, 
Lukina
E
, 
Liu
J
, 
Fan
R
. Development of antibody resistance in emerging mutant strains of SARS CoV‐2: impediment for COVID‐19 vaccines.",PMC9111059
B.1.617.1,"In this review, we assess the reported mutation‐acquiring potential of coronaviruses and compare efficacies of current COVID‐19 vaccines against ‘parent’ and ‘mutant’ strains of SARS‐CoV‐2 (Kappa (B.1.617.1), Delta (B.1.617.2), and Omicron (B.1.1.529))..




Beeraka
NM
, 
Sukocheva
OA
, 
Lukina
E
, 
Liu
J
, 
Fan
R
. Development of antibody resistance in emerging mutant strains of SARS CoV‐2: impediment for COVID‐19 vaccines.",PMC9111059
B.1.36,"100
 For instance, Alpha and Beta variants were shown to contain numerous mutations in S1 subunit, including ΔRDR1 (recurrent deletion region (RDR)), ΔHV 69–70, ΔRDR2, ΔY144, ΔRDR4, and ΔLAL 242–244; whereas ΔRDR3 and ΔI210 were reported in B.1.36 (Indian Delta variant).",PMC9111059
B.1.617,"Growing number of SARS cases and deaths in India was associated with the emergence of a novel variant, B.1.617 (defined as Delta variant).",PMC9111059
B.1.427,"Recently discovered ε variant B.1.427/429 (reported in the USA along another new variant B.1.526
123
, 
124
 and B.1.617.1 (κ variant, reported in India also contain mutations in the RBD of the S‐protein, including L452R.",PMC9111059
C.37,"118

.

WHO registered the emergence of Lambda variant (also named as the C.37 lineage, designated on 14 June 2021) in many South American countries (“Tracking SARS‐CoV‐2 variants”
126
).",PMC9111059
B.1.117,"209
 The vaccine sera was shown to contain a wide range of neutralising titres of <1:4 and predominantly mitigated the mutant UK B.1.117 viral titres by 3.85‐fold.",PMC9111059
B.1.1.298,"Similarly, P.1 strain (with 3 RBD‐located mutations),
224
 B.1.1.298, and B.1.429 also exhibited a significant potential to avoid neutralisation by vaccine‐induced antibodies.",PMC9111059
B.1.429,"Similarly, P.1 strain (with 3 RBD‐located mutations),
224
 B.1.1.298, and B.1.429 also exhibited a significant potential to avoid neutralisation by vaccine‐induced antibodies.",PMC9111059
B.1.1.7,"This strain clade 201/501Y.V1, Pango lineage B.1.1.7, and GISAID clade are all recognized Alpha variant by various scientific names.",PMC9088647
B.1.351,"26
 There are three mutations of significant importance in the spike area of the lineage, B.1.351 genome, K417N, E484K, N501Y, and a further five spike mutations, L18F, D80A, D215G, R246I, A701V, that have so far raised little concern.",PMC9088647
P.1,"56
 Safety and immunogenicity study of a SARS‐CoV‐2 variant vaccine (mRNA‐1273.351) is currently ongoing sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) (NCT04785144)..

Lineage P.1, frequently referred to as the gamma variant, is a cause of COVID‐19.",PMC9088647
P.2,Gamma variant is particularly found from the other Brazilian zeta variant (Lineage P.2).,PMC9088647
B.1.427,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA).",PMC9088647
B.1.429,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA).",PMC9088647
B.1.617,"B.1.617.2 (Delta variant) is a variant of lineage B.1.617 of SARS‐CoV‐2, which is the reason for India's second wave in this pandemic of COVID‐19.",PMC9088647
B.1.617.1,"83
 The B.1.617.1 strain is 6.8‐fold more resistant to neutralization by sera from COVID‐19 convalescent and Moderna and Pfizer vaccinated patients, according to a live virus experiment.",PMC9088647
C.1.2,"92
 Researchers discovered that this new C.1.2 variant is evolving and mutating at a faster pace inside its genome than other VOC or VOI along with the Delta variant.",PMC9088647
B.1.1.529,"K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, and P681H are the most common spike protein mutations found in omicron variant.”
94
 According to preliminary laboratory findings, three doses of the Pfizer‐BioNTech COVID‐19 vaccine neutralize the Omicron variation (B.1.1.529 lineage), but two doses had much lower neutralization titers.",PMC9088647
B.1.351,"compared the efficacy of molnupiravir against different SARS-CoV-2 strains including Wuhan strain, B.1.1.7 and B.1.351 variants in the Syrian hamster infection model.",PMC9013824
B.1.1.7,"compared the efficacy of molnupiravir against different SARS-CoV-2 strains including Wuhan strain, B.1.1.7 and B.1.351 variants in the Syrian hamster infection model.",PMC9013824
B.1.1.529,"Recently, a newly emerging SARS-CoV-2 variant B.1.1.529 (Omicron) with 32 different mutation sites on the spike protein is attracting widespread attention.",PMC9013824
A.1,"The nonvariant strains include lineages A, A.1, B and B.1; the sublineages of four VOCs are aggregated with the parent lineages.",PMC9005350
B.1.621,"The sublineages of four VOCs were aggregated with the parent lineages; the designated variants of interest include lineages C.37, B.1.621 and their sublineages; other lineages include nonvariant strains and other variants.",PMC9005350
C.37,"The sublineages of four VOCs were aggregated with the parent lineages; the designated variants of interest include lineages C.37, B.1.621 and their sublineages; other lineages include nonvariant strains and other variants.",PMC9005350
B.1.1.529,"Considering that a new VOC (Omicron, B.1.1.529) was designated on 26 November 2021, we additionally downloaded all the genomic data of Omicron variants from GISAID on 31 December 2021..

To gain additional insights regarding the extent of public availability of genomic data of SARS-CoV-2 variants, we extracted country-specific, variant-specific and time-specific aggregated data on the number of SARS-CoV-2 variant cases from official websites, using the same sources as above, except for the literature source.",PMC9005350
B.1.1.529,"The emergence of the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VOC) in November 2021 coincided with the fourth wave of South Africa’s COVID-19 epidemic (Viana et al., 2022).",PMC8947963
C.1.2,"In addition to testing the variants used above, we also tested C.1.2, a variant that has several neutralization-evasive mutations and circulated at low levels during the third and fourth COVID-19 waves in South Africa (Scheepers et al., 2021), and BA.2, a sub-lineage of Omicron.",PMC8947963
B.1,"For example, the common ancestor of globally circulating SARS-CoV-2 viruses is currently no earlier than January 2020, corresponding to the base of clade 20A or lineage B.1 (https://nextstrain.org/ncov/gisaid/global).",PMC8938189
B.1.525,"The common variants are the alpha (B.1.1.7, first isolated from United Kingdom and then Q lineages) with 50% increase transmission, may increase mortality; beta (B.1.351, first isolated in South Africa followed by descendent lineages, increased immune evasiveness, 50% increased transmission); delta (B.1.617.2) first isolated in India, the variant is almost twice as contagious as earlier variants and might cause more severe illness, may evade fully vaccinated people and increase rate of infection, possibly increases mortality; gamma (P.1, first isolated in Brazil/Japan, likely increased disease transmissibility and severity and then its descendent lineages); epsilon (B.1.427 and B.1.429, first isolated in California, 20% increased risk of transmissibility); eta (B.1.525); and iota (B.1.526, first isolated in New York, reported to likely increase rate of transmission).",PMC8951506
B.1.429,"The common variants are the alpha (B.1.1.7, first isolated from United Kingdom and then Q lineages) with 50% increase transmission, may increase mortality; beta (B.1.351, first isolated in South Africa followed by descendent lineages, increased immune evasiveness, 50% increased transmission); delta (B.1.617.2) first isolated in India, the variant is almost twice as contagious as earlier variants and might cause more severe illness, may evade fully vaccinated people and increase rate of infection, possibly increases mortality; gamma (P.1, first isolated in Brazil/Japan, likely increased disease transmissibility and severity and then its descendent lineages); epsilon (B.1.427 and B.1.429, first isolated in California, 20% increased risk of transmissibility); eta (B.1.525); and iota (B.1.526, first isolated in New York, reported to likely increase rate of transmission).",PMC8951506
P.1,"The common variants are the alpha (B.1.1.7, first isolated from United Kingdom and then Q lineages) with 50% increase transmission, may increase mortality; beta (B.1.351, first isolated in South Africa followed by descendent lineages, increased immune evasiveness, 50% increased transmission); delta (B.1.617.2) first isolated in India, the variant is almost twice as contagious as earlier variants and might cause more severe illness, may evade fully vaccinated people and increase rate of infection, possibly increases mortality; gamma (P.1, first isolated in Brazil/Japan, likely increased disease transmissibility and severity and then its descendent lineages); epsilon (B.1.427 and B.1.429, first isolated in California, 20% increased risk of transmissibility); eta (B.1.525); and iota (B.1.526, first isolated in New York, reported to likely increase rate of transmission).",PMC8951506
B.1.617.2,"The common variants are the alpha (B.1.1.7, first isolated from United Kingdom and then Q lineages) with 50% increase transmission, may increase mortality; beta (B.1.351, first isolated in South Africa followed by descendent lineages, increased immune evasiveness, 50% increased transmission); delta (B.1.617.2) first isolated in India, the variant is almost twice as contagious as earlier variants and might cause more severe illness, may evade fully vaccinated people and increase rate of infection, possibly increases mortality; gamma (P.1, first isolated in Brazil/Japan, likely increased disease transmissibility and severity and then its descendent lineages); epsilon (B.1.427 and B.1.429, first isolated in California, 20% increased risk of transmissibility); eta (B.1.525); and iota (B.1.526, first isolated in New York, reported to likely increase rate of transmission).",PMC8951506
B.1.351,"The common variants are the alpha (B.1.1.7, first isolated from United Kingdom and then Q lineages) with 50% increase transmission, may increase mortality; beta (B.1.351, first isolated in South Africa followed by descendent lineages, increased immune evasiveness, 50% increased transmission); delta (B.1.617.2) first isolated in India, the variant is almost twice as contagious as earlier variants and might cause more severe illness, may evade fully vaccinated people and increase rate of infection, possibly increases mortality; gamma (P.1, first isolated in Brazil/Japan, likely increased disease transmissibility and severity and then its descendent lineages); epsilon (B.1.427 and B.1.429, first isolated in California, 20% increased risk of transmissibility); eta (B.1.525); and iota (B.1.526, first isolated in New York, reported to likely increase rate of transmission).",PMC8951506
B.1.526,"The common variants are the alpha (B.1.1.7, first isolated from United Kingdom and then Q lineages) with 50% increase transmission, may increase mortality; beta (B.1.351, first isolated in South Africa followed by descendent lineages, increased immune evasiveness, 50% increased transmission); delta (B.1.617.2) first isolated in India, the variant is almost twice as contagious as earlier variants and might cause more severe illness, may evade fully vaccinated people and increase rate of infection, possibly increases mortality; gamma (P.1, first isolated in Brazil/Japan, likely increased disease transmissibility and severity and then its descendent lineages); epsilon (B.1.427 and B.1.429, first isolated in California, 20% increased risk of transmissibility); eta (B.1.525); and iota (B.1.526, first isolated in New York, reported to likely increase rate of transmission).",PMC8951506
B.1.1.7,"The common variants are the alpha (B.1.1.7, first isolated from United Kingdom and then Q lineages) with 50% increase transmission, may increase mortality; beta (B.1.351, first isolated in South Africa followed by descendent lineages, increased immune evasiveness, 50% increased transmission); delta (B.1.617.2) first isolated in India, the variant is almost twice as contagious as earlier variants and might cause more severe illness, may evade fully vaccinated people and increase rate of infection, possibly increases mortality; gamma (P.1, first isolated in Brazil/Japan, likely increased disease transmissibility and severity and then its descendent lineages); epsilon (B.1.427 and B.1.429, first isolated in California, 20% increased risk of transmissibility); eta (B.1.525); and iota (B.1.526, first isolated in New York, reported to likely increase rate of transmission).",PMC8951506
B.1.427,"The common variants are the alpha (B.1.1.7, first isolated from United Kingdom and then Q lineages) with 50% increase transmission, may increase mortality; beta (B.1.351, first isolated in South Africa followed by descendent lineages, increased immune evasiveness, 50% increased transmission); delta (B.1.617.2) first isolated in India, the variant is almost twice as contagious as earlier variants and might cause more severe illness, may evade fully vaccinated people and increase rate of infection, possibly increases mortality; gamma (P.1, first isolated in Brazil/Japan, likely increased disease transmissibility and severity and then its descendent lineages); epsilon (B.1.427 and B.1.429, first isolated in California, 20% increased risk of transmissibility); eta (B.1.525); and iota (B.1.526, first isolated in New York, reported to likely increase rate of transmission).",PMC8951506
B.1.621.1,"Other variants being monitored (VBM) are kappa (B.1.617.1), mu (B.1.621, B.1.621.1), and zeta (P.2) and the two most recent variants of concern (VOC) are the delta (B.1.617.2 and AY lineages) and omicron (B.1.1.529 and BA lineages, which are now present in more than 150 countries, it was first isolated in South Africa and presently, the most common strain in both UK and U.S. with over 50 mutations in spike protein).",PMC8951506
B.1.617.1,"Other variants being monitored (VBM) are kappa (B.1.617.1), mu (B.1.621, B.1.621.1), and zeta (P.2) and the two most recent variants of concern (VOC) are the delta (B.1.617.2 and AY lineages) and omicron (B.1.1.529 and BA lineages, which are now present in more than 150 countries, it was first isolated in South Africa and presently, the most common strain in both UK and U.S. with over 50 mutations in spike protein).",PMC8951506
B.1.621,"Other variants being monitored (VBM) are kappa (B.1.617.1), mu (B.1.621, B.1.621.1), and zeta (P.2) and the two most recent variants of concern (VOC) are the delta (B.1.617.2 and AY lineages) and omicron (B.1.1.529 and BA lineages, which are now present in more than 150 countries, it was first isolated in South Africa and presently, the most common strain in both UK and U.S. with over 50 mutations in spike protein).",PMC8951506
B.1.1.529,"Other variants being monitored (VBM) are kappa (B.1.617.1), mu (B.1.621, B.1.621.1), and zeta (P.2) and the two most recent variants of concern (VOC) are the delta (B.1.617.2 and AY lineages) and omicron (B.1.1.529 and BA lineages, which are now present in more than 150 countries, it was first isolated in South Africa and presently, the most common strain in both UK and U.S. with over 50 mutations in spike protein).",PMC8951506
P.2,"Other variants being monitored (VBM) are kappa (B.1.617.1), mu (B.1.621, B.1.621.1), and zeta (P.2) and the two most recent variants of concern (VOC) are the delta (B.1.617.2 and AY lineages) and omicron (B.1.1.529 and BA lineages, which are now present in more than 150 countries, it was first isolated in South Africa and presently, the most common strain in both UK and U.S. with over 50 mutations in spike protein).",PMC8951506
B.1.1.389,A Costa Rican PANGOLIN lineage B.1.1.389 with a spike (S: T11171) was reported to be the cause mutation T11171 in SARS-CoV-2 genomic sequence which was believed to be responsible for almost 30% of the cases that were reported in Costa Rica back in December of 2020 [43].,PMC8951506
B.1.617.2,"In October 2021, WHO lists two VOIs (Lambda, C.37; and Mu, B.1.621) and four VOCs (Alpha, B.1.1.7; Beta, B.1.351; Gamma, P.1; and Delta, B.1.617.2).",PMC9045126
B.1.621,"In October 2021, WHO lists two VOIs (Lambda, C.37; and Mu, B.1.621) and four VOCs (Alpha, B.1.1.7; Beta, B.1.351; Gamma, P.1; and Delta, B.1.617.2).",PMC9045126
B.1.525,"SIG classifies only B.1.617.2 as VOC and all others, including also Epsilon (B.1.427 and B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1, 1.617.3), and Zeta (P.2), as VBMs.",PMC9045126
B.1.429,"SIG classifies only B.1.617.2 as VOC and all others, including also Epsilon (B.1.427 and B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1, 1.617.3), and Zeta (P.2), as VBMs.",PMC9045126
B.1.617.1,"SIG classifies only B.1.617.2 as VOC and all others, including also Epsilon (B.1.427 and B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1, 1.617.3), and Zeta (P.2), as VBMs.",PMC9045126
B.1.526,"SIG classifies only B.1.617.2 as VOC and all others, including also Epsilon (B.1.427 and B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1, 1.617.3), and Zeta (P.2), as VBMs.",PMC9045126
P.2,"SIG classifies only B.1.617.2 as VOC and all others, including also Epsilon (B.1.427 and B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1, 1.617.3), and Zeta (P.2), as VBMs.",PMC9045126
B.1.427,"SIG classifies only B.1.617.2 as VOC and all others, including also Epsilon (B.1.427 and B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1, 1.617.3), and Zeta (P.2), as VBMs.",PMC9045126
B.1.351,"Indeed, studies have shown decreased neutralization of Beta (B.1.351) by vaccine-induced antibodies (8–10).",PMC9045126
B.1.1.7,"Vaccine effectiveness studies on BNT162b2 mRNA COVID-19 vaccine have estimated 75–84% vaccine efficacy against Beta (B.1.351) infection (11, 12) compared to 90–94% efficacy against Alpha (B.1.1.7) (11, 13), 88% efficacy against Delta (B.1.617.2) (13), and 93% efficacy against non-VOC infection (12)..

As a prerequisite for making decisions on vaccine booster doses and global prevention measures, it is crucial to analyze the persistence of antibodies in geographically and demographically diverse groups of vaccinees and assess the neutralizing capacity of antibodies against VOIs and VOCs.",PMC9045126
B.1,"Amino acid substitutions and deletions present in over 20% of the NGS-obtained sequence reads are indicated for the variants used in this study: original Wuhan-like strain (B), D614G (B.1), Alpha (B.1.1.7), Eta (B.1.525), Beta (B.1.351), and Delta (B.1.617.2) variants.",PMC9045126
B.1.1.529,"At the time of this study (summer and autumn 2021), the circulating dominant variant in Finland was Delta (B.1.617.2) (15), while a new variant, Omicron (B.1.1.529), has subsequently spread rapidly after its emergence at the end of November 2021 (2).",PMC9045126
B.1.311,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
P.1,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
B.1,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
B.1.1.7,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
B.1.526,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
P.1,"So far, five variants of concern (VOCs) have been designated: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529; World Health Organization, 2022; Centers for Disease Control and Prevention, 2022).",PMC8898742
B.1.617.2,"So far, five variants of concern (VOCs) have been designated: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529; World Health Organization, 2022; Centers for Disease Control and Prevention, 2022).",PMC8898742
B.1.351,"So far, five variants of concern (VOCs) have been designated: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529; World Health Organization, 2022; Centers for Disease Control and Prevention, 2022).",PMC8898742
B.1.1.7,"So far, five variants of concern (VOCs) have been designated: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529; World Health Organization, 2022; Centers for Disease Control and Prevention, 2022).",PMC8898742
B.1.617.1,"Besides, numerous variants of interest (VOIs) were also identified, including the Epsilon (B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), et al.",PMC8898742
B.1.525,"Besides, numerous variants of interest (VOIs) were also identified, including the Epsilon (B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), et al.",PMC8898742
B.1.429,"Besides, numerous variants of interest (VOIs) were also identified, including the Epsilon (B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), et al.",PMC8898742
B.1.526,"Besides, numerous variants of interest (VOIs) were also identified, including the Epsilon (B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), et al.",PMC8898742
B.1.1.529,"The Omicron (B.1.1.529), a recently documented and highly contagious VOC harboring ∼15 RBD mutations, is spreading rapidly worldwide and has become a severe threat due to its more aggressive immune evasion ability (Dejnirattisai et al., 2022; Hoffmann et al., 2021).",PMC8898742
B.1.620,"Data are mean ± SD of greater than or equal to three replicates (six for S-614G; four for Kappa, Delta, B.1.620, and Omicron; and three for others).",PMC8898742
B.1.351,"As of 20 May 2021, there are currently 4 VOCs identified by the US SARS-CoV-2 Interagency Group (P.1, B.1.351, B.1.427, and B.1.429) that show reduced neutralization by convalescent and postvaccination sera [3]..",PMC8394820
B.1.427,"As of 20 May 2021, there are currently 4 VOCs identified by the US SARS-CoV-2 Interagency Group (P.1, B.1.351, B.1.427, and B.1.429) that show reduced neutralization by convalescent and postvaccination sera [3]..",PMC8394820
P.1,"As of 20 May 2021, there are currently 4 VOCs identified by the US SARS-CoV-2 Interagency Group (P.1, B.1.351, B.1.427, and B.1.429) that show reduced neutralization by convalescent and postvaccination sera [3]..",PMC8394820
B.1.429,"As of 20 May 2021, there are currently 4 VOCs identified by the US SARS-CoV-2 Interagency Group (P.1, B.1.351, B.1.427, and B.1.429) that show reduced neutralization by convalescent and postvaccination sera [3]..",PMC8394820
B.1.1.7,"The control group consisted of genomes sequenced by UWVL (n = 5174) during the same period as the vaccine breakthrough cohort (Supplementary Table 1)..

All 20 of 20 vaccine breakthrough cases were classified as VOCs: 8 (40%) B.1.1.7, 1 (5%) B.1.351, 2 (10%) B.1.427, 8 (40%) B.1.429, and 1 (5%) P.1 (Figure 1A, Supplementary Table 2).",PMC8394820
B.1,"Phylogenetic analysis and haplotype reconstruction were carried out with IQ-TREE software and RegressHaplo tool, respectively..

All viral strains isolated from patients infected in the nursing home were classified as B.1 lineage, clade G. Overall, 14 major single nucleotide variations (SNVs) (frequency > 80%) and 12 minor SNVs (frequency comprised between 20% and 80%) were identified with reference to the Wuhan-H-1 sequence (NC_045512.2)..

All patients presented the same 6 major SNVs: D614G in the S gene; P4715L, ntC3037T (F924F) and S5398P in Orf1ab gene; ntC26681T (F53F) in the M gene; and ntC241T in the non-coding UTR region.",PMC8855624
A.2,"In Europe, the dominant viral lineages from February to April 2020 were A.2 and A.5, while from January to May 2020 were B.1 and B.2 (Rambaut et al., 2020)..",PMC8855624
A.5,"In Europe, the dominant viral lineages from February to April 2020 were A.2 and A.5, while from January to May 2020 were B.1 and B.2 (Rambaut et al., 2020)..",PMC8855624
C.1,"The numbers on the right represent the percentage of the viral population characterized by the indicated haplotype..

As regard patient #6, a single haplotype (Hap C) was present at baseline while 2 haplotypes (Hap C and Hap C.1, with frequencies of 67% and 33%, respectively) were present on day 7 (Fig.",PMC8855624
B.1.1.529,"1
             The lineage B.1.1.529 (Omicron) harbors 15 mutations located in the RBD and 8 mutated residues in the NTD relative to the wildtype (WT) virus.",PPR453676
B.1.617.2,"Using pseudovirus-based neutralization assay, we assessed the cross-reactivity of neutralizing antibodies against the Wuhan-1 (WT), B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants.",PPR453676
B.1.351,"Using pseudovirus-based neutralization assay, we assessed the cross-reactivity of neutralizing antibodies against the Wuhan-1 (WT), B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants.",PPR453676
B.1.1.7,"Using pseudovirus-based neutralization assay, we assessed the cross-reactivity of neutralizing antibodies against the Wuhan-1 (WT), B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants.",PPR453676
B.1,The primary SARS-CoV-2 screening focused on the B.1 (Wuhan) lineage.,PMC8840742
B.1.1.7,"Interestingly, compound 1 showed a similar activity against the B.1 lineage and the B.1.1.7 (UK or Alpha variant) and B.1.617.2 (Indian or Delta variant) lineages in Vero E6 cells (Table 5).",PMC8840742
B.1.617.2,"Interestingly, compound 1 showed a similar activity against the B.1 lineage and the B.1.1.7 (UK or Alpha variant) and B.1.617.2 (Indian or Delta variant) lineages in Vero E6 cells (Table 5).",PMC8840742
B.1.617,"Using this approach, we were able to classify suites of mutations found in the RBD amplicons as consistent with Pango lineages B.1.1.7 (Alpha), B.1.351 (Beta), B.1.427/429 (Epsilon), B.1.526 (Iota), B.1.617 (Delta and Kappa), and P.1 (Gamma).",PMC8813986
P.1,"Using this approach, we were able to classify suites of mutations found in the RBD amplicons as consistent with Pango lineages B.1.1.7 (Alpha), B.1.351 (Beta), B.1.427/429 (Epsilon), B.1.526 (Iota), B.1.617 (Delta and Kappa), and P.1 (Gamma).",PMC8813986
B.1.351,"Using this approach, we were able to classify suites of mutations found in the RBD amplicons as consistent with Pango lineages B.1.1.7 (Alpha), B.1.351 (Beta), B.1.427/429 (Epsilon), B.1.526 (Iota), B.1.617 (Delta and Kappa), and P.1 (Gamma).",PMC8813986
B.1.526,"Using this approach, we were able to classify suites of mutations found in the RBD amplicons as consistent with Pango lineages B.1.1.7 (Alpha), B.1.351 (Beta), B.1.427/429 (Epsilon), B.1.526 (Iota), B.1.617 (Delta and Kappa), and P.1 (Gamma).",PMC8813986
B.1.1.7,"Using this approach, we were able to classify suites of mutations found in the RBD amplicons as consistent with Pango lineages B.1.1.7 (Alpha), B.1.351 (Beta), B.1.427/429 (Epsilon), B.1.526 (Iota), B.1.617 (Delta and Kappa), and P.1 (Gamma).",PMC8813986
B.1.427,"Using this approach, we were able to classify suites of mutations found in the RBD amplicons as consistent with Pango lineages B.1.1.7 (Alpha), B.1.351 (Beta), B.1.427/429 (Epsilon), B.1.526 (Iota), B.1.617 (Delta and Kappa), and P.1 (Gamma).",PMC8813986
B.1.1.7,"The Alpha (B.1.1.7) variant has two deletions (sites 69–70 and site 144) and seven amino acid changes (N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H) in the S protein.",PMC9047652
B.1.351,"The Beta (B.1.351) variant carries three mutations in the RBD (K417N, E484K, and N501Y), three in the N-terminal domain (D80A, D215G, and a deletion of sites 241–243), and one mutation in the S2 subunit (A701V).",PMC9047652
P.1,"The Gamma (P.1) variant has three mutations (K417T, E484K, and N501Y) in the RBD and nine other mutations (L18F, T20N, P26S, D138Y, R190S, D614G, H655Y, T1027I, and V1176F) in the S protein.",PMC9047652
B.1.617.2,"The Delta (B.1.617.2) lineage has one deletion (sites 157–158) and seven amino acid mutations in the S protein (T19R, E156G, L452R, T478K, D614G, P681R, and D950N).",PMC9047652
B.1.1.529,"The Omicron variant (B.1.1.529) was first detected in patients traveling from South Africa in November 2021, and has rapidly expanded globally.",PMC9047652
P.1,"These VOCs include the Alpha (B.1.1.7) lineage first detected in the United Kingdom (29), the Beta (B.1.351) lineage in South Africa (30), the Gamma (P.1) lineage in Brazil (31), and the Delta (B.1.617.2) lineage in India (32) (Fig.",PMC8769538
B.1.617.2,"These VOCs include the Alpha (B.1.1.7) lineage first detected in the United Kingdom (29), the Beta (B.1.351) lineage in South Africa (30), the Gamma (P.1) lineage in Brazil (31), and the Delta (B.1.617.2) lineage in India (32) (Fig.",PMC8769538
B.1.351,"These VOCs include the Alpha (B.1.1.7) lineage first detected in the United Kingdom (29), the Beta (B.1.351) lineage in South Africa (30), the Gamma (P.1) lineage in Brazil (31), and the Delta (B.1.617.2) lineage in India (32) (Fig.",PMC8769538
B.1.1.7,"These VOCs include the Alpha (B.1.1.7) lineage first detected in the United Kingdom (29), the Beta (B.1.351) lineage in South Africa (30), the Gamma (P.1) lineage in Brazil (31), and the Delta (B.1.617.2) lineage in India (32) (Fig.",PMC8769538
B.6,"(2021)n.a.0.17% = 8792 sequences worldwide (100% of several B.6 sublineages, B.1.431, B.1.104)P314LP323L-40-fold decreaseMohammad et al.",PMC8755559
B.1.431,"(2021)n.a.0.17% = 8792 sequences worldwide (100% of several B.6 sublineages, B.1.431, B.1.104)P314LP323L-40-fold decreaseMohammad et al.",PMC8755559
B.1.104,"(2021)n.a.0.17% = 8792 sequences worldwide (100% of several B.6 sublineages, B.1.431, B.1.104)P314LP323L-40-fold decreaseMohammad et al.",PMC8755559
B.1.370,"(2021)n.a.98% = 5,106,626 sequences worldwide (vs. 0.5% in first 90,000 sequences (Martin et al., 2021))V464FV473F---n.a.0.05% = 2849 sequences worldwide (peaking at 13% within B.1.370) ((Mari et al., 2021))F471 L/S/CF480 L/S/C (F476L in MHV numbering)MHV and mouse-adapted SARS-CoV5.6-fold increaseAgostini et al.",PMC8755559
B.1.108,"(2018)n.a.F471L: 14 sequencesF471S: 2 sequencesF471C: 8 sequencesN482SN491S----363 sequences worldwide, mostly B.1.108 ((Mari et al., 2021))R546PR555P---n.a.4 sequences worldwide ((Mari et al., 2021))V548LV557L (V553L in MHV numbering)MHV and Mouse-adapted SARS-CoV5.6-fold increaseAgostini et al.",PMC8755559
P.1,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta).",PPR442789
B.1.617.2,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta).",PPR442789
B.1.351,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta).",PPR442789
B.1.1.7,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta).",PPR442789
B.1.1.529,"The most recent VOC, first identified in South Africa and named Omicron (B.1.1.529), is rapidly spreading worldwide
3
.",PPR442789
B.1.529,"Their neutralization spectrum is different and complementary, with NE12 being extremely potent against an early SARS-CoV-2 strain, WA-1, as well as against the B.1.1.7/Alpha and B.1.617.2/Delta variants, and NA8 exhibiting an unusually broad spectrum of action with ultrapotent activity against the two most challenging current VOCs, B.1.351/Beta and B.1.529/Omicron.",PPR442789
B.1.617,"Residues mutated in B.1.1.7, B.1.617 and B.1.351 (g, h) or B.1.1.529/Omicron (i, j) variants of concern are colored in magenta.",PPR442789
B.1.160,"The results show that the first infection was caused by clades 20C (3 cases; 2 lineages B.1.597 and 1 lineage B.1.428.2) and 20A (1 case; lineage B.1), whereas the second infection was caused by clades 20A.EU2 (3 cases; 2 lineages B.1.160 and lineage B.1) and 20A (1 case; lineage B.1) (Figure 2
, Table S2).Figure 2Nextclade analysis of the 8 SARS-CoV-2 isolates from the 4 reinfection cases.",PMC8743858
B.1.597,"The results show that the first infection was caused by clades 20C (3 cases; 2 lineages B.1.597 and 1 lineage B.1.428.2) and 20A (1 case; lineage B.1), whereas the second infection was caused by clades 20A.EU2 (3 cases; 2 lineages B.1.160 and lineage B.1) and 20A (1 case; lineage B.1) (Figure 2
, Table S2).Figure 2Nextclade analysis of the 8 SARS-CoV-2 isolates from the 4 reinfection cases.",PMC8743858
B.1,"The results show that the first infection was caused by clades 20C (3 cases; 2 lineages B.1.597 and 1 lineage B.1.428.2) and 20A (1 case; lineage B.1), whereas the second infection was caused by clades 20A.EU2 (3 cases; 2 lineages B.1.160 and lineage B.1) and 20A (1 case; lineage B.1) (Figure 2
, Table S2).Figure 2Nextclade analysis of the 8 SARS-CoV-2 isolates from the 4 reinfection cases.",PMC8743858
B.1.428.2,"The results show that the first infection was caused by clades 20C (3 cases; 2 lineages B.1.597 and 1 lineage B.1.428.2) and 20A (1 case; lineage B.1), whereas the second infection was caused by clades 20A.EU2 (3 cases; 2 lineages B.1.160 and lineage B.1) and 20A (1 case; lineage B.1) (Figure 2
, Table S2).Figure 2Nextclade analysis of the 8 SARS-CoV-2 isolates from the 4 reinfection cases.",PMC8743858
B.1.526,"None of the variants of concern (VOC) according to the Centers for Disease Control and Prevention (CDC) https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html) carry the D614G/S477N mutations, and a single variant of interest carries S477N (B.1.526, detected in the Iota, United States in November 2020) that has reduced neutralization by convalescent and post-vaccination sera (Annavajhala et al.",PMC8743858
C.37,"In December 2021, WHO has defined five variants of concern (VOC), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages), as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)
4
.",PPR439846
P.1,"In December 2021, WHO has defined five variants of concern (VOC), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages), as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)
4
.",PPR439846
B.1.617.2,"In December 2021, WHO has defined five variants of concern (VOC), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages), as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)
4
.",PPR439846
B.1.621,"In December 2021, WHO has defined five variants of concern (VOC), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages), as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)
4
.",PPR439846
B.1.1.529,"In December 2021, WHO has defined five variants of concern (VOC), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages), as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)
4
.",PPR439846
B.1.351,"In December 2021, WHO has defined five variants of concern (VOC), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages), as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)
4
.",PPR439846
B.1.1.7,"In December 2021, WHO has defined five variants of concern (VOC), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages), as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)
4
.",PPR439846
B.1.1,"On November 24, 2021, the B.1.1.529 lineage, a descendant of the SARS-CoV-2 B.1.1 lineage
14
, was first reported to WHO as a novel variant spreading in South Africa
15
.",PPR439846
C.1.2,"For South Africa, the dynamics of Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2 and AY lineages), Omicron (B.1.1.529, BA.1, and BA.2), and the C.1.2 lineage were used.",PPR439846
B.1.177,"For the UK, the dynamics of Alpha, Beta, Delta, Omicron, and the B.1.177 lineage (including its sublineages) were used..

We prepared the input data to estimate the relative transmissibility of each viral lineage for each country.",PPR439846
B.1.617.2,"B.1.1.7 exhibits higher transmissibility, targeting a larger proportion of young people under 20 years of age [33].The third SARS-CoV-2 strain is hCoV-19/Russia/PSK-2804/2021, SARS-CoV-2 lineage B.1.617.2 (Delta).",PMC8746574
B.1.429,"Reports from several countries on the identification of VOCs (United Kingdom—B.1.1.7 [alpha], South Africa—B.1.351 [Beta], Japan/Brazil—P.1 [Gamma], India—B.1.617.2 [Delta]) and variants of interest (Peru—C.37 [Lambda], Colombia—B.1.621 [Mu], U.S.A.—B.1.427 and B.1.429 [Epsilon]), confirm amino acid substitutions and/or deletions acquired in key antigenic sites, such as the RBD and N-terminal domain (NTD) of the S protein, which facilitate viral cell entry [27–32].",PMC8722410
B.1.351,"Evidence has shown that some of these mutations (N501Y, particularly) are convergent, arisen independently in different lineages (B.1.351, P.1 [sublineage of B.1.1.28]) [26].",PMC8722410
P.1,"Evidence has shown that some of these mutations (N501Y, particularly) are convergent, arisen independently in different lineages (B.1.351, P.1 [sublineage of B.1.1.28]) [26].",PMC8722410
B.1.1.7,"Part of these efforts resulted in the creation of two highly efficacious vaccines, BNT162b2 by Pfizer–BioNTech and mRNA-1273 by Moderna; both vaccines use nanotechnology as an essential part of their design to deliver mRNA [87].Table 1Characteristics of SARS-CoV-2 nanotechnology-enabled vaccine candidates.Candidate vaccineDeveloperNanoparticle typeCompositionMolecule deliveredEncoded or delivered SARS-CoV-2 antigenClinical Trial NumberNumber of dosesVaccine efficacyCountryBNT162 (a1, b1, b2, c2)Pfizer–BioNTechLNPRNA, lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-Distearoyl-sn-glycero-3- phosphocholine [DSPC], and cholesterol), potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose [177]a1: uRNAb1: modRNAb2: modRNAc2: saRNAa1: RBDb1: RBDb2: S proteinc2: S proteinPhase I/IINCT04380701, EudraCT 2020–001,038-36Phase I/II/IIINCT04368728282% after first dose against symptomatic COVID-19 [178]b2: 95% [179]89.5% against B.1.1.7 [134]75.0% against B.1.351 [134]Germany, USmRNA-1273Moderna/NIAIDLNPMessenger ribonucleic acid (mRNA), lipids (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose[180]modRNAS proteinPhase INCT04283461Phase IIANCT04405076Phase IIINCT04470427282% after first dose against symptomatic COVID-19 [178]94.1% [178]USNVX-CoV2373NovavaxProtein subunitFull-length recombinant S protein of SARS-CoV-2 combined with saponin-based Matrix-M™ adjuvantProteinS proteinPhase I/IINCT04368988Phase IIA/BNCT04533399Phase IIIEUCTR2020-004,123–16NCT04583995NCT046118022Phase IIB 60.1% inHIV-negative; 51.0% against B.1.351 variant andHIV-negative;49.4% overall [181] Phase III96.4% against original strain; 86.3% against B.1.1.7/501Y.V1 variant;89.7% overall [182]Phase III91% against high-risk populations, 100% against original strain;90.4% overall [183]US, AustraliaLUNAR-COV19/ARCT-021ArcturusLNPLipid-enabled and unlocked nucleomonomer agent modified RNA (LUNAR) composed of50% ionizable amino lipids or MC3, 7% 1,2-distearoyl-sn-glycero-3-phosphocholine, 40% cholesterol, 3% 1,2-dimyristoyl-sn-glycerol and methoxypolyethylene glycolSelf-transcribing and replicating RNA (STARR)S proteinPhase I/IINCT04480957Phase IIANCT04728347––US, SingaporeLNP-nCoV saRNAImperial College LondonLNPIonizable cationic lipid (proprietary to Acuitas), phosphatidylcholine, cholesterol and PEG-lipidsaRNAS proteinPhase IISRCTN17072692––UK, ChinaPlant-derived virus-like particle of SARS-CoV-2Medicago/Glaxo Smith KlineVLNPSARS-CoV-2 antigenic proteinsProteinS proteinPhase INCT04450004Phase II/IIINCT04636697––Canada, USCucumber mosaic virus-derived VLNPSaibaVLNPConjugated SARS-CoV-2 antigenic proteinsProteinS proteinNo clinical trial––SwitzerlandNIAID  National Institute of Allergy and Infectious Diseases, LNP lipid nanoparticle, VLNP virus-like nanoparticle, PEG polyethylene glycol, uRNA uridine containing mRNA, modRNA N1-methyl-pseudouridine (m1Ψ) nucleoside-modified mRNA, saRNA self-amplifying mRNA, RBD receptor-binding domain.",PMC8722410
B.1.427,"directly compared SARS-CoV-2-specific CD4+ and CD8+ T cell responses of COVID-19 convalescent patients previously infected by B.1.1.7, B.1.351, P.1, and CAL.20C (B.1.427/B.1.429) viral lineages, and that were recipients of either mRNA-1273 or BNT162b2 vaccines [168].",PMC8722410
B.1.1.529,"Finally, within this evolutionary context, we discuss the recently emerged Omicron (B.1.1.529) VoC..",PMC8778387
B.1.1.7,A non-coding deletion in the B.1.1.7 SARS-CoV-2 lineage increases the translational efficiency of the accessory ORF9b (an interferon antagonist); it interacts with other non-synonymous point mutations and increases viral transmissibility [88].,PMC8778387
A.30,The emergence of the A.30 variant and its cell entry properties [191] shows that new strains may not only evade current spike-targeted vaccines but also evolve a preference for other cell types that would promote extrapulmonary spread.,PMC8778387
B.1.351,"In the South Africa Phase 2b trial, NVX-CoV2373 was seen to be 60% efficacy in prevention of mild, moderate, and serious disease in 94% of the study population but only 50% effective against the SA variant B.1.351, mirroring results with the other vaccines.105 In May 2021, further results from trials in South Africa confirmed the impact the B.1.351 variant, circulating at the time of the trial, had on infection, generating an overall efficacy against this South Africa variant of only 50%.106 In June 2021, Novavax published an updated analysis of the UK Phase 3 trial conducted at 33 sites around the UK in adults with an age range of 19–84 years, concluding“…the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant… no hospitalizations or deaths were reported among the 10 cases in the vaccine group.",PMC8989432
B.1.1.7,"In the South Africa Phase 2b trial, NVX-CoV2373 was seen to be 60% efficacy in prevention of mild, moderate, and serious disease in 94% of the study population but only 50% effective against the SA variant B.1.351, mirroring results with the other vaccines.105 In May 2021, further results from trials in South Africa confirmed the impact the B.1.351 variant, circulating at the time of the trial, had on infection, generating an overall efficacy against this South Africa variant of only 50%.106 In June 2021, Novavax published an updated analysis of the UK Phase 3 trial conducted at 33 sites around the UK in adults with an age range of 19–84 years, concluding“…the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant… no hospitalizations or deaths were reported among the 10 cases in the vaccine group.",PMC8989432
B.1.617.2,"The development of variants that can elude the antibody repertoire generated by the wildtype virus would seem to suggest a rethinking of vaccine compositions, a not too unfamiliar story in the influenza vaccine arena and suggested by the observations of Nussenzweig and others.114 But a multicenter study in the UK, coordinated by Public Health England and published on July 21, 2021, offered a somewhat more optimistic message when comparing vaccine effectiveness against either the alpha (B.1.1.7) or the delta (B.1.617.2) variants.",PMC8989432
B.1.351,"Of particular interest in B.1.1.7, B.1.351, B.1.617.2, P.1 are the mutations affecting the Spike protein and Receptor Binding Domain, as they directly affect infectivity and susceptibility to neutralization.",PMC8713537
B.1.617.2,"Of particular interest in B.1.1.7, B.1.351, B.1.617.2, P.1 are the mutations affecting the Spike protein and Receptor Binding Domain, as they directly affect infectivity and susceptibility to neutralization.",PMC8713537
P.1,"Of particular interest in B.1.1.7, B.1.351, B.1.617.2, P.1 are the mutations affecting the Spike protein and Receptor Binding Domain, as they directly affect infectivity and susceptibility to neutralization.",PMC8713537
B.1.1.7,"Of particular interest in B.1.1.7, B.1.351, B.1.617.2, P.1 are the mutations affecting the Spike protein and Receptor Binding Domain, as they directly affect infectivity and susceptibility to neutralization.",PMC8713537
B.1.621,"For example, we detected the Mu (B.1.621) variant via wastewater genomic surveillance on July 27th, nearly four weeks prior to its first detection through clinical genomic surveillance on campus, on August 23rd (Figure 4A,C).",PPR436978
B.1.1.529,"In more recent data, we identified the Omicron variant (B.1.1.529 and descendants) at an abundance of near 1% on November 27th, more than 1 week prior to the first clinical detection in San Diego on December 8th (Extended Data Table 2).",PPR436978
B.1.617.2,"To confirm these findings, we applied our VOC qPCR panel to the same samples and consistently detected two mutations associated with the Omicron variant (DelHV69/70 and N501Y) in samples detected after November 27th, while neither was detected in samples from earlier in November..

To test if Freyja continues to provide representative estimates of lineage prevalence for mixtures containing closely related lineages, we analyzed the rise of the Delta variant (B.1.617.2) and its sublineages (AY.",PPR436978
P.1,"*), along with low but persistent levels of the P.1 (Gamma) variant.",PPR436978
B.1.1.318,"However, we also found occasions when rarer lineages, like B.1.1.318, were detected in clinical samples but not in wastewater.",PPR436978
B.1.351,"(A, B.1.1.7, B.1.351, P.1, or B.1.617.2)..",PPR436978
B.1.1.7,"(A, B.1.1.7, B.1.351, P.1, or B.1.617.2)..",PPR436978
B.1.1.529,"In November 2021 a new SARS-CoV-2 variant, named Omicron (Pango lineage B.1.1.529), was identified as a variant of concern (VOC).",PPR436126
B.1.2,"A total of 2/10 and 0/20 individuals infected with WT (B.1 and B.1.2) variants, respectively, had a response above the threshold against Omicron, whereas 2/5 and 2/2 individuals infected with Alpha (B.1.1.7) and Beta (B.1.351) variants, respectively, were above threshold.",PPR436126
B.1,"A total of 2/10 and 0/20 individuals infected with WT (B.1 and B.1.2) variants, respectively, had a response above the threshold against Omicron, whereas 2/5 and 2/2 individuals infected with Alpha (B.1.1.7) and Beta (B.1.351) variants, respectively, were above threshold.",PPR436126
B.1.1.7,"A total of 2/10 and 0/20 individuals infected with WT (B.1 and B.1.2) variants, respectively, had a response above the threshold against Omicron, whereas 2/5 and 2/2 individuals infected with Alpha (B.1.1.7) and Beta (B.1.351) variants, respectively, were above threshold.",PPR436126
B.1.351,"A total of 2/10 and 0/20 individuals infected with WT (B.1 and B.1.2) variants, respectively, had a response above the threshold against Omicron, whereas 2/5 and 2/2 individuals infected with Alpha (B.1.1.7) and Beta (B.1.351) variants, respectively, were above threshold.",PPR436126
B.1.617,"Convalescent sera from individuals infected with Delta (B.1.617 and AY.14/.25/.44/.47/.62/.74/.119) variants generally had higher neutralization titers against Delta (2.8 to 13.5-fold) compared to WT, indicating more focused antibody responses to epitopes in the Delta spike.",PPR436126
B.1.617.2,"However, a total of 6/7 individuals infected with the B.1.617.2 variant and 9/10 individuals infected with an AY variant had titers above threshold against Omicron..

We applied antigenic cartography to explore how the convalescent and post-vaccination sera distinguish the different spike antigens.",PPR436126
B.1.1.1,"An original strain of SARS-CoV-2 (Pango lineage B/B.1) relinquished its global dominance to the Alpha (B.1.1.1, first described in the United Kingdom) around April 2021.",PMC8692065
B.1,"An original strain of SARS-CoV-2 (Pango lineage B/B.1) relinquished its global dominance to the Alpha (B.1.1.1, first described in the United Kingdom) around April 2021.",PMC8692065
B.1.1.529,"A newly emerged SARS-CoV-2 variant B.1.1.529 has worried the health policy makers worldwide due to the presence of a large number of mutations in its genomic sequence, especially in the spike protein region.",PPR435130
B.1,"4)..

Our analysis of the SARS-CoV-2 genomic sequences coupled with epidemiological data from SA unravels multiple observations regarding host-virus interactions which may help predicting the epidemiological potentials of the Omicron..

Our analyses showed that Omicron has significantly greater variantions than current VOCs and VOIs in comparisons with the wild type strains (Wuhan strain and B.1).",PPR435130
B.1.621,"P681H is characteristically present in multiple VOCs/VOIs such as B.1.1.7, P.1, Q.1 and B.1.621 lineage variants
30
.",PPR435130
B.1.1.7,"P681H is characteristically present in multiple VOCs/VOIs such as B.1.1.7, P.1, Q.1 and B.1.621 lineage variants
30
.",PPR435130
P.1,"P681H is characteristically present in multiple VOCs/VOIs such as B.1.1.7, P.1, Q.1 and B.1.621 lineage variants
30
.",PPR435130
Q.1,"P681H is characteristically present in multiple VOCs/VOIs such as B.1.1.7, P.1, Q.1 and B.1.621 lineage variants
30
.",PPR435130
P.1,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
B.1.617.2,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
B.1.1.529,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
B.1.351,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
B.1.1.7,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
A.1,"The first samples sequenced in March and April 2020 were similar to strains at the root of the pandemic (lineage A and sublineages) and are classified as A.1, A.3 etc., collectively designated as Pango lineage “other” in Figure 1A and C. The “other” category also contains B lineages and was used for any lineage with 12 or less representatives.",PPR432949
A.3,"The first samples sequenced in March and April 2020 were similar to strains at the root of the pandemic (lineage A and sublineages) and are classified as A.1, A.3 etc., collectively designated as Pango lineage “other” in Figure 1A and C. The “other” category also contains B lineages and was used for any lineage with 12 or less representatives.",PPR432949
B.1,The large European lineage B.1 was detected in six samples in April 2020.,PPR432949
B.1.526,"The former VOC, B.1.526 (Iota), which is a lineage predominantly circulating in New York, was detected from March to June 2021 in 29 samples.",PPR432949
B.1.351,"While over ∼1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a, 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a, 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PMC8673750
B.1.617.2,"While over ∼1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a, 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a, 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PMC8673750
P.1,"While over ∼1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a, 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a, 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PMC8673750
B.1.1.7,"While over ∼1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a, 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a, 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PMC8673750
B.1.525,"Moreover, since many antibodies that bind S are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι), and B.1.617.1 (κ).",PMC8673750
B.1.429,"Moreover, since many antibodies that bind S are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι), and B.1.617.1 (κ).",PMC8673750
B.1.617.1,"Moreover, since many antibodies that bind S are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι), and B.1.617.1 (κ).",PMC8673750
B.1.526,"Moreover, since many antibodies that bind S are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι), and B.1.617.1 (κ).",PMC8673750
B.1.617,"The importance of this position is further underscored by the convergent appearance of the E484Q mutation in the Indian B.1.617 lineage (Table 2)..

A series of other mutations have been identified in the RBD [6] that provide resistance to nAbs and plasma from convalescent or vaccinated individuals.",PMC8705434
B.1.1.7,"They were initially defined by the date of first appearance and their level of concern (i.e., VOC-202012/01), or by any of the mutations they bear (i.e., 20I/501Y.V1) or according to their genetic Pango lineage (i.e., B.1.1.7).",PMC8705434
B.1.351,"Towards the end of 2020, rising concern was reported in South Africa regarding lineage B.1.351 [104,105], which bears some worrying mutations in the spike gene—D614G, N501Y, E484K, and K417N (Figure 2)—with proven functional significance [129,179,180].",PMC8705434
B.1,"This Gamma variant became abundant in all of America and Europe (https://cov-lineages.org, accessed on 23 October 2021)..

Like many other B.1 lineages, the Gamma variant also has the B.1-defining mutation, D614G, related to increased spike on the virus surface [79].",PMC8705434
B.1.617.3,"It is divided into three sublineages [129,168]: B.1.617.1 (Kappa variant), B.1.617.2 (Delta variant) and B.1.617.3 (Table 2).",PMC8705434
B.1.617.2,"It is divided into three sublineages [129,168]: B.1.617.1 (Kappa variant), B.1.617.2 (Delta variant) and B.1.617.3 (Table 2).",PMC8705434
B.1.617.1,"It is divided into three sublineages [129,168]: B.1.617.1 (Kappa variant), B.1.617.2 (Delta variant) and B.1.617.3 (Table 2).",PMC8705434
B.1.427,"Among these is the Epsilon variant, which comprises two lineages (B.1.427/B.1.429) and was identified in California in January 2021.",PMC8705434
B.1.525,"The variant Eta corresponds to lineage B.1.525, first appearing towards the end of 2020 in Nigeria.",PMC8705434
P.2,"The variant Zeta, or lineage P.2, which independently acquired the E484K mutation, has been detected in many locations in Brazil, including in Manaus [132].",PMC8705434
P.1,"Unlike P.1 (Gamma), P.2 was removed from the VOI list due to declining prevalence and very few detections..",PMC8705434
P.3,"That is the case, for example, of variants Iota (lineage B.1.526), identified in New York in late December 2020 [188] and Theta (lineage P.3), both bearing mutations E484K and D614G, among others [89,90,91,112,171].",PMC8705434
B.1.526,"That is the case, for example, of variants Iota (lineage B.1.526), identified in New York in late December 2020 [188] and Theta (lineage P.3), both bearing mutations E484K and D614G, among others [89,90,91,112,171].",PMC8705434
B.1.1.7,"Gradually, different variants e.g., GRY (B.1.1.7)/α variant [24] and mink variants [25] have also been detected in animal populations.",PMC8673647
B.1.617.2,"And most recently in a zoo in Hyderabad, India, eight Asiatic lions are found to be infected by delta variant, (B.1.617.2)..

To date, SARS-CoV-2 has been identified in mink (Neovison vison) farms from Denmark, the Netherlands, France, Spain, Sweden, Canada, Greece, Lithuania, Poland, Latvia, Italy, and the USA [37].",PMC8673647
B.1.621.1,"Finally, evolutionary pattern of Mu variant (VOI Mu GH (B.1.617.2 + B.1.621.1)) also expressed the similar types of genetic relatedness as other variants (Fig 6)..

Blue dots denote Alpha sequences, lime (Gamma), maroon (Delta), teal (Beta), lambda (Navy), green (Mu).",PMC8673647
A.21,"Bat strains were found to be under lineage A.3, A.21, A.23, B.1.177, B.4, and clade O, S. On the other hand, Malayan pangolin strains belong to lineage A, B.5, and B.15, clade O and S. Fig 10 illustrates the overall species variation under each clade.",PMC8673647
B.4,"Bat strains were found to be under lineage A.3, A.21, A.23, B.1.177, B.4, and clade O, S. On the other hand, Malayan pangolin strains belong to lineage A, B.5, and B.15, clade O and S. Fig 10 illustrates the overall species variation under each clade.",PMC8673647
B.5,"Bat strains were found to be under lineage A.3, A.21, A.23, B.1.177, B.4, and clade O, S. On the other hand, Malayan pangolin strains belong to lineage A, B.5, and B.15, clade O and S. Fig 10 illustrates the overall species variation under each clade.",PMC8673647
A.23,"Bat strains were found to be under lineage A.3, A.21, A.23, B.1.177, B.4, and clade O, S. On the other hand, Malayan pangolin strains belong to lineage A, B.5, and B.15, clade O and S. Fig 10 illustrates the overall species variation under each clade.",PMC8673647
B.1.177,"Bat strains were found to be under lineage A.3, A.21, A.23, B.1.177, B.4, and clade O, S. On the other hand, Malayan pangolin strains belong to lineage A, B.5, and B.15, clade O and S. Fig 10 illustrates the overall species variation under each clade.",PMC8673647
B.15,"Bat strains were found to be under lineage A.3, A.21, A.23, B.1.177, B.4, and clade O, S. On the other hand, Malayan pangolin strains belong to lineage A, B.5, and B.15, clade O and S. Fig 10 illustrates the overall species variation under each clade.",PMC8673647
A.3,"Bat strains were found to be under lineage A.3, A.21, A.23, B.1.177, B.4, and clade O, S. On the other hand, Malayan pangolin strains belong to lineage A, B.5, and B.15, clade O and S. Fig 10 illustrates the overall species variation under each clade.",PMC8673647
B.1.2,"In the tiger, we found mainly clade GH (85.7%) and GRY (14.3%) whereas in gorilla 66.7% were under clade GRY and 33.3% were under clade G. In ferret and leopard cat, clade G and GRY were found, respectively (S1 Fig)..

B.1.1, B.1.1.7, B.1.177, B.1.2, B.1.243, B.43 lineages were found in the dog.",PMC8673647
B.43,"In the tiger, we found mainly clade GH (85.7%) and GRY (14.3%) whereas in gorilla 66.7% were under clade GRY and 33.3% were under clade G. In ferret and leopard cat, clade G and GRY were found, respectively (S1 Fig)..

B.1.1, B.1.1.7, B.1.177, B.1.2, B.1.243, B.43 lineages were found in the dog.",PMC8673647
B.1.243,"In the tiger, we found mainly clade GH (85.7%) and GRY (14.3%) whereas in gorilla 66.7% were under clade GRY and 33.3% were under clade G. In ferret and leopard cat, clade G and GRY were found, respectively (S1 Fig)..

B.1.1, B.1.1.7, B.1.177, B.1.2, B.1.243, B.43 lineages were found in the dog.",PMC8673647
B.1,"In the cat, the predominant lineage type was B.1 (10.5%) and α variant lineage B.1.1.7 prevalence was 2.6%.",PMC8673647
B.1.258,The α variant was also detected in leopard cats but in ferret B.1.258 lineage was identified.,PMC8673647
B.1.1.298,"Mink strains were mostly under lineage B.1.1.298 (43.8%) followed by B.1.8 (21.7%), B.1 (16.5%), B.1.22 (6.7%) (Fig 11)..",PMC8673647
B.1.8,"Mink strains were mostly under lineage B.1.1.298 (43.8%) followed by B.1.8 (21.7%), B.1 (16.5%), B.1.22 (6.7%) (Fig 11)..",PMC8673647
B.1.22,"Mink strains were mostly under lineage B.1.1.298 (43.8%) followed by B.1.8 (21.7%), B.1 (16.5%), B.1.22 (6.7%) (Fig 11)..",PMC8673647
B.1.1.529,"The WHO has classified this lineage (previously known as Pango lineage B.1.1.529) as a Variant of Concern (VOC) on November 26, 2021 
1
.",PPR433169
B.1,"The Spike protein contained 32 changes, when compared to the D614G strain (belonging to the basal B.1 lineage) used here as a reference, including 7 changes in the N terminal domain (NTD), with substitutions, deletions and a three amino-acid insertion (A67V, Δ69-70, T95I, G142D, Δ141-143, Δ211L212I, Ins214EPE), 15 mutations in the RBD (G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R and N501Y, Y505H) the T574K mutation, 3 mutations close to the furin cleavage site (H655Y, N679K and P681H) and 6 in the S2 region (N764K, D796Y, N856K, Q954H, N969, L981F) (Fig.",PPR433169
B.1.529,"A subset of complete and high coverage sequences, as indicated in GISAID, assigned to lineages B.1.529 or BA.1 and BA.2 were randomly subsampled.",PPR433169
B.1.617,"For instance, B.1.617.1 is the first-named descendant of B.1.617 and in turn, it is the 617th named descendant of lineage B.1 and so on.",PMC8669229
B.1,"For instance, B.1.617.1 is the first-named descendant of B.1.617 and in turn, it is the 617th named descendant of lineage B.1 and so on.",PMC8669229
B.1.617.1,"For instance, B.1.617.1 is the first-named descendant of B.1.617 and in turn, it is the 617th named descendant of lineage B.1 and so on.",PMC8669229
B.1.526.1,"In conclusion, the Pango system provides a detailed and more informative outbreak cluster information while the other two systems are simpler..

Variants of B.1.526, B.1.526.1, B.1.527, and P.2 lineages have been classified under VOI and those belonging to B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.617, and P.1 lineages have been categorized under VOC [16].",PMC8669229
B.1.429,"In conclusion, the Pango system provides a detailed and more informative outbreak cluster information while the other two systems are simpler..

Variants of B.1.526, B.1.526.1, B.1.527, and P.2 lineages have been classified under VOI and those belonging to B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.617, and P.1 lineages have been categorized under VOC [16].",PMC8669229
B.1.527,"In conclusion, the Pango system provides a detailed and more informative outbreak cluster information while the other two systems are simpler..

Variants of B.1.526, B.1.526.1, B.1.527, and P.2 lineages have been classified under VOI and those belonging to B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.617, and P.1 lineages have been categorized under VOC [16].",PMC8669229
P.1,"In conclusion, the Pango system provides a detailed and more informative outbreak cluster information while the other two systems are simpler..

Variants of B.1.526, B.1.526.1, B.1.527, and P.2 lineages have been classified under VOI and those belonging to B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.617, and P.1 lineages have been categorized under VOC [16].",PMC8669229
B.1.351,"In conclusion, the Pango system provides a detailed and more informative outbreak cluster information while the other two systems are simpler..

Variants of B.1.526, B.1.526.1, B.1.527, and P.2 lineages have been classified under VOI and those belonging to B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.617, and P.1 lineages have been categorized under VOC [16].",PMC8669229
B.1.526,"In conclusion, the Pango system provides a detailed and more informative outbreak cluster information while the other two systems are simpler..

Variants of B.1.526, B.1.526.1, B.1.527, and P.2 lineages have been classified under VOI and those belonging to B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.617, and P.1 lineages have been categorized under VOC [16].",PMC8669229
B.1.1.7,"In conclusion, the Pango system provides a detailed and more informative outbreak cluster information while the other two systems are simpler..

Variants of B.1.526, B.1.526.1, B.1.527, and P.2 lineages have been classified under VOI and those belonging to B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.617, and P.1 lineages have been categorized under VOC [16].",PMC8669229
P.2,"In conclusion, the Pango system provides a detailed and more informative outbreak cluster information while the other two systems are simpler..

Variants of B.1.526, B.1.526.1, B.1.527, and P.2 lineages have been classified under VOI and those belonging to B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.617, and P.1 lineages have been categorized under VOC [16].",PMC8669229
B.1.427,"In conclusion, the Pango system provides a detailed and more informative outbreak cluster information while the other two systems are simpler..

Variants of B.1.526, B.1.526.1, B.1.527, and P.2 lineages have been classified under VOI and those belonging to B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.617, and P.1 lineages have been categorized under VOC [16].",PMC8669229
B.1.417,"Currently, the VOCs B.1.1.7, B.1.351, B.1.1.28, and B.1.617.2 are being referred to as alpha, beta, gamma, and Delta variants respectively while VOI such as B.1.417/B.1.419 are labeled as epsilon, B.1.525 as eta, B.1.617.1 as kappa, and so on [22]..

Antiviral pharmaceuticals and immunotherapies are the main therapeutic and prophylactic approaches currently employed to treat COVID-19.",PMC8669229
B.1.525,"Currently, the VOCs B.1.1.7, B.1.351, B.1.1.28, and B.1.617.2 are being referred to as alpha, beta, gamma, and Delta variants respectively while VOI such as B.1.417/B.1.419 are labeled as epsilon, B.1.525 as eta, B.1.617.1 as kappa, and so on [22]..

Antiviral pharmaceuticals and immunotherapies are the main therapeutic and prophylactic approaches currently employed to treat COVID-19.",PMC8669229
B.1.1.28,"Currently, the VOCs B.1.1.7, B.1.351, B.1.1.28, and B.1.617.2 are being referred to as alpha, beta, gamma, and Delta variants respectively while VOI such as B.1.417/B.1.419 are labeled as epsilon, B.1.525 as eta, B.1.617.1 as kappa, and so on [22]..

Antiviral pharmaceuticals and immunotherapies are the main therapeutic and prophylactic approaches currently employed to treat COVID-19.",PMC8669229
B.1.617.2,"Currently, the VOCs B.1.1.7, B.1.351, B.1.1.28, and B.1.617.2 are being referred to as alpha, beta, gamma, and Delta variants respectively while VOI such as B.1.417/B.1.419 are labeled as epsilon, B.1.525 as eta, B.1.617.1 as kappa, and so on [22]..

Antiviral pharmaceuticals and immunotherapies are the main therapeutic and prophylactic approaches currently employed to treat COVID-19.",PMC8669229
B.1.258,"This is the second most commonly observed mutation that was first reported in Scotland and later emerged as B.1.258 lineage, detected in more than 30 countries worldwide [35].",PMC8669229
B.1.36,Recent data suggest the widespread occurrence of N440K (also known as B.1.36) mutation in variants worldwide.,PMC8669229
B.1.298,"Also known as ‘Cluster 5 variant’ or B.1.298, variants carrying this substitution involves a total of 5 mutations in the S protein: a deletion at positions H69-V70 and substitutions at Y453F, I692V, and M1229I (Figs.",PMC8669229
B.1.177,"Variant B.1.177 (20E.EU1) is characterized by A222V substitution and was first reported in Spain, which later became prevalent in more than 65% of all sequenced genomes in England in November 2020 [41].",PMC8669229
B.1.426,"Similar to B.1.426/B.1.427 lineage, substitution of L452R abolishes neutralizing activity of RBD-directed mAbs and helps in escape from HLA-24-restricted cellular immunity [6, 81].",PMC8669229
B.1.351,"The viral variants as well as their characterizing mutations are color coded.Table 6Most studied amino acid mutations that characterize SARS-2 variants and their potential roles in viral fitness.MutantDescriptionRoleL18FLeucine-to-phenylalanineReduce neutralization by some antibodies.ΔH69–70Histidine deletionChange the conformation of an exposed NTD loop and associated with increasing infectivity.ΔY144Tyrosine deletionSeem to change the conformation of the N3 NTD loop (amino acid positions 140–156) and reduces antibody binding affinity.K417NLysine-to- asparagineReduces virus sensitivity to antibodies and increases binding affinity to human ACE2 receptor.N439KAsparagine-to-lysineIncrease the binding affinity for the ACE2 receptor and reduces the neutralizing activity.L452RLeucine-to-arginineConfer stronger affinity of the S protein for the ACE2 receptor.T478KThreonine-to-lysineMay enhances viral virulence as it was found in the rapidly rising SARS in Mexico and South America.E484KGlutamic acid-to-lysineAn escape mutation: immune dominant spike protein residue with various substitutions; facilitating escape from several mAbs and evade the immune system.E484QGlutamic acid-to-glutamineMay be functionally similar to the antibody-escape mutation E484K.N501YAsparagine to tyrosineIncreases in human ACE2 binding affinity conferred by a single RBD mutation.D614GAspartic acid-to-glycineFound in highly transmissible lineages like B.1.1.7, B.1.351 and P.1.",PMC8667566
B.1.1.7,"The viral variants as well as their characterizing mutations are color coded.Table 6Most studied amino acid mutations that characterize SARS-2 variants and their potential roles in viral fitness.MutantDescriptionRoleL18FLeucine-to-phenylalanineReduce neutralization by some antibodies.ΔH69–70Histidine deletionChange the conformation of an exposed NTD loop and associated with increasing infectivity.ΔY144Tyrosine deletionSeem to change the conformation of the N3 NTD loop (amino acid positions 140–156) and reduces antibody binding affinity.K417NLysine-to- asparagineReduces virus sensitivity to antibodies and increases binding affinity to human ACE2 receptor.N439KAsparagine-to-lysineIncrease the binding affinity for the ACE2 receptor and reduces the neutralizing activity.L452RLeucine-to-arginineConfer stronger affinity of the S protein for the ACE2 receptor.T478KThreonine-to-lysineMay enhances viral virulence as it was found in the rapidly rising SARS in Mexico and South America.E484KGlutamic acid-to-lysineAn escape mutation: immune dominant spike protein residue with various substitutions; facilitating escape from several mAbs and evade the immune system.E484QGlutamic acid-to-glutamineMay be functionally similar to the antibody-escape mutation E484K.N501YAsparagine to tyrosineIncreases in human ACE2 binding affinity conferred by a single RBD mutation.D614GAspartic acid-to-glycineFound in highly transmissible lineages like B.1.1.7, B.1.351 and P.1.",PMC8667566
P.1,"The WHO designates the Alpha (B.1.1.7), Beta (B.1.351, Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants as variants of concern (VOC) to help track SARS-CoV-2 genetic lineages.",PPR431823
B.1.617.2,"The WHO designates the Alpha (B.1.1.7), Beta (B.1.351, Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants as variants of concern (VOC) to help track SARS-CoV-2 genetic lineages.",PPR431823
B.1.1.529,"The WHO designates the Alpha (B.1.1.7), Beta (B.1.351, Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants as variants of concern (VOC) to help track SARS-CoV-2 genetic lineages.",PPR431823
B.1.351,"The WHO designates the Alpha (B.1.1.7), Beta (B.1.351, Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants as variants of concern (VOC) to help track SARS-CoV-2 genetic lineages.",PPR431823
B.1.1.7,"The WHO designates the Alpha (B.1.1.7), Beta (B.1.351, Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants as variants of concern (VOC) to help track SARS-CoV-2 genetic lineages.",PPR431823
B.1.617.1,The Kappa variant (B.1.617.1) originated from the same lineage as the Delta and is categorized as variants under monitoring (VUM) based on the epidemiological significance (15).,PPR431823
B.1.621,The newly recognized Mu variant of interest (B.1.621) is described as 10.6-fold and 9.1-fold more resistant to sera from COVID convalescents or BNT162b2-vaccinated individuals respectively compared to the ancestral wild type virus (16)..,PPR431823
B.1.526,"Time series US Variant and Mutation data from the GISAID database..

Primary outcomes were statistical modeling of US state deviations from epidemiological predictions, percentage of COVID-19 variants, percentage of COVID-19 mutations, and reported SARS-CoV-2 infections..

Deviations in epidemiological predictions of COVID-19 case declines in the North Eastern US in March 2021 were highly positively related to percentage of B.1.526 (Iota) lineage (p < 10e − 7) and B.1.526.2 (p < 10 − 8) and the T95I mutation (p < 10e − 9).",PPR429683
B.1.526.2,"Time series US Variant and Mutation data from the GISAID database..

Primary outcomes were statistical modeling of US state deviations from epidemiological predictions, percentage of COVID-19 variants, percentage of COVID-19 mutations, and reported SARS-CoV-2 infections..

Deviations in epidemiological predictions of COVID-19 case declines in the North Eastern US in March 2021 were highly positively related to percentage of B.1.526 (Iota) lineage (p < 10e − 7) and B.1.526.2 (p < 10 − 8) and the T95I mutation (p < 10e − 9).",PPR429683
B.1.429,"They were related inversely to B.1.427 and B.1.429 (Epsilon) and there was a trend for association with B.1.1.7 (Alpha) lineage..

Deviations from accurate predictive models are useful for investigating potential immune escape of COVID-19 variants at the population level.",PPR429683
B.1.1.7,"They were related inversely to B.1.427 and B.1.429 (Epsilon) and there was a trend for association with B.1.1.7 (Alpha) lineage..

Deviations from accurate predictive models are useful for investigating potential immune escape of COVID-19 variants at the population level.",PPR429683
B.1.427,"They were related inversely to B.1.427 and B.1.429 (Epsilon) and there was a trend for association with B.1.1.7 (Alpha) lineage..

Deviations from accurate predictive models are useful for investigating potential immune escape of COVID-19 variants at the population level.",PPR429683
B.1.617.2,"The T95I mutation which is present in the B.1.526, B.1.526.2, and B.1.617.2(Delta) lineages in the US warrants further investigation as a mutation of concern..",PPR429683
P.1,"It can be expected that so long as transmission rates are high, new variants will continue to emerge, and each must be treated as a new threat with the potential to escape prior immunity..

Other variants of concern, which included the P.1 and P.2 (Zeta) lineages (Brazilian origin) and the B.1.351 (Beta, S. African origin) were not in the US in significant enough numbers to pose an immediate threat.",PPR429683
B.1.351,"It can be expected that so long as transmission rates are high, new variants will continue to emerge, and each must be treated as a new threat with the potential to escape prior immunity..

Other variants of concern, which included the P.1 and P.2 (Zeta) lineages (Brazilian origin) and the B.1.351 (Beta, S. African origin) were not in the US in significant enough numbers to pose an immediate threat.",PPR429683
P.2,"It can be expected that so long as transmission rates are high, new variants will continue to emerge, and each must be treated as a new threat with the potential to escape prior immunity..

Other variants of concern, which included the P.1 and P.2 (Zeta) lineages (Brazilian origin) and the B.1.351 (Beta, S. African origin) were not in the US in significant enough numbers to pose an immediate threat.",PPR429683
B.1.526.1,"The variants B.1.526, B.1.526.1, and B.1.526.2 (NYC origins) had the most significant positive relationships to case numbers, p < 2e−7 and p < 8e–9, respectively for March Fig 2.",PPR429683
B.1.617,"These mutations are part of the B.1.427 and B.1.429 variants..

We also found that less than 30 cases of B.1.617 were present in the US during this time period and that both B.1.526 and B.1.526.2 variants share the T95I mutation with B.1.617.",PPR429683
B.1.1.526,"We support this conclusion by also preforming relative importance analysis and showing that in many of the North-Eastern states B.1.526 family of variants are the most influential variants..

We have also explored the relationship between mutations and variant prevalence and found that the mutations present in the variants B.1.1.526 family of variants and B.1.1.7 seems to show a positive correlation with the number of cases in each state..",PPR429683
B.1.519,The west coast has B.1.519 as the dominant variant and B.1.1.7 has its presence in six states.,PPR429683
B.1,The None represents B.1 which is the original strain.,PPR429683
B.1.351,The B.1.351 variant was first detected in South Africa in October 2020 and the United States in late January 2021.,PMC8673343
B.1.1.28,The P.1 variant initially was identified on routine screening of travelers from Brazil to Japan and is related to the B.1.1.28 variant lineage.,PMC8673343
P.1,The P.1 variant initially was identified on routine screening of travelers from Brazil to Japan and is related to the B.1.1.28 variant lineage.,PMC8673343
B.1.617.2,The Delta variant (B.1.617.2) has become the predominant variant in much of the world during the second half of 2021.,PMC8673343
B.1.1.28,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
B.1.617.2,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
B.1.351,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
B.1.1.7,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
B.1.427,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
B.1.429,"Mutations S13I and W152C for B1.427/B.1.429 synergistically reduce 4A8 binding, which recapitulates recent findings of nAb evasion through novel disulfide bond formation and NTD structural remodeling (McCallum et al., 2021a).",PMC8675084
B.1.525,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion.",PMC8648019
P.1,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion.",PMC8648019
B.1.617.2,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion.",PMC8648019
B.1,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion.",PMC8648019
B.1.351,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion.",PMC8648019
B.1.1.7,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion.",PMC8648019
B.1.177.75,During SARS-CoV-2 diagnostic activities performed in Abruzzo region (central Italy) several strains belonging to the B.1.177.75 lineage tested negative for the N gene but positive for the ORF1ab and S genes (+/+/- pattern) by the TaqPath COVID-19 CE-IVD RT-PCR Kit manufactured by Thermofisher.,PMC8205086
B.1.351,"Within these lineages, B.1.1.7, P.1, and B.1.351 gained international concern as for their enhanced transmission capabilities, mortality rates and/or reduced neutralization of specific immunity stimulated by previous infections or by vaccines against them [7]..",PMC8205086
P.1,"Within these lineages, B.1.1.7, P.1, and B.1.351 gained international concern as for their enhanced transmission capabilities, mortality rates and/or reduced neutralization of specific immunity stimulated by previous infections or by vaccines against them [7]..",PMC8205086
B.1.1.7,"Within these lineages, B.1.1.7, P.1, and B.1.351 gained international concern as for their enhanced transmission capabilities, mortality rates and/or reduced neutralization of specific immunity stimulated by previous infections or by vaccines against them [7]..",PMC8205086
B.1.177.8,All B.1.177.75 (n = 686) and B.1.177.8 (n = 1251) sequences available in GISAID (up to 15 April 2021) were downloaded and aligned using MAFFT implementing an FFT-NS-2 algorithm [19].,PMC8205086
B.1.177,"(B) Maximum likelihood (ML) trees for SARS-CoV-2 full genomes (n=1858) including lineages B.1.177 (n=246), B.1.177.8 (n=910), B.1.177.75 (n=642), and others (n=62).",PMC8205086
P.1,"Variants designated G, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are important lineages that emerged sequentially and are considered variants of concern.",PMC8629736
B.1.617.2,"Variants designated G, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are important lineages that emerged sequentially and are considered variants of concern.",PMC8629736
B.1.351,"Variants designated G, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are important lineages that emerged sequentially and are considered variants of concern.",PMC8629736
B.1.1.7,"Variants designated G, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are important lineages that emerged sequentially and are considered variants of concern.",PMC8629736
P.2,"20
 In Brazil, 69.4% of the strains were identified as P.2 lineage variant
and 30.6% were identified as Wuhan-H1 variant D614G.",PMC8637774
B.1.351,"66
 Since then, there have been many viral lineages to note, most notable VOC
include the B.1.1.7/20I/501.Y.V1 variant that was first detected in the United
Kingdom in October 2020, the B.1.351/20 H/501Y.V2 variant that was detected in South
Africa in December 2020, and the Lineage P.1.",PMC8637774
B.1.1.7,"66
 Since then, there have been many viral lineages to note, most notable VOC
include the B.1.1.7/20I/501.Y.V1 variant that was first detected in the United
Kingdom in October 2020, the B.1.351/20 H/501Y.V2 variant that was detected in South
Africa in December 2020, and the Lineage P.1.",PMC8637774
B.1.5,"The five distinct mink farm sequence clusters (A–E) were derived from four lineages B.1.8 (Cluster A), B.11 (Cluster B and D), B.1.22 (Cluster C) and B.1.5 (Cluster E), which have been dominantly circulating in the general human population in the Netherlands according to the Pango-lineage descriptions5 (version on 1 April 2021)..",PMC8611045
B.1.8,"The five distinct mink farm sequence clusters (A–E) were derived from four lineages B.1.8 (Cluster A), B.11 (Cluster B and D), B.1.22 (Cluster C) and B.1.5 (Cluster E), which have been dominantly circulating in the general human population in the Netherlands according to the Pango-lineage descriptions5 (version on 1 April 2021)..",PMC8611045
B.11,"The five distinct mink farm sequence clusters (A–E) were derived from four lineages B.1.8 (Cluster A), B.11 (Cluster B and D), B.1.22 (Cluster C) and B.1.5 (Cluster E), which have been dominantly circulating in the general human population in the Netherlands according to the Pango-lineage descriptions5 (version on 1 April 2021)..",PMC8611045
B.1.22,"The five distinct mink farm sequence clusters (A–E) were derived from four lineages B.1.8 (Cluster A), B.11 (Cluster B and D), B.1.22 (Cluster C) and B.1.5 (Cluster E), which have been dominantly circulating in the general human population in the Netherlands according to the Pango-lineage descriptions5 (version on 1 April 2021)..",PMC8611045
B.1.1.298,"Acquisition of relevant amino acid substitutions was also observed in the Cluster V variant, found in farmed minks in Denmark, which was derived from a Danish-specific lineage B.1.1.298 (https://cov-lineages.org/pango_lineages.html).",PMC8611045
B.1.1.318,"Three (8.3%) were identified as beta variants, two (5.5%) were identified as alpha variants, three (8.3%) were identified as having a B.1.1.318 lineage, and one sample was identified as an eta variant (B.1.525) carrying an additional V687L mutation.",PMC8623815
B.1.525,"Three (8.3%) were identified as beta variants, two (5.5%) were identified as alpha variants, three (8.3%) were identified as having a B.1.1.318 lineage, and one sample was identified as an eta variant (B.1.525) carrying an additional V687L mutation.",PMC8623815
B.1.351,"In March 2021, routine SARS CoV-2 RT-PCR screening of health care workers by the Child Health Research Foundation (CHRF) in Dhaka confirmed the PANGO lineage B.1.351 (beta variant) by genome sequencing [25].",PMC8623815
B.1.1.7,"In the first and second pandemic waves in Bangladesh, the alpha and beta variants of the B.1.1.7 and B.1.351 lineages were associated with an Ro of approximately 1.2 [27].",PMC8623815
B.1,"In this study, we investigated the replicative cycle of Delta variant compared to the Alpha and B.1 variants.",PMC8603409
B.1.617.2,"1Evaluation of viral production kinetics for Delta (B.1.617.2 – AY.40) strain, in blue, Alpha (B.1.1.7), in green and B.1, in red.",PMC8603409
B.1.1.7,"1Evaluation of viral production kinetics for Delta (B.1.617.2 – AY.40) strain, in blue, Alpha (B.1.1.7), in green and B.1, in red.",PMC8603409
B.1.1.33,"Our analysis, based on 333 genomes, revealed that the first variants detected in the state of Paraná in March 2020 were the B.1.1.33 and B.1.1.28 variants.",PMC8596384
B.1.1.28,"Our analysis, based on 333 genomes, revealed that the first variants detected in the state of Paraná in March 2020 were the B.1.1.33 and B.1.1.28 variants.",PMC8596384
P.1,"The variants B.1.1.28 and B.1.1.33 were predominant throughout 2020 until the introduction of the variant P.2 in August 2020 and a variant of concern (VOC), Gamma (P.1), in January 2021.",PMC8596384
P.2,"The variants B.1.1.28 and B.1.1.33 were predominant throughout 2020 until the introduction of the variant P.2 in August 2020 and a variant of concern (VOC), Gamma (P.1), in January 2021.",PMC8596384
N.10,The lineage N.10 is highlighted in red; the lineage P.2 is highlighted in light yellow; the Gamma-like-II genomes are highlighted in light green; Gamma sequences harboring S:E661D are highlighted in shadow golden and Wuhan-Hu-1 is highlighted in orange.,PMC8596384
B.1.1.7,"We also highlight the identification of 2 high-quality genomes of the variant Alpha (B.1.1.7), first identified in the United Kingdom, and one high quality genome of the N.10 variant, recently identified in the Brazilian state of Maranhão [27].",PMC8596384
B.1.429,"The S:W152C mutation occurs in the N-terminal domain (NTD) of the S protein and was previously described in another VOI, named B.1.429 (CAL.20C) (Additional file 6: Table S1).",PMC8596384
B.1.617,"Of note, there was no evidence for the circulation of the B.1.617 variant (first observed in India) or the B.1.351 variant (first observed in South Africa) in Paraná.",PMC8596384
B.1.351,"Of note, there was no evidence for the circulation of the B.1.617 variant (first observed in India) or the B.1.351 variant (first observed in South Africa) in Paraná.",PMC8596384
P.1,"A subset of these variants have been reported to increase viral transmission, such as Alpha B.1.1.7 (5, 6) and Delta B.1.617.2 (7, 8), while others have been reported to escape humoral immunity (Beta B.1.351 and Gamma P.1) (9–11).",PMC8597642
B.1.617.2,"A subset of these variants have been reported to increase viral transmission, such as Alpha B.1.1.7 (5, 6) and Delta B.1.617.2 (7, 8), while others have been reported to escape humoral immunity (Beta B.1.351 and Gamma P.1) (9–11).",PMC8597642
B.1.351,"A subset of these variants have been reported to increase viral transmission, such as Alpha B.1.1.7 (5, 6) and Delta B.1.617.2 (7, 8), while others have been reported to escape humoral immunity (Beta B.1.351 and Gamma P.1) (9–11).",PMC8597642
B.1.1.7,"A subset of these variants have been reported to increase viral transmission, such as Alpha B.1.1.7 (5, 6) and Delta B.1.617.2 (7, 8), while others have been reported to escape humoral immunity (Beta B.1.351 and Gamma P.1) (9–11).",PMC8597642
B.1.351.2,"b This VOC was previously characterized additionally by the presence of L18F, which currently is only in about 38% of sequences, and 2 sublineages have evolved recently (B.1.351.2 and B.1.351.3) that have L18F at prevalences of about 94% and 93%, respectively.",PMC8597642
B.1.351.3,"b This VOC was previously characterized additionally by the presence of L18F, which currently is only in about 38% of sequences, and 2 sublineages have evolved recently (B.1.351.2 and B.1.351.3) that have L18F at prevalences of about 94% and 93%, respectively.",PMC8597642
B.1.429,e The mutations S13I and W152C are only present in the B.1.429 variant.,PMC8597642
B.1.526.2,"Recently, the B.1.526 variant has evolved into 2 sublineages (B.1.526.1 and B.1.526.2) that appear to have several more unique mutations.",PMC8597642
B.1.526,"Recently, the B.1.526 variant has evolved into 2 sublineages (B.1.526.1 and B.1.526.2) that appear to have several more unique mutations.",PMC8597642
B.1.526.1,"Recently, the B.1.526 variant has evolved into 2 sublineages (B.1.526.1 and B.1.526.2) that appear to have several more unique mutations.",PMC8597642
A.23.1,"Notably, the currently identified variants are undergoing a further genetic diversification with the accumulation of novel mutations and generation of novel variants like the Alpha B.1.1.7 and A.23.1 variants, which have further genetic signatures in the spike glycoprotein, including E484K (22) and E484K along with Q613H (23), respectively.",PMC8597642
A.27,"These concepts support the evidence that extending sequencing from the spike to the full genome can provide more information for surveillance purposes and in regard to SARS-CoV-2 lineages, disease severity, and replication enhancement..

S13I was only detected in the Epsilon VOI and has been reported to reduce susceptibility to several NTD-targeting monoclonal antibodies, suggesting a potential role in immune escape (26)..

L18F was detected in the Gamma P.1 VOC and A.27 variant.",PMC8597642
R.1,"These mutations have been shown to confer different degrees of resistance to neutralizing antibodies targeting the N terminus of the spike protein, suggesting that their potential role is to act as immune escape mutations (27, 29, 30)..

W152C, W152L, and W152R were detected in the Epsilon VOI, R.1 variant, and C.36.3 variant, respectively.",PMC8597642
C.36.3,"These mutations have been shown to confer different degrees of resistance to neutralizing antibodies targeting the N terminus of the spike protein, suggesting that their potential role is to act as immune escape mutations (27, 29, 30)..

W152C, W152L, and W152R were detected in the Epsilon VOI, R.1 variant, and C.36.3 variant, respectively.",PMC8597642
B.1.616,"W152C has been reported to reduce susceptibility to several NTD-binding monoclonal antibodies, again suggesting a potential role in immune escape (26)..

D215G was detected in the Beta B.1.351 VOC, B.1.616 VOI, and AT.1 variant.",PMC8597642
B.1.177,"This mutation has been shown to cause partial resistance to neutralization (27)..

A222V has been a typical genetic marker of the B.1.177 variant since it emerged in Spain and then spread throughout Europe during the summer of 2020.",PMC8597642
B.1.466.2,"Recently, it has also been detected in Delta B.1.617.2 VOC sublineages (AY.1 and AY.2)..

N439K was detected in the B.1.258, B.1.466.2, and AV.1 variants.",PMC8597642
B.1.258,"Recently, it has also been detected in Delta B.1.617.2 VOC sublineages (AY.1 and AY.2)..

N439K was detected in the B.1.258, B.1.466.2, and AV.1 variants.",PMC8597642
B.1.617.1,"However, it is noteworthy that this reduction in susceptibility applied to only a small number of plasma samples and was much smaller than the reductions observed with other variants..

L452R characterizes the Delta B.1.617.2 VOC and the Epsilon B.1.427/B.1.429 and Kappa B.1.617.1 and B.1.617.3 VOIs.",PMC8597642
B.1.617.3,"However, it is noteworthy that this reduction in susceptibility applied to only a small number of plasma samples and was much smaller than the reductions observed with other variants..

L452R characterizes the Delta B.1.617.2 VOC and the Epsilon B.1.427/B.1.429 and Kappa B.1.617.1 and B.1.617.3 VOIs.",PMC8597642
B.1.427,"However, it is noteworthy that this reduction in susceptibility applied to only a small number of plasma samples and was much smaller than the reductions observed with other variants..

L452R characterizes the Delta B.1.617.2 VOC and the Epsilon B.1.427/B.1.429 and Kappa B.1.617.1 and B.1.617.3 VOIs.",PMC8597642
C.16,"It was also detected in other variants, including C.16, A.27, and C36.3.",PMC8597642
C.37,"Recently, L452Q has been reported in the Lambda C.37 VOI, with an impact similar to that of L452R (41)..

Y453F was detected in the B.1.1.298 variant, briefly sustaining a cluster of human infections that arose initially in minks in the summer of 2020.",PMC8597642
B.1.1.298,"Recently, L452Q has been reported in the Lambda C.37 VOI, with an impact similar to that of L452R (41)..

Y453F was detected in the B.1.1.298 variant, briefly sustaining a cluster of human infections that arose initially in minks in the summer of 2020.",PMC8597642
B.1.160,"Furthermore, preliminary evidence suggests that Y453F may also act as an immune escape mutation conferring reduced susceptibility to monoclonal antibodies (37)..

S477N was originally detected in the B.1.160 variant circulating in Portugal and was recently identified in the B.1.620 VOI and a sublineage of the Iota B.1.526 VOI.",PMC8597642
B.1.620,"Furthermore, preliminary evidence suggests that Y453F may also act as an immune escape mutation conferring reduced susceptibility to monoclonal antibodies (37)..

S477N was originally detected in the B.1.160 variant circulating in Portugal and was recently identified in the B.1.620 VOI and a sublineage of the Iota B.1.526 VOI.",PMC8597642
B.1.1.519,"The role of this mutation in affecting the neutralization efficiency of vaccine-elicited antibodies is still controversial, even if some studies showed no reduction in susceptibility to antibodies (30, 40)..

T478K was originally identified in the Delta B.1.617.2 VOC and recently in the B.1.1.519 variant.",PMC8597642
P.3,"By structural analysis, this mutation has been associated with partial resistance to monoclonal antibodies (31)..

E484K, which was first identified in the Beta B.1.351 and Gamma P.1 VOCs, is increasingly being reported in other variants, including the Alpha B.1.1.7 VOC and the following VOIs: Eta B.1.525, Zeta P.2, Theta P.3, B.1.621, and B.1.620, as well as the B.1.1.318, AT.1, R.1, and AV.1 variants.",PMC8597642
B.1.1.318,"By structural analysis, this mutation has been associated with partial resistance to monoclonal antibodies (31)..

E484K, which was first identified in the Beta B.1.351 and Gamma P.1 VOCs, is increasingly being reported in other variants, including the Alpha B.1.1.7 VOC and the following VOIs: Eta B.1.525, Zeta P.2, Theta P.3, B.1.621, and B.1.620, as well as the B.1.1.318, AT.1, R.1, and AV.1 variants.",PMC8597642
B.1.525,"By structural analysis, this mutation has been associated with partial resistance to monoclonal antibodies (31)..

E484K, which was first identified in the Beta B.1.351 and Gamma P.1 VOCs, is increasingly being reported in other variants, including the Alpha B.1.1.7 VOC and the following VOIs: Eta B.1.525, Zeta P.2, Theta P.3, B.1.621, and B.1.620, as well as the B.1.1.318, AT.1, R.1, and AV.1 variants.",PMC8597642
B.1.621,"By structural analysis, this mutation has been associated with partial resistance to monoclonal antibodies (31)..

E484K, which was first identified in the Beta B.1.351 and Gamma P.1 VOCs, is increasingly being reported in other variants, including the Alpha B.1.1.7 VOC and the following VOIs: Eta B.1.525, Zeta P.2, Theta P.3, B.1.621, and B.1.620, as well as the B.1.1.318, AT.1, R.1, and AV.1 variants.",PMC8597642
P.2,"By structural analysis, this mutation has been associated with partial resistance to monoclonal antibodies (31)..

E484K, which was first identified in the Beta B.1.351 and Gamma P.1 VOCs, is increasingly being reported in other variants, including the Alpha B.1.1.7 VOC and the following VOIs: Eta B.1.525, Zeta P.2, Theta P.3, B.1.621, and B.1.620, as well as the B.1.1.318, AT.1, R.1, and AV.1 variants.",PMC8597642
A.28,"Recently, it has also been detected in the Theta P.3 and B.1.621 VOIs, as well as in the A.27 and A.28 variants.",PMC8597642
B.1.221,"However, the role of these mutations still needs to be elucidated..

S98F was detected in the B.1.221 variant and is located in the N-terminal domain of subunit S1.",PMC8597642
B.1.214.2,"There is initial evidence that this mutation may induce escape from monoclonal antibodies (31)..

Q414K and N450K were recently identified in a B.1.214.2 variant, and both reside in the RBD.",PMC8597642
P.1,"By September 2021, VOCs in the U.S. have included the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants, and since June 2021, Delta has outcompeted Alpha to become the predominant strain circulating in the country
3
..",PPR420942
B.1.617.2,"By September 2021, VOCs in the U.S. have included the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants, and since June 2021, Delta has outcompeted Alpha to become the predominant strain circulating in the country
3
..",PPR420942
B.1.351,"By September 2021, VOCs in the U.S. have included the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants, and since June 2021, Delta has outcompeted Alpha to become the predominant strain circulating in the country
3
..",PPR420942
B.1.1.7,"By September 2021, VOCs in the U.S. have included the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants, and since June 2021, Delta has outcompeted Alpha to become the predominant strain circulating in the country
3
..",PPR420942
B.1.258.19,"However, HV69-70 was also present in other variants such as B.1.258.19 where it was present in all 141 B.1.258.19 sequences in GISAID, and B.1.617.2 where it was present in 647 (0.2%) of 402,038 sequences.",PPR420942
B.1.617.3,"While this combination of mutations can also be present in other variants, it is rarer; the non-delta variant with the highest percentage of sequences with these mutations is B.1.617.3, for which there were 266 isolates in the global GISAID database and only 77 (29%) of them possessing these mutations.",PPR420942
B.1.1.7,R203K/G204R incur positive selection and associate with the emergence of B.1.1.7 (Alpha).,PMC8590493
P.1,"These mutations are carried by the increasingly frequent lineages B.1.1.7 (Alpha) (Collier et al., 2021; C. Caserta et al., 2021) and P.1 (Gamma) (Dejnirattisai et al., 2021; Faria et al., 2021).",PMC8590493
P.3,"The lineages showing rapid increases (Figures S4A–S4H), including B.1.1.7, P.1, P.2 (Zeta), P.3 (Theta), and C.37 (Lambda), are all carrying R203K/G204R mutations (Tables S3A and S3B).",PMC8590493
C.37,"The lineages showing rapid increases (Figures S4A–S4H), including B.1.1.7, P.1, P.2 (Zeta), P.3 (Theta), and C.37 (Lambda), are all carrying R203K/G204R mutations (Tables S3A and S3B).",PMC8590493
P.2,"The lineages showing rapid increases (Figures S4A–S4H), including B.1.1.7, P.1, P.2 (Zeta), P.3 (Theta), and C.37 (Lambda), are all carrying R203K/G204R mutations (Tables S3A and S3B).",PMC8590493
B.1.617.2,"The recently evolved Indian lineages B.1.617.1 (Kappa) (Yadav et al., 2021), B.1.617.2 (Delta), and AY.1 (Delta-plus) also carry a point mutation at 28,881, which is a novel N mutation, R203M, instead of R203K/G204R (Table S3A).",PMC8590493
B.1.617.1,"The recently evolved Indian lineages B.1.617.1 (Kappa) (Yadav et al., 2021), B.1.617.2 (Delta), and AY.1 (Delta-plus) also carry a point mutation at 28,881, which is a novel N mutation, R203M, instead of R203K/G204R (Table S3A).",PMC8590493
B.1.351,"The AYR variants mostly belong to the B.1.351 (Beta) (Mwenda et al., 2021) lineage (1211/1379, 87.8%)..",PMC8590493
B.1.1.7,We then focus on the 9 spike (S) protein mutations that delineate the UK B.1.1.7 lineage and how their founder effect in Cyprus has impacted the number of cases and deaths in the population.,PMC8590444
B.1.258,"Dominant lineages included: (i) B.1.258 (51.03% of sequenced strains), with most common countries of origin being UK, Denmark and Czech Republic and (ii) the UK lineage, B.1.1.7, having drawn attention by the recent outbreak in the UK with reported increased rates of viral transmission [29–31], which was detected with high prevalence within the Cypriot population (13.1% of analysed strains).",PMC8590444
P.1,"Sequences for three infectious variants of SARS-CoV-2 including SARS-CoV-2/B.1.617.2 (Delta variant), SARS-CoV-2/ B.1.1.7 (Alpha variant) and SARS-CoV-2/ P.1 (Gamma variant) were also included in analysis.",PMC8592051
B.1.617.2,"Sequences for three infectious variants of SARS-CoV-2 including SARS-CoV-2/B.1.617.2 (Delta variant), SARS-CoV-2/ B.1.1.7 (Alpha variant) and SARS-CoV-2/ P.1 (Gamma variant) were also included in analysis.",PMC8592051
B.1.1.7,"Sequences for three infectious variants of SARS-CoV-2 including SARS-CoV-2/B.1.617.2 (Delta variant), SARS-CoV-2/ B.1.1.7 (Alpha variant) and SARS-CoV-2/ P.1 (Gamma variant) were also included in analysis.",PMC8592051
C.37,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
P.1,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
B.1.617.2,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
B.1.621,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
B.1.351,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
B.1.1.7,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
B.1.1.523,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.1.318,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
R.1,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.1.519,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.525,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.617.1,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
C.1.2,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.619,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.620,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.466.2,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.214.2,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
C.36.3,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.526,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.427,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
P.3,"Some former VOIs but no longer designated as VUMs include P.2 (first detected in Brazil) and P.3 (first detected in the Philippines) (
Supplementary Figures 1
, 
2
) [Variants: distribution of cases data, 20 May 2021-GOV.UK (www.gov.uk)]..",PMC8602852
P.2,"Some former VOIs but no longer designated as VUMs include P.2 (first detected in Brazil) and P.3 (first detected in the Philippines) (
Supplementary Figures 1
, 
2
) [Variants: distribution of cases data, 20 May 2021-GOV.UK (www.gov.uk)]..",PMC8602852
B.1.1.28,"P.3 as well as P.1 belong to B.1.1.28 lineage (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

With increased infectivity and virulence, a new variant with an L452R mutation in S protein appeared in California in March 2020, which was named B.1.427/429.",PMC8602852
B.1.617,"At the same time, B.1.525 was resistant to neutralization of convalescent serum, vaccine-elicited serum, and monoclonal antibodies (44)..

As of September 26, 2021, India’s confirmed cases in has reached 33,652,745, becoming the country with the second largest cumulative number of confirmed cases in the world, which was propelled by variant B.1.617 [https://coronavirus.jhu.edu/map.html].",PMC8602852
B.1.617.3,"With the spread of the local epidemic in India, B.1.617.1, B.1.617.2, and B.1.617.3 strains emerged successively.",PMC8602852
B.1.1.298,"On the other hand, the M1229I mutation, occurring in the hydrophobic transmembrane domain of the spike protein, was only considered as co-occurring to several other mutations in the lineage B.1.1.298 (cluster 5), which was characterised as a variant of concern [29].",PMC8654520
B.1.1.33,"(2021)GreeceApr/2020-May/2020Raw sewage, Sludge samplesWTP116/29 (55%)1.6 × 106 to 3.2 × 106 (g.c./L)BViral loads in sewage samples showed a declining trend up to undetectable levels in line with the very low number of infections and hospital admissions in area under observation49Prado, (2020)BrazilApr/2020Raw sewageWTP, hospital, sewers network125/12 (42%)Not reportedASARS-CoV-2 RNA detected prevalently in samples from areas with a higher number of reported COVID-19 casesSARS-CoV-2 RNA was also detected in one sample from an area not yet reached by the outbreak50Prado, (2021)BrazilApr/2020-Aug/2020Raw sewageWTP2188/223 (84.3%)6.3 × 105 to 5.0 × 106 (g.c./L)A, DSARS-CoV-2 RNA was detected in sewage in a community where no COVID-19 cases had been reportedSequencing of SARS-CoV-2 in sewage showed three strains sharing the same nucleotide mutations (clade G, B.1.1.33), which were also observed in clinical strains circulating in the same area during the study period51Randazzo, (2020a)SpainFeb/2020-Apr/2020Raw sewageWTP312/15 (83%)1.65 × 105 to 9.77 × 105 (g.c./L)ASARS-CoV-2 RNA was consistently detected in wastewater samples taken in late February 2020, when COVID-19 cases in that region were only incipientRT-qPCR signal in wastewaters increased and reached a plateau faster than reported casesStrong indication that SARS-CoV-2 was undergoing community transmission earlier than previously believed52Randazzo, (2020b)SpainMar/2020-Apr/2020Raw sewageWTP635/42 (84%)2.5 × 105 (g.c./L)ASARS-CoV-2 RNA was detected in wastewater samples in low prevalence municipalities, 12–16 days before COVID-19 cases were reported53Rimoldi, (2020)ItalyApr/2020Raw sewageWTP34/8 (50%)Not reportedDA SARS-CoV-2 genome from a sewage sample collected in Northern Italy in April 2020 was similar to a clinical sampe from the same region54Saguti, (2021)SwedenFeb/2020-Jul/2020Raw sewageWTP518/21 (86%)7.9 × 103 to 1.8 × 106 (g.c./L)AAnalysis of multiple WTPs in one city displayed differences in the local incidence of SARS-CoV-2, thus enabling the detection of local outbreaksSARS-CoV-2 RNA peaks in wastewater preceded the peaks of COVID-19 hospitalized patients by 3–4 weeks55Saththasivam, (2021)QatarJun/2020-Aug/2020Raw sewageWTP543/43 (100%)7.8 × 103 to 5.4 × 105 (g.c./L)B, CFirst report of SARS-CoV-2 RNA in wastewaters in QatarThe trend of PCR Ct values in wastewater samples mirrored the number of new daily positive casesThe number of infected subjects was estimated by mathematical model using viral concentrations of wastewater samples; the estimated number was significantly higher than the officially reported ceses56Sharma et al.",PMC8561373
P.1,"Alpha, Beta, Gamma, and Delta (B.1.1.7, B.1.351, P.1, and B.1.617.2 pango lineages, respectively, recently relabelled by the WHO) are the so-called variants of concern for which clear evidence is available indicating a significant impact on transmissibility, severity and/or immunity that is likely to affect the epidemiological situation (European Centre for Disease Prevention and Control 2021).",PMC8561373
B.1.617.2,"Alpha, Beta, Gamma, and Delta (B.1.1.7, B.1.351, P.1, and B.1.617.2 pango lineages, respectively, recently relabelled by the WHO) are the so-called variants of concern for which clear evidence is available indicating a significant impact on transmissibility, severity and/or immunity that is likely to affect the epidemiological situation (European Centre for Disease Prevention and Control 2021).",PMC8561373
B.1.351,"Alpha, Beta, Gamma, and Delta (B.1.1.7, B.1.351, P.1, and B.1.617.2 pango lineages, respectively, recently relabelled by the WHO) are the so-called variants of concern for which clear evidence is available indicating a significant impact on transmissibility, severity and/or immunity that is likely to affect the epidemiological situation (European Centre for Disease Prevention and Control 2021).",PMC8561373
B.1.1.7,"Alpha, Beta, Gamma, and Delta (B.1.1.7, B.1.351, P.1, and B.1.617.2 pango lineages, respectively, recently relabelled by the WHO) are the so-called variants of concern for which clear evidence is available indicating a significant impact on transmissibility, severity and/or immunity that is likely to affect the epidemiological situation (European Centre for Disease Prevention and Control 2021).",PMC8561373
P.2,"From 720 SARS-CoV-2 genome sequences, we found few sites under positive selection pressure, such as the D614G (98.5 %) in the spike, that has replaced the old variant; the V1167F in the spike (41 %), identified in the P.2 variant that emerged from Brazil during the period of analysis; and I292T (39 %) in the N protein.",PMC8743548
B.1.1,"The proposal is labelled considering the major lineages (A and B), and the descendant lineages assigned by numerical values (B.1, B.1.1, B.1.1.28, among others) [10].",PMC8743548
B.1,"The proposal is labelled considering the major lineages (A and B), and the descendant lineages assigned by numerical values (B.1, B.1.1, B.1.1.28, among others) [10].",PMC8743548
B.1.1.28,"The proposal is labelled considering the major lineages (A and B), and the descendant lineages assigned by numerical values (B.1, B.1.1, B.1.1.28, among others) [10].",PMC8743548
A.1,"There are six lineages derived from lineage A (denoted A.1–A.6), two sublineages of A.1 (A.1.1 and A.3), and 16 lineages derived from lineage B.",PMC8743548
A.3,"There are six lineages derived from lineage A (denoted A.1–A.6), two sublineages of A.1 (A.1.1 and A.3), and 16 lineages derived from lineage B.",PMC8743548
P.1,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
B.1.617.2,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
B.1.351,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
B.1.1.7,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
P.3,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
B.1.525,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
B.1.617.1,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
C.37,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
B.1.526,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
B.1.427,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
B.1.1.33,"The most common sublineage was B.1.1.28 with 38.6% of prevalence (IC 95 % 42.2–35.1 %), followed by sublineage B.1.1.33, with 37.4 % (IC 95 % 41–33.9 %), and 15.8 % of B.1.1 (IC 95 % 15.8–13.3 %).",PMC8743548
N.4,We also identified sequences from lineages P.2 and N.4 (Fig.,PMC8743548
B.1.429,"Moreover, the variants of concern B.1.351, B.1.427, and B.1.429 feature the T205I substitution, which were identified in 0.69% of our sequences from May to September (Table S1) [62].",PMC8743548
P.4,"This can be evidenced by the emergence of the variants P.3 and P.4 in the Philippines and Mexico, respectively, which possess mutations that were identified in the P.2 variant, such as the V1176F [80, 81].",PMC8743548
M.1,"Ali M.H1, Shuma M.S1, Dohra H2, Yamazaki, M.1,3.",PMC8551951
N.1,"Calaça G. N.1, Lima, D.2, Santos, C. S.3, Manica, G.C.M4, Klassen, G4, Pessôa, C.A.2, Wohnrath, K.2, Juliana Inaba
1.",PMC8551951
D.2,"Calaça G. N.1, Lima, D.2, Santos, C. S.3, Manica, G.C.M4, Klassen, G4, Pessôa, C.A.2, Wohnrath, K.2, Juliana Inaba
1.",PMC8551951
K.2,"Calaça G. N.1, Lima, D.2, Santos, C. S.3, Manica, G.C.M4, Klassen, G4, Pessôa, C.A.2, Wohnrath, K.2, Juliana Inaba
1.",PMC8551951
A.1,"The RhCl3/pCD was more potent to reduce the NF-κB expression in RAW 264.7 and J774 A.1, than RhCl3, at all tested concentrations.",PMC8551951
V.2,"Adeline Neiverth-Chagas1,2, Souza , S. G. H.3, Zingali , R.B.4, Rezende H. K.2, Fernandes, B. V.2, Klein, M.K.2, Klein, N. K.2, Vendruscolo, E. C. G.2, Marise Fonseca dos Santos 1.",PMC8551951
B.1.617.2,"The most recent strain of concern of SARS-CoV-2 is Delta (B.1.617.2), responsible for an increase in infections in India and reported with a large increase in viral transmissibility..",PMC8551951
C.1,"Carneiro, G. C.1, Parmera, J. B.2, Almeida, I. J.3, Oliveira, M. C. B2,4, Silagi, M. L.5, Studart-Neto, A.2, Ono, C. R1, Barbosa, E. R.2, Nitrini, R.2, Buchpiguel, C. A.1, Brucki, S. M. D.2, Coutinho, A. M.1.",PMC8551951
A.2,"Carneiro, G. C.1, Parmera, J. B.2, Almeida, I. J.3, Oliveira, M. C. B2,4, Silagi, M. L.5, Studart-Neto, A.2, Ono, C. R1, Barbosa, E. R.2, Nitrini, R.2, Buchpiguel, C. A.1, Brucki, S. M. D.2, Coutinho, A. M.1.",PMC8551951
R.2,"Carneiro, G. C.1, Parmera, J. B.2, Almeida, I. J.3, Oliveira, M. C. B2,4, Silagi, M. L.5, Studart-Neto, A.2, Ono, C. R1, Barbosa, E. R.2, Nitrini, R.2, Buchpiguel, C. A.1, Brucki, S. M. D.2, Coutinho, A. M.1.",PMC8551951
B.1.351,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with comparable potency.",PMC8528426
B.1.617,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with comparable potency.",PMC8528426
P.1,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with comparable potency.",PMC8528426
B.1.1.7,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with comparable potency.",PMC8528426
B.1.617.2,"The B.1.617.2 (Delta) variant, which was initially identified in India, has become a dominant strain in many countries (11, 12) and responsible for most of the new COVID-19 cases.",PMC8528426
P.1,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176].",PMC8535385
B.1.617.2,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176].",PMC8535385
B.1.351,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176].",PMC8535385
B.1.1.7,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176].",PMC8535385
B.1.351,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccinees.",PPR407661
B.1.427,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccinees.",PPR407661
P.1,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccinees.",PPR407661
B.1.526,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccinees.",PPR407661
B.1.1.7,"The SARS-CoV-2 viruses USA-WA1/2020 (WA1), hC0V-19/USA/CACDC_5574/2020 (B.1.1.7), hCoV-19/South Africa/KRISP-K005325/2020 (B.1.351), hCoV-19/Japan/TY7-503/2021 (P.1), and hCoV-19/USA/NY-NP-DOH1/2021 (B.1.526) were obtained from BEI Resources (NIAID, NIH).",PPR407661
R.1,"Here we assessed 2-36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PPR407661
B.1.617.1,"Here we assessed 2-36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PPR407661
B.1.525,"Here we assessed 2-36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PPR407661
B.1.1.1,"Here we assessed 2-36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PPR407661
B.1.617.2,"Here we assessed 2-36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PPR407661
B.1.117,At the time of the first clinical trials the “original” virus was gradually replaced by the alpha variant (B.1.117) and at the moment almost all cases e.g.,PMC8501352
B.1.1.7,"In September 2020, the B.1.1.7 lineage emerged as a variant of concern in the United Kingdom (UK), subsequently termed the alpha variant, with 9 spike protein mutations (del69/70HV, del144Y, N501Y, A570D, D614G, P681H, T761I, S982A, and D1118H) [4,5].",PMC8487322
B.1.351,"Two subsequent variants of concern, B.1.351 (beta variant), first identified in South Africa, and P.1 (gamma variant), first identified in Brazil, were found to harbor the D614G and N501Y mutations, as well as 2 additional key mutations in the receptor binding domain (RBD), K417N/T and E484K, which increase binding affinity to the ACE2 receptor [14].",PMC8487322
P.1,"Two subsequent variants of concern, B.1.351 (beta variant), first identified in South Africa, and P.1 (gamma variant), first identified in Brazil, were found to harbor the D614G and N501Y mutations, as well as 2 additional key mutations in the receptor binding domain (RBD), K417N/T and E484K, which increase binding affinity to the ACE2 receptor [14].",PMC8487322
B.1.617.2,"Recently, variant delta (B.1.617.2), first identified in India, has rapidly spread in England and Scotland where it has outcompeted the variant alpha [19], [20], [21], [22].",PMC8487322
B.1.617.1,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
B.1.525,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
C.37,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
B.1.526,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
P.2,This class includes B.1.427/B.1.429 and P.2 variants.,PMC8487322
B.1.427,This class includes B.1.427/B.1.429 and P.2 variants.,PMC8487322
B.1.438.1,The occasional mutation E484K reported in multiple lineages was only detected in the B.1.438.1 lineage where 8 out of 15 specimens had that specific mutation.,PMC8487322
R.1,"This adds to existing literature, with only one other recent study reporting use of the Allplex™ SARS-CoV-2 Variants I assay on 30 nasopharyngeal swab specimens, where 4 variants belonging to R.1 lineage were detected [29].",PMC8487322
P.3,"The SARS-CoV-2 mutations targeted by the Allplex assay are currently found in VOC lineages B.1.1.7, P1, B.1.351 and VOI lineages P.2, P.3, B.1.525, B.1.526 and R.1.",PMC8487322
P.1,"Until recently, SARS-CoV-2 VOCs with recognized importance, according to the CDC, included the Alpha variant (B.1.1.7 lineage), Beta variant (B.1.371 lineage) and Gamma variant (P.1 lineage).",PMC8540511
B.1.371,"Until recently, SARS-CoV-2 VOCs with recognized importance, according to the CDC, included the Alpha variant (B.1.1.7 lineage), Beta variant (B.1.371 lineage) and Gamma variant (P.1 lineage).",PMC8540511
B.1.1.7,"Until recently, SARS-CoV-2 VOCs with recognized importance, according to the CDC, included the Alpha variant (B.1.1.7 lineage), Beta variant (B.1.371 lineage) and Gamma variant (P.1 lineage).",PMC8540511
B.1.617.2,The Delta variant (lineage B.1.617.2) is a VOC that emerged more recently.,PMC8540511
B.1.1.318,"Lineages categorized within such variants also possess some of the described mutations and amino-acid substitutions, e.g., the 484K phenotype is present in lineage B.1.1.318, which is categorized under the Iota variant [9,10].",PMC8540511
B.1.1,RNA extracts from oropharyngeal swabs obtained from previously investigated cats (N = 2) infected by a WT strain (B.1.1 lineage) were analyzed [18].,PMC8540511
B.1.1.305,SARS-CoV-2-positive oropharyngeal samples from minks (N = 3) infected by a WT strain (B.1.1.305 lineage) originating from a heavily affected farm were tested [21].,PMC8540511
B.1.1.7,"The revisions have greatly improved the manuscript, and the reviewers and I ask only that small changes be made for clarity, to help future readers..

1) As suggested by reviewer 2, please mention the lack of information on face mask usage in index cases and the impact this might have on the results..

2) As suggested by reviewer 1 (point 2), please reconsider whether the data have sufficient power to demonstrate saturation and revise accordingly..

3) Please also consider the conflicting evidence on B.1.1.7 viral loads (reviewer 1, point 3)..


Reviewer #1:
.",PMC8476126
P.1,"Naveca, F. G. et al., COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence.",PMC8476126
B.1.1.7,"This is a variant of B.1.1.7 strain and most of the new mutations in this variant occurred in the S gene. .

During uncontrolled viral replication, as found in a large pandemic, viral variants can emerge if they provide either increased infectivity, immune escape, or both.",PMC8537260
P.1,"Four notable variants of concern have been described to date, including the alpha variant (also known as B.1.1.7, 20I/501Y.V1, VOC 202012/01, or the UK variant), the beta variant (also known as B.1.351, 20H/501Y.V2, or the South African variant), the gamma variant (also known as P.1, GR/501Y.V3 or the Brazilian variant), and the delta variant (also known as B.1.671.2, G/478K.V1 or the Indian variant (Table 1 and Table 2). .",PMC8537260
B.1.351,"Four notable variants of concern have been described to date, including the alpha variant (also known as B.1.1.7, 20I/501Y.V1, VOC 202012/01, or the UK variant), the beta variant (also known as B.1.351, 20H/501Y.V2, or the South African variant), the gamma variant (also known as P.1, GR/501Y.V3 or the Brazilian variant), and the delta variant (also known as B.1.671.2, G/478K.V1 or the Indian variant (Table 1 and Table 2). .",PMC8537260
B.1.617.2,"In May 2021 the delta variant (B.1.617.2) emerged in India, where it is now the most frequent strain, with a reported 97% increase in transmissibility (Table 2).",PMC8537260
B.1.1.33,"E484K has been linked to cases of reinfection in Brazilian patients who had previously been infected with B.1.1.33 variant (E484) and were reinfected with variant B.1.1.28, which contains the E484K mutation [96,97].",PMC8537260
B.1.1.28,"E484K has been linked to cases of reinfection in Brazilian patients who had previously been infected with B.1.1.33 variant (E484) and were reinfected with variant B.1.1.28, which contains the E484K mutation [96,97].",PMC8537260
P.3,"Another important RBD mutation is the N501Y mutation that has been reported in alpha, beta, gamma, and other variants such as theta (P.3), B.1.x, B1.621 and A.27 variants.",PMC8537260
A.27,"Another important RBD mutation is the N501Y mutation that has been reported in alpha, beta, gamma, and other variants such as theta (P.3), B.1.x, B1.621 and A.27 variants.",PMC8537260
B.1.617.1,"on convalescent and post-vaccination (mRNA-1273 or BNT162b2) sera, reported that the majority (79%) of convalescent sera and all post-vaccination sera were able to neutralise the B.1.617.1 variant.",PMC8537260
B.1.429,"In a pseudovirus neutralisation assay, they found a 2- and 2.5-fold reduction in the neutralisation of epsilon (B.1.429) variant by sera post vaccination with mRNA-1273 or NVX-CoV2373, respectively, compared with an ancestral variant containing D614G.",PMC8537260
B.1,"examined the ability of sera from convalescent COVID-19 patients who had subsequently been given one dose of BNT162b2 to neutralise the original B.1 virus, and the alpha, beta, and gamma variants in live virus neutralisation assays.",PMC8537260
B.1.427,"Compared with mRNA-1273, a primary two-dose vaccination course with mRNA-1273.351 resulted in a small (1.4-fold) increase in neutralising antibody tires against the beta variant but a 6.1-fold decrease in neutralising antibody titres against the wild-type (Wuhan with D614G mutation), a 2.6-fold decrease against the gamma variant, and a 3.8 fold decrease against B.1.427/B.1.429.",PMC8537260
B.1.357,"Spike protein monomer ribbon structures from (D) B.1.1.7 (UK variant/Alpha) spike structure in monomer, (E) P.1 (Brazil variant/Gamma) spike structure in monomer, (F) B.1.357 (South African variant/Beta) spike structure in monomer, and (G) B.1.617.2 (Indian variant/Delta) spike structure in monomer.",PMC8537260
B.1.617.2,"The Delta strain, or B.1.617.2 variant of SARS-CoV-2, was first described in India in October 2020.13 By mid-2021, it had been detected in >142 countries.11 An additional spike amino acid change, K417N, was reported on 11 June (classified as the Delta Plus).14 As of 6 July 2021, this variant and another sub-lineage have been aggregated with the Delta variant.15 As of 17 August, >98% of the newly diagnosed COVID-19 cases in the USA result from the Delta variant.16 This mini review, with specific emphasis on the biology, clinical and public implications of the Delta variant, will provide the latest information related to the Delta variant as of 18 August 2021 to complement our previous review so that readers can have an update on the latest on COVID-19..

COVID-19 gets its spike protein features from the coronavirus family.17 The spike proteins are flexible and hinge at three different points, thereby allowing easier access to the receptors on human cells.18 The receptor-binding domain (RBD) of the spike protein is the key binding element to the human angiotensin-converting enzyme 2 (hACE2) receptor.18 Two glycans play a key role in the positioning of the RBD and binding affinity to the hACE2 receptors, and there is evidence that the unique presence of the furin cleavage site found in SARS-CoV-2 is associated with its high infectivity in lungs.18.",PMC8499995
B.1.1.519,"T478K mutation is also found in the B.1.1.519 and B.1.214.3 lineages, located within the interaction domain of ACE2, and can possibly alter the electrostatic surface of the protein which greatly influences how treatments interact with the virus.25 An in vitro experiment suggested the mutation can escape immune recognition.25 An additional amino acid substitution K417N was also reported on 11 June 2021 with the new variant Delta Plus/AY.1.14,26 This variant has already spread to >30 countries by August 2021 and has been classified as a VOC in India.13,26.",PMC8499995
B.1.214.3,"T478K mutation is also found in the B.1.1.519 and B.1.214.3 lineages, located within the interaction domain of ACE2, and can possibly alter the electrostatic surface of the protein which greatly influences how treatments interact with the virus.25 An in vitro experiment suggested the mutation can escape immune recognition.25 An additional amino acid substitution K417N was also reported on 11 June 2021 with the new variant Delta Plus/AY.1.14,26 This variant has already spread to >30 countries by August 2021 and has been classified as a VOC in India.13,26.",PMC8499995
P.1,"Some of the most consequential amino acid substitutions observed so far have occurred in the RBD, particularly N501Y in the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages, and the additional combination of K417N/T and E484K in the Gamma and Beta lineages.",PMC8443366
B.1.351,"Some of the most consequential amino acid substitutions observed so far have occurred in the RBD, particularly N501Y in the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages, and the additional combination of K417N/T and E484K in the Gamma and Beta lineages.",PMC8443366
B.1.1.7,"Some of the most consequential amino acid substitutions observed so far have occurred in the RBD, particularly N501Y in the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages, and the additional combination of K417N/T and E484K in the Gamma and Beta lineages.",PMC8443366
B.1.617.2,"The L452R substitution, detected in both the B.1.429 (Epsilon) and B.1.617.2 (Delta) variants also permits escape to monoclonal antibodies and a reduction in neutralization titer in comparison to USA-WA1 in vaccinees as well as individuals recovered from COVID-19 infection (McCallum et al., 2021; Mlcochova et al., 2021).",PMC8443366
B.1.429,"The L452R substitution, detected in both the B.1.429 (Epsilon) and B.1.617.2 (Delta) variants also permits escape to monoclonal antibodies and a reduction in neutralization titer in comparison to USA-WA1 in vaccinees as well as individuals recovered from COVID-19 infection (McCallum et al., 2021; Mlcochova et al., 2021).",PMC8443366
B.1.617,"For example, RBD residue Asn501 (present as Tyr501 in several VOCs, including Alpha, Beta, and Gamma) lies just outside of the 54042-4 epitope, whereas the Cα atoms of Glu484 (present as Lys484 or Gln484 in, e.g., Beta, Gamma, and B.1.617 [Kappa]) and Leu452 (present as Arg452 in Epsilon and Delta) are ∼18 Å and ∼14 Å away from the Cα atoms of the nearest 54042-4 residue, respectively (Figure 3B).",PMC8443366
B.1.141,"These substitutions included K417N found in many isolates in the Beta lineage, as well as E484K (Beta, Gamma), N501Y (Alpha, Beta, Gamma), L452R (Delta, Epsilon), and N439K found in lineages B.1.141 and B.1.258 (Thomson et al., 2021).",PMC8443366
B.1.258,"These substitutions included K417N found in many isolates in the Beta lineage, as well as E484K (Beta, Gamma), N501Y (Alpha, Beta, Gamma), L452R (Delta, Epsilon), and N439K found in lineages B.1.141 and B.1.258 (Thomson et al., 2021).",PMC8443366
B.1.617.1,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
P.1,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
B.1.617.2,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
B.1.351,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
B.1.1.7,"The Alpha (B.1.1.7) variant was the first VOC, was identified in the United Kingdom in September 2020 and emerged to global dominance that peaked in mid-March 2021.",PPR394177
B.1.617,"In early 2021, the B.1.617 lineage was reported in India.",PPR394177
B.1.617.3,"The higher order assembly of S-Kappa can be attributed to the unique E484Q substitution that is primarily found in the Kappa (B.1.617.1), B.1.617.3, B.1.630 and P5 variants per PANGO lineage but not in other VOCs and VOIs1.",PPR394177
B.1.630,"The higher order assembly of S-Kappa can be attributed to the unique E484Q substitution that is primarily found in the Kappa (B.1.617.1), B.1.617.3, B.1.630 and P5 variants per PANGO lineage but not in other VOCs and VOIs1.",PPR394177
B.1.351,"However, several new SARS-CoV-2 variants of concern (VOCs), i.e., Alpha (B.1.1.7), Beta (B.1.351), and Gamma (B.1.1.28.1), have been detected from United Kingdom, South Africa, and Brazil, respectively, from September to December 2020 and have also been reported from India [2,3,4].",PMC8472862
B.1.1.7,"However, several new SARS-CoV-2 variants of concern (VOCs), i.e., Alpha (B.1.1.7), Beta (B.1.351), and Gamma (B.1.1.28.1), have been detected from United Kingdom, South Africa, and Brazil, respectively, from September to December 2020 and have also been reported from India [2,3,4].",PMC8472862
B.1.617.1,"Genomic surveillance led to the detection of VOCs, i.e., Alpha and Beta; variants of interest (VOIs), i.e., Eta (B.1.525), Kappa (B.1.617.1), and Zeta (B.1.1.28.2); and variant under monitoring, i.e., B.1.617.3 [2,3,4,5,9,10].",PMC8472862
B.1.525,"Genomic surveillance led to the detection of VOCs, i.e., Alpha and Beta; variants of interest (VOIs), i.e., Eta (B.1.525), Kappa (B.1.617.1), and Zeta (B.1.1.28.2); and variant under monitoring, i.e., B.1.617.3 [2,3,4,5,9,10].",PMC8472862
B.1.617.3,"Genomic surveillance led to the detection of VOCs, i.e., Alpha and Beta; variants of interest (VOIs), i.e., Eta (B.1.525), Kappa (B.1.617.1), and Zeta (B.1.1.28.2); and variant under monitoring, i.e., B.1.617.3 [2,3,4,5,9,10].",PMC8472862
B.1.617,The recent emergence of the B.1.617 lineage has created a grave public health problem in India.,PMC8472862
B.1.617.2,"The lineage evolved further to generate sub-lineages B.1.617.1, B.1.617.2, and B.1.617.3 [11].",PMC8472862
B.1.1.294,"Kappa (B.1.617.1) (n = 22), B.1.617.3 (n = 2), B (n = 1), B.1.36 (n = 5), B.1.1.294 (n = 1), B.1.36.16 (n = 1), B.1.1.306 (n = 1), and Delta AY.2 (n = 1) pangolin lineage variants were also observed along with others; details are given in Supplementary Table S1.",PMC8472862
B.1.36.16,"Kappa (B.1.617.1) (n = 22), B.1.617.3 (n = 2), B (n = 1), B.1.36 (n = 5), B.1.1.294 (n = 1), B.1.36.16 (n = 1), B.1.1.306 (n = 1), and Delta AY.2 (n = 1) pangolin lineage variants were also observed along with others; details are given in Supplementary Table S1.",PMC8472862
B.1.36,"Kappa (B.1.617.1) (n = 22), B.1.617.3 (n = 2), B (n = 1), B.1.36 (n = 5), B.1.1.294 (n = 1), B.1.36.16 (n = 1), B.1.1.306 (n = 1), and Delta AY.2 (n = 1) pangolin lineage variants were also observed along with others; details are given in Supplementary Table S1.",PMC8472862
B.1.1.306,"Kappa (B.1.617.1) (n = 22), B.1.617.3 (n = 2), B (n = 1), B.1.36 (n = 5), B.1.1.294 (n = 1), B.1.36.16 (n = 1), B.1.1.306 (n = 1), and Delta AY.2 (n = 1) pangolin lineage variants were also observed along with others; details are given in Supplementary Table S1.",PMC8472862
B.1.351,"We assessed the recognition of three VOCs (B.1.1.7, B.1.351, and P.1) in cohorts of COVID-19 convalescent patients (n = 69) and Pfizer-BioNTech vaccine recipients (n = 50).",PMC8442901
P.1,"We assessed the recognition of three VOCs (B.1.1.7, B.1.351, and P.1) in cohorts of COVID-19 convalescent patients (n = 69) and Pfizer-BioNTech vaccine recipients (n = 50).",PMC8442901
B.1.1.7,"We assessed the recognition of three VOCs (B.1.1.7, B.1.351, and P.1) in cohorts of COVID-19 convalescent patients (n = 69) and Pfizer-BioNTech vaccine recipients (n = 50).",PMC8442901
B.1,"Last, all these variants have the D614G mutation that defines the B.1 lineage and became dominant throughout 2020, now being present in the large majority of sequenced SARS-CoV-2 variants (>99%) (Fig.",PMC8442901
B.1.1.7,This emergent lineage has been termed B.1.1.7 or 202012/01 (Public Health England Report) [100].,PMC8413106
B.1.1.28,"Thus, new variants that are currently under study have emerged in Brazil (gamma, P.1 or B.1.1.248 and P2, descendants from B.1.1.28, with notable mutations N501Y, E484K) and South Africa (B.1.351, with notable mutations the same as Brazil strains but adding K417N) in January 2021.",PMC8413106
P.1,"Thus, new variants that are currently under study have emerged in Brazil (gamma, P.1 or B.1.1.248 and P2, descendants from B.1.1.28, with notable mutations N501Y, E484K) and South Africa (B.1.351, with notable mutations the same as Brazil strains but adding K417N) in January 2021.",PMC8413106
B.1.1.248,"Thus, new variants that are currently under study have emerged in Brazil (gamma, P.1 or B.1.1.248 and P2, descendants from B.1.1.28, with notable mutations N501Y, E484K) and South Africa (B.1.351, with notable mutations the same as Brazil strains but adding K417N) in January 2021.",PMC8413106
B.1.351,"Thus, new variants that are currently under study have emerged in Brazil (gamma, P.1 or B.1.1.248 and P2, descendants from B.1.1.28, with notable mutations N501Y, E484K) and South Africa (B.1.351, with notable mutations the same as Brazil strains but adding K417N) in January 2021.",PMC8413106
C.37,"The more recent variants of concern that could affect the effectivity of the vaccines and/or increase the rate of infection are the so-called delta variant from India (B1.617.2), with mutations in the spike protein like D614G, T478K, P681R and L452R [108], and the lambda variant from southern Brazil and Peru (C.37), with mutations in the ORF1a gene: Δ3675–3677; Spike gene: Δ246–252, G75V, T76I, L452Q, F490S, D614G, and T859N [109].",PMC8413106
B.1.351,"The variant B.1.1.7 of SARS-CoV-2 (UK variant), also named as 501Y.V1 or variant of concern 202012/01, first emerged in England, has caused a surge in COVID-19 cases.115 This variant has been reported to be spread to >50 countries and seems to become virulent in the future.116–118 It has eight S protein mutations except for D614G.119 SARS-CoV-2 B.1.351 (501Y.V2) and P.1 (501Y.V3), also termed as South Africa variant and Brazil variant, respectively, were claimed to have more strong infectious ability.",PMC8390046
P.1,"The variant B.1.1.7 of SARS-CoV-2 (UK variant), also named as 501Y.V1 or variant of concern 202012/01, first emerged in England, has caused a surge in COVID-19 cases.115 This variant has been reported to be spread to >50 countries and seems to become virulent in the future.116–118 It has eight S protein mutations except for D614G.119 SARS-CoV-2 B.1.351 (501Y.V2) and P.1 (501Y.V3), also termed as South Africa variant and Brazil variant, respectively, were claimed to have more strong infectious ability.",PMC8390046
B.1.1.7,"The variant B.1.1.7 of SARS-CoV-2 (UK variant), also named as 501Y.V1 or variant of concern 202012/01, first emerged in England, has caused a surge in COVID-19 cases.115 This variant has been reported to be spread to >50 countries and seems to become virulent in the future.116–118 It has eight S protein mutations except for D614G.119 SARS-CoV-2 B.1.351 (501Y.V2) and P.1 (501Y.V3), also termed as South Africa variant and Brazil variant, respectively, were claimed to have more strong infectious ability.",PMC8390046
B.1.1.7,"However, given the limited availability, technical requirements, and turnaround time for viral genome sequencing, broadly accessible and inexpensive assays would be advantageous to track specific mutations around the world, analogous to the initial use of the S gene target failure to track and monitor the emergence of B.1.1.7 (8, 9).",PMC8601233
B.1.351,"The Spike SNP assay was designed from an alignment of all whole-genome sequences of B.1.351 and P.1 variants that were uploaded into the GISAID database between 1 September 2020, and 4 February 2021.",PMC8601233
P.1,"The Spike SNP assay was designed from an alignment of all whole-genome sequences of B.1.351 and P.1 variants that were uploaded into the GISAID database between 1 September 2020, and 4 February 2021.",PMC8601233
B.1.429,"Inactivated variant sample pools were obtained through the NIH/RADx Variant Task Force for the following variants: B.1.1.7, B.1.2, B.1.351, B.1.375, B.1.427, B.1.429, B.1.525, B.1.526, P.1, and P.2 (Table 2).",PMC8601233
B.1.525,"Inactivated variant sample pools were obtained through the NIH/RADx Variant Task Force for the following variants: B.1.1.7, B.1.2, B.1.351, B.1.375, B.1.427, B.1.429, B.1.525, B.1.526, P.1, and P.2 (Table 2).",PMC8601233
B.1.375,"Inactivated variant sample pools were obtained through the NIH/RADx Variant Task Force for the following variants: B.1.1.7, B.1.2, B.1.351, B.1.375, B.1.427, B.1.429, B.1.525, B.1.526, P.1, and P.2 (Table 2).",PMC8601233
B.1.2,"Inactivated variant sample pools were obtained through the NIH/RADx Variant Task Force for the following variants: B.1.1.7, B.1.2, B.1.351, B.1.375, B.1.427, B.1.429, B.1.525, B.1.526, P.1, and P.2 (Table 2).",PMC8601233
B.1.526,"Inactivated variant sample pools were obtained through the NIH/RADx Variant Task Force for the following variants: B.1.1.7, B.1.2, B.1.351, B.1.375, B.1.427, B.1.429, B.1.525, B.1.526, P.1, and P.2 (Table 2).",PMC8601233
P.2,"Inactivated variant sample pools were obtained through the NIH/RADx Variant Task Force for the following variants: B.1.1.7, B.1.2, B.1.351, B.1.375, B.1.427, B.1.429, B.1.525, B.1.526, P.1, and P.2 (Table 2).",PMC8601233
B.1.427,"Inactivated variant sample pools were obtained through the NIH/RADx Variant Task Force for the following variants: B.1.1.7, B.1.2, B.1.351, B.1.375, B.1.427, B.1.429, B.1.525, B.1.526, P.1, and P.2 (Table 2).",PMC8601233
P.3,"The assay demonstrated an analytical sensitivity correlating to a limit of detection ∼1 to 2 GE/reaction, excellent clinical performance, including detection of samples with N2 CT values of >30, and perfect concordance with SARS-CoV-2 genome sequencing..

Mutations in the spike protein such as N501Y (present in B.1.1.7, B.1.351, and P.1) and E484K (present in B.1.351, B.1.525, B.1.526, B.1.620, B.1.621, P.1, P.2 and P.3), among others, are likely driving worrisome phenotypes seen with emerging variants (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html).",PMC8601233
B.1.620,"The assay demonstrated an analytical sensitivity correlating to a limit of detection ∼1 to 2 GE/reaction, excellent clinical performance, including detection of samples with N2 CT values of >30, and perfect concordance with SARS-CoV-2 genome sequencing..

Mutations in the spike protein such as N501Y (present in B.1.1.7, B.1.351, and P.1) and E484K (present in B.1.351, B.1.525, B.1.526, B.1.620, B.1.621, P.1, P.2 and P.3), among others, are likely driving worrisome phenotypes seen with emerging variants (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html).",PMC8601233
B.1.621,"The assay demonstrated an analytical sensitivity correlating to a limit of detection ∼1 to 2 GE/reaction, excellent clinical performance, including detection of samples with N2 CT values of >30, and perfect concordance with SARS-CoV-2 genome sequencing..

Mutations in the spike protein such as N501Y (present in B.1.1.7, B.1.351, and P.1) and E484K (present in B.1.351, B.1.525, B.1.526, B.1.620, B.1.621, P.1, P.2 and P.3), among others, are likely driving worrisome phenotypes seen with emerging variants (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html).",PMC8601233
B.1,"Therefore, we performed a similar competition experiment between a mixed inoculum of 40% Cluster 5 isolate and 60% early B.1 lineage, D614G containing virus (‘WT’; IC19).",PPR386579
B.1.351,"The B.1.351 (Beta) spike showed a significant, ˜5-fold drop in mean NT50 (Figure 5C), consistent with this virus being more difficult to neutralise with first wave antisera 
31
.",PPR386579
B.1.1.7,"These generally locally, or globally, outcompeted other lineages to become predominant, including the Alpha variant (B.1.1.7), first associated with infections the UK 
23
.",PPR386579
B.1.525,"B.1.1.7/E484K, Iota/B.1.526+E484K (first associated with infections in New York), Eta/B.1.525 (a variant with associations with West Africa) and L452R (in multiple variants of concern, including Epsilon/B.1.427/B.1.429, first associated with infections in California and Delta/B.1.617.2, which is currently replacing all other SARS-CoV-2 lineages globally) all allowed pseudovirus to utilise ferret ACE2 for cell entry to almost the same degree as human ACE2.",PPR386579
B.1.617.2,"B.1.1.7/E484K, Iota/B.1.526+E484K (first associated with infections in New York), Eta/B.1.525 (a variant with associations with West Africa) and L452R (in multiple variants of concern, including Epsilon/B.1.427/B.1.429, first associated with infections in California and Delta/B.1.617.2, which is currently replacing all other SARS-CoV-2 lineages globally) all allowed pseudovirus to utilise ferret ACE2 for cell entry to almost the same degree as human ACE2.",PPR386579
B.1.427,"B.1.1.7/E484K, Iota/B.1.526+E484K (first associated with infections in New York), Eta/B.1.525 (a variant with associations with West Africa) and L452R (in multiple variants of concern, including Epsilon/B.1.427/B.1.429, first associated with infections in California and Delta/B.1.617.2, which is currently replacing all other SARS-CoV-2 lineages globally) all allowed pseudovirus to utilise ferret ACE2 for cell entry to almost the same degree as human ACE2.",PPR386579
P.1,Alpha/B.1.1.7 and Beta/B.1.351 spikes showed a much more modest boost while Gamma/P.1 (first found in Japan in travellers from Brazil) showed no improved usage of ferret ACE2.,PPR386579
B.1,"Therefore, we performed a similar competition experiment between a mixed inoculum of 40% Cluster 5 isolate and 60% early B.1 lineage, D614G containing virus (‘WT’; IC19).",PPR385148
B.1.351,"The B.1.351 (Beta) spike showed a significant, ~5-fold drop in mean NT50 (Figure 5C), consistent with this virus being more difficult to neutralise with first wave antisera 
31
.",PPR385148
B.1.1.7,"These generally locally, or globally, outcompeted other lineages to become predominant, including the Alpha variant (B.1.1.7), first associated with infections the UK 
23
.",PPR385148
B.1.525,"B.1.1.7/E484K, Iota/B.1.526+E484K (first associated with infections in New York), Eta/B.1.525 (a variant with associations with West Africa) and L452R (in multiple variants of concern, including Epsilon/B.1.427/B.1.429, first associated with infections in California and Delta/B.1.617.2, which is currently replacing all other SARS-CoV-2 lineages globally) all allowed pseudovirus to utilise ferret ACE2 for cell entry to almost the same degree as human ACE2.",PPR385148
B.1.617.2,"B.1.1.7/E484K, Iota/B.1.526+E484K (first associated with infections in New York), Eta/B.1.525 (a variant with associations with West Africa) and L452R (in multiple variants of concern, including Epsilon/B.1.427/B.1.429, first associated with infections in California and Delta/B.1.617.2, which is currently replacing all other SARS-CoV-2 lineages globally) all allowed pseudovirus to utilise ferret ACE2 for cell entry to almost the same degree as human ACE2.",PPR385148
B.1.427,"B.1.1.7/E484K, Iota/B.1.526+E484K (first associated with infections in New York), Eta/B.1.525 (a variant with associations with West Africa) and L452R (in multiple variants of concern, including Epsilon/B.1.427/B.1.429, first associated with infections in California and Delta/B.1.617.2, which is currently replacing all other SARS-CoV-2 lineages globally) all allowed pseudovirus to utilise ferret ACE2 for cell entry to almost the same degree as human ACE2.",PPR385148
P.1,Alpha/B.1.1.7 and Beta/B.1.351 spikes showed a much more modest boost while Gamma/P.1 (first found in Japan in travellers from Brazil) showed no improved usage of ferret ACE2.,PPR385148
B.1.351,"We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine.",PMC8371089
B.1.1.7,"We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine.",PMC8371089
P.1,"In early 2021, three variants B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) were identified as variants of concern (VOC1).",PMC8371089
B.1,"In early 2021, E484K had been detected first in lineage B.1.1.7 in the United Kingdom (UK)6 and subsequently in lineages A23.1, B.1 and B.1.177, as well as in imported cases of B.1.51 and P.21.",PMC8371089
B.1.177,"In early 2021, E484K had been detected first in lineage B.1.1.7 in the United Kingdom (UK)6 and subsequently in lineages A23.1, B.1 and B.1.177, as well as in imported cases of B.1.51 and P.21.",PMC8371089
B.1.617,"Residue identities are shown at each of these positions for a prototype lineage B isolate, and at each position in four lineages of interest, B.1.1.7 (α—Alpha), B.1.351 (β—Beta), P.1 (γ—Gamma) and B.1.617 (δ—Delta), at which the respective lineage differs from prototype.",PMC8371089
B.1.351,"One such success story in the area is The
Coronavirus Disease 2019 (COVID19) Genomics UK Consortium (COG) that
was launched in March 2020 to sequence SARS-CoV-2 in up to 230,000
people with COVID-19 disease.25 This consortium
has already contributed to finding varying lineages of SARS-CoV-2
within the U.K., such as the D614G spike mutation, the globally concerning
the B.1.1.7 lineage, and the variant of concern (VOC2020/1201).26−28 Moreover, in South Africa, genome sequencing revealed a new SARS-CoV-2
variant B.1.351 which has caused further concern as the rise of such
mutations may lead to increased transmissibility and virulence of
the virus in the future.29.",PMC8386036
B.1.1.7,"One such success story in the area is The
Coronavirus Disease 2019 (COVID19) Genomics UK Consortium (COG) that
was launched in March 2020 to sequence SARS-CoV-2 in up to 230,000
people with COVID-19 disease.25 This consortium
has already contributed to finding varying lineages of SARS-CoV-2
within the U.K., such as the D614G spike mutation, the globally concerning
the B.1.1.7 lineage, and the variant of concern (VOC2020/1201).26−28 Moreover, in South Africa, genome sequencing revealed a new SARS-CoV-2
variant B.1.351 which has caused further concern as the rise of such
mutations may lead to increased transmissibility and virulence of
the virus in the future.29.",PMC8386036
A.2,"In January, February and March 2020, the L84S mutation was present in 35%, 18% and 11% of the available GISAID sequences (Table S1, Figure S1), corresponding to Nextstrain clade 19B, GISAID Clade S (98% of L84S sequences) or several Pango A lineages (20% A[basal], 37% A.1, 18% A.2 of L84S sequences).",PPR382902
A.1,"In January, February and March 2020, the L84S mutation was present in 35%, 18% and 11% of the available GISAID sequences (Table S1, Figure S1), corresponding to Nextstrain clade 19B, GISAID Clade S (98% of L84S sequences) or several Pango A lineages (20% A[basal], 37% A.1, 18% A.2 of L84S sequences).",PPR382902
A.3,"The majority (87%) of the V62L mutations co-occur with L84S in Clade S or Pango lineage A[basal] (70%) and A.3 (28%) for the period December 2019-March 2020 (Figure S1), and these sequences with both L84S and V62L were mostly (86%) detected in North America (Figure S2)..",PPR382902
B.1.1.7,"However, with the subsequent rise of the Variant of Concern (VOC) Alpha (B.1.1.7) in autumn 2020, viruses with truncated ORF8 (mutation Q27*) have been circulating.",PPR382902
B.1.617.2,"During Spring 2021, the VOC Delta (B.1.617.2 and others) strains which have mostly L84 and V62 have risen to dominance, and by June 2021 less than 0.1% of available sequences have L84S in an intact ORF8 polypeptide.",PPR382902
B.1.617,"Recently, the B.1.1.7 (N501Y; Alpha), B.1.351 (E484K, N501Y, K417N; Beta), B.1.427 (L452R; Epsilon), B.1.617 (L452R, E484Q; Delta), and C.37 (L452Q, F490S; Lambda) viral lineages have emerged (mutations listed are for S receptor binding domain [RBD] only).",PMC8352667
C.37,"Recently, the B.1.1.7 (N501Y; Alpha), B.1.351 (E484K, N501Y, K417N; Beta), B.1.427 (L452R; Epsilon), B.1.617 (L452R, E484Q; Delta), and C.37 (L452Q, F490S; Lambda) viral lineages have emerged (mutations listed are for S receptor binding domain [RBD] only).",PMC8352667
B.1.1.7,"Recently, the B.1.1.7 (N501Y; Alpha), B.1.351 (E484K, N501Y, K417N; Beta), B.1.427 (L452R; Epsilon), B.1.617 (L452R, E484Q; Delta), and C.37 (L452Q, F490S; Lambda) viral lineages have emerged (mutations listed are for S receptor binding domain [RBD] only).",PMC8352667
B.1.351,"Recently, the B.1.1.7 (N501Y; Alpha), B.1.351 (E484K, N501Y, K417N; Beta), B.1.427 (L452R; Epsilon), B.1.617 (L452R, E484Q; Delta), and C.37 (L452Q, F490S; Lambda) viral lineages have emerged (mutations listed are for S receptor binding domain [RBD] only).",PMC8352667
B.1.427,"Recently, the B.1.1.7 (N501Y; Alpha), B.1.351 (E484K, N501Y, K417N; Beta), B.1.427 (L452R; Epsilon), B.1.617 (L452R, E484Q; Delta), and C.37 (L452Q, F490S; Lambda) viral lineages have emerged (mutations listed are for S receptor binding domain [RBD] only).",PMC8352667
B.1.526,"E484K shared by the B.1.351 and B.1.526 lineages is identified as an escape mutant for this nAb, but the structurally adjacent S477N mutation newly identified in the B.1.526 lineage does not escape CC6.29 neutralization.",PMC8352667
B.1.1.7,"Here we investigated the relative efficiency of aerosol transmission of two variants of SARS-CoV-2, B.1.1.7 (alpha) and lineage A, in the Syrian hamster.",PPR380669
B.1.351,"C. BHK cells expressing either human ACE2 or hamster ACE2 were infected with pseudotyped VSV reporter particles with the spike proteins of WA1 and B.1.1.7 and B.1.351, luciferase was measured and normalized to no spike controls as a readout for cell entry Relative entry to no spike control for human and hamster ACE2 is depicted.",PPR380669
B.1.1.7,"The situation worsened with the occurrence of even more virulent and transmissible strains, such as Alpha/UK/B.1.1.7 carrying the strain‐charactering N501Y Spike mutation or the Beta/South African strain B.1.351.",PMC8420576
B.1.617.1,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.429,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.617,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.617.3,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
P.1,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.617.2,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.351,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.526,"These include the Alpha/UK B.1.1.7 variant with an N501Y mutation in the RBD, the Beta/South African B.1.351 variant (K417N, E484K, N501Y), Gamma/Brazilian P.1 (K417T, E484K, N501Y), Iota/New York City B.1.526 (E484K), Epsilon/Californian B.1.429 (L452R), and the Indian B.1.617 lineage (with L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage)..",PMC8420576
B.1.427,"For low‐affinity measurements, biotinylated RBD (see above) was immobilized on the sensors, dipped into wells containing 60, 30, 15, 7.5, 3.75, or 1.875 nM VHH for 300 s, followed by buffer for 600 s. For high‐affinity measurements, biotinylated nanobodies were immobilized, incubated with 20, 10, 5, 2.5, 1.25 nM RBD (Z03479, GenScript) for 600 s, and followed by dissociation with buffer for 1 h. For RBD variant experiments, biotinylated nanobodies were immobilized, incubated with 20, 6.66, and 2.22 nM RBD wt (Z03479, GenScript) and mutants (Sino Biological; B.1.1.7/Alpha/""UK"" 40592‐V08H82, B.1.351/Beta/""South African"" 40592‐V085H85, P.1/Gamma/""Brazilian"" 40592‐V08H86, and B.1.427/B.1.429/Epsilon/Californian 40592‐V08H28) for 450 s and then with buffer for 900 s. For testing the quadruple mutant (a combination of the Gamma/Brazilian and Epsilon/Californian variants), biotinylated RBD K417T, L452R, E484K, N501Y was immobilized and incubated with 100 nM nanobodies for 450 s, followed by buffer for 900 s. For thermostability BLI experiments, VHH antibodies (1 µM) were incubated at room temperature (RT) or at 90°C for 5 min and centrifuged for 20 min at 20,000 g. The supernatants were recovered and diluted 50‐fold in running buffer (corresponding to 20 nM of the starting material).",PMC8420576
P.1,"In late 2020, three SARS-CoV-2 variants of concern (VOC); B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma), rapidly spread due to enhanced transmission rates and have since been linked to increased hospitalizations and mortalities [1–9].",PPR380399
B.1.351,"In late 2020, three SARS-CoV-2 variants of concern (VOC); B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma), rapidly spread due to enhanced transmission rates and have since been linked to increased hospitalizations and mortalities [1–9].",PPR380399
B.1.1.7,"In late 2020, three SARS-CoV-2 variants of concern (VOC); B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma), rapidly spread due to enhanced transmission rates and have since been linked to increased hospitalizations and mortalities [1–9].",PPR380399
B.1.617,"In early 2021, several new VOC appeared including, B.1.617 (Delta), B.1.427 (Epsilon), and B.1.526 (Iota).",PPR380399
B.1.526,"In early 2021, several new VOC appeared including, B.1.617 (Delta), B.1.427 (Epsilon), and B.1.526 (Iota).",PPR380399
B.1.427,"In early 2021, several new VOC appeared including, B.1.617 (Delta), B.1.427 (Epsilon), and B.1.526 (Iota).",PPR380399
D.2,"The D.2 variant in Australia was defined by an initial I120F substitution in nsp2 followed by S477N in S, which led to its rapid expansion.",PPR380399
B.1.160,"In contrast, B.1.160, which carries S S477N solely, did not rapidly expand.",PPR380399
B.1.429,"The substitution D260Y, present in B.1.427 and B.1.429, is located at the entrance of the NTPase active site and may favor π-π stacking interactions with nucleobases (Figure 6e-f).",PPR380399
B.1.177,"Several lineages show introgression from others (e.g., cyan nodes, B.1.160, into brick red, B.1.177).",PPR380399
B.1,c. Population-level analysis of new mutations per day (accounting for multiple mutations per site) displays a declining rate of mutations after the emergence of B.1 (S D614G and nsp12 P323L).,PPR380399
B.1,"Here, we evaluated genomic sequences of SARS-CoV-2 and observed a high frequency (0.72%) mutation occurring in the RBM region, N439K, which was first sampled in March 2020 in Scotland from lineage B.1 on the background of D614G, has arisen independently multiple times.",PMC8369991
B.1.1.7,"The B.1.1.7 variants with increased transmission have 9 amino-acid changes in Spike, including N501Y, and N501Y compromises neutralization by many antibodies with public V-region IGHV3-53 (Supasa et al., 2021).",PMC8369991
B.1.351,"The B.1.351 variants of SARS-CoV-2 containing multiple mutations in Spike are now dominant in South Africa, indicating the potential for impaired efficacy of potential monoclonal antibodies and vaccines (Li et al., 2021).",PMC8369991
B.1.351,"While over ~1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a; Sadoff et al., 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a; Planas et al., 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PPR377777
B.1.617.2,"While over ~1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a; Sadoff et al., 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a; Planas et al., 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PPR377777
P.1,"While over ~1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a; Sadoff et al., 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a; Planas et al., 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PPR377777
B.1.1.7,"While over ~1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a; Sadoff et al., 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a; Planas et al., 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PPR377777
B.1.525,"Moreover, since many antibodies that bind spike are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι) and B.1.617.1 (κ).",PPR377777
B.1.429,"Moreover, since many antibodies that bind spike are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι) and B.1.617.1 (κ).",PPR377777
B.1.617.1,"Moreover, since many antibodies that bind spike are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι) and B.1.617.1 (κ).",PPR377777
B.1.526,"Moreover, since many antibodies that bind spike are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι) and B.1.617.1 (κ).",PPR377777
B.1.1,"Indeed, all patient S samples form a single clade within the B.1.1 lineage on the global SARS-CoV-2 phylogeny, with the patient A sample as its ancestor (Fig.",PPR375612
B.1.1.7,"This is consistent with the hypothesis that immunocompromised patients represent a hotspot of viral adaptation, causing “saltations” in the otherwise clock-like evolutionary rate of SARS-CoV-2
1
; notably, such a jump could have happened at the origin of the B.1.1.7 (“alpha”) variant which has attained global dominance in early 2021
1,37
..",PPR375612
B.1,"FFPE (black dot), patient A sample (the presumed source of infection for patient S)..

Neutralizing activity of serum obtained from 16 convalescent donors against patient S virus samples obtained on August 20, 2020 and February 19, 2021, as well as a reference viral strain of the B.1 lineage isolated from a swab sample in the beginning of the pandemic in Russia in March 2020.",PPR375612
B.1.617.2,"Rows, from top to bottom: VOCs Delta (B.1.617.2), Beta (B.1.351), Alpha (B.1.1.7); Cluster 5 variant; immunosuppressed individual with persistent infection for 290 days (Williamson et al., 2021); three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 (Truong et al., 2021); immunosuppressed individual treated with immunoglobulin (Sepulcri et al.",PPR375612
B.1.351,"Rows, from top to bottom: VOCs Delta (B.1.617.2), Beta (B.1.351), Alpha (B.1.1.7); Cluster 5 variant; immunosuppressed individual with persistent infection for 290 days (Williamson et al., 2021); three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 (Truong et al., 2021); immunosuppressed individual treated with immunoglobulin (Sepulcri et al.",PPR375612
B.1.1.7,"Here we investigated the relative efficiency of aerosol transmission of two variants of SARS-CoV-2, B.1.1.7 (alpha) and lineage A, in the Syrian hamster.",PPR374984
B.1.351,"C. BHK cells expressing either human ACE2 or hamster ACE2 were infected with pseudotyped VSV reporter particles with the spike proteins of WA1 and B.1.1.7 and B.1.351, luciferase was measured and normalized to no spike controls as a readout for cell entry Relative entry to no spike control for human and hamster ACE2 is depicted.",PPR374984
B.1.351,"SARSeq S-tiling uncovered several infection clusters with variants of concern such as the biggest known cluster of Beta/B.1.351 outside Africa and successfully informed public health measures in a timely manner, allowing their successful implementation.",PPR373950
B.1,Some of these variants have swept through the globe (B.1 and B.1.1.7=Alpha) or are dominating locally.,PPR373950
R.1,"Mutations L452R (found in B.1.617 among others) and E484K or E484Q as observed in strains Gamma (P.1), R.1, Beta (B.1.351), and B.1.617 as well as mutation of N439K (B.1.258), K417N (Beta) or K417T (P.1) are such examples
2,5,6,24
.",PPR373950
B.1.617,"Mutations L452R (found in B.1.617 among others) and E484K or E484Q as observed in strains Gamma (P.1), R.1, Beta (B.1.351), and B.1.617 as well as mutation of N439K (B.1.258), K417N (Beta) or K417T (P.1) are such examples
2,5,6,24
.",PPR373950
P.1,"Mutations L452R (found in B.1.617 among others) and E484K or E484Q as observed in strains Gamma (P.1), R.1, Beta (B.1.351), and B.1.617 as well as mutation of N439K (B.1.258), K417N (Beta) or K417T (P.1) are such examples
2,5,6,24
.",PPR373950
B.1.258,"Mutations L452R (found in B.1.617 among others) and E484K or E484Q as observed in strains Gamma (P.1), R.1, Beta (B.1.351), and B.1.617 as well as mutation of N439K (B.1.258), K417N (Beta) or K417T (P.1) are such examples
2,5,6,24
.",PPR373950
B.1.617.1,"Complex sets of mutations such as those found in Alpha, Beta, Gamma, Delta, Kappa (B.1.617.1), Eta (B.1.525), B.1.258, R.1, and others, yielded sufficient certainty to be assigned a lineage annotation..",PPR373950
B.1.525,"Complex sets of mutations such as those found in Alpha, Beta, Gamma, Delta, Kappa (B.1.617.1), Eta (B.1.525), B.1.258, R.1, and others, yielded sufficient certainty to be assigned a lineage annotation..",PPR373950
B.1.1.7,"The second most frequent mutation in the B.1.1.7 backbone was E484K, which is located in the RBD and seems to change an epitope important for antibody-mediated neutralization.",PPR373950
B.1.1.7,"Finally, end of the year data and 2021 revealed the gradual increase to prevalence of known variants of concern, particularly B.1.1.7, that have acquired additional Spike mutations.",PMC8301627
B.1.375,"Others, then rare, lineages carry the H69/V70 deletion together with a handful of other mutations, matching the B.1.375 variant.",PMC8301627
B.1.2,These signatures are known as part of the B.1.2 clade.,PMC8301627
B.1.427,"Genomic surveillance of this and other variants is critical to guard against the possibility that an escape clade, now lurking in the population, might expand and take over, as mitigation measures are relaxed..

6 variants of concern (VOCs), B.1.1.7, B1.351, B.1.427, B.1.429 and P.1, were detected in the cohort of sequences we explored, primarily in the last quartile of 2020 and the first of 2021.",PMC8301627
P.1,"Genomic surveillance of this and other variants is critical to guard against the possibility that an escape clade, now lurking in the population, might expand and take over, as mitigation measures are relaxed..

6 variants of concern (VOCs), B.1.1.7, B1.351, B.1.427, B.1.429 and P.1, were detected in the cohort of sequences we explored, primarily in the last quartile of 2020 and the first of 2021.",PMC8301627
B.1.429,"Genomic surveillance of this and other variants is critical to guard against the possibility that an escape clade, now lurking in the population, might expand and take over, as mitigation measures are relaxed..

6 variants of concern (VOCs), B.1.1.7, B1.351, B.1.427, B.1.429 and P.1, were detected in the cohort of sequences we explored, primarily in the last quartile of 2020 and the first of 2021.",PMC8301627
B.1.617,"In fact, at the time of this publication, a new variant, (B.1.617, now termed “Delta”) is starting to take a hold on the US population.",PMC8301627
B.1.351,"Click here for additional data file..

A number of variants of concern (P.1, B.1.351, B.1.526, B.1.429, B.1.427, B.1.1.7) were detected primarily in 2021, while genomes of the B.1.2 lineage remained abundant.",PMC8301627
B.1.526,"Click here for additional data file..

A number of variants of concern (P.1, B.1.351, B.1.526, B.1.429, B.1.427, B.1.1.7) were detected primarily in 2021, while genomes of the B.1.2 lineage remained abundant.",PMC8301627
B.1.617.2,Phylogenetic analysis revealed that newly identified lineages B.1.617.1 and B.1.617.2 were predominantly circulating.,PMC8307577
B.1.617.1,Phylogenetic analysis revealed that newly identified lineages B.1.617.1 and B.1.617.2 were predominantly circulating.,PMC8307577
P.1,"Three recently emerged “variants of concern” (VOCs) of SARS-CoV-2 are GRY (formerly GR/501Y.V1)/B.1.1.7 (alpha), GH/501Y.V2/B.1.351 (beta) and GR/501Y.V3/P.1 (gamma) [6].",PMC8307577
B.1.351,"Three recently emerged “variants of concern” (VOCs) of SARS-CoV-2 are GRY (formerly GR/501Y.V1)/B.1.1.7 (alpha), GH/501Y.V2/B.1.351 (beta) and GR/501Y.V3/P.1 (gamma) [6].",PMC8307577
B.1.1.7,"Three recently emerged “variants of concern” (VOCs) of SARS-CoV-2 are GRY (formerly GR/501Y.V1)/B.1.1.7 (alpha), GH/501Y.V2/B.1.351 (beta) and GR/501Y.V3/P.1 (gamma) [6].",PMC8307577
B.1.36.29,"Lineages B.1.617.1 (n = 779), B.1.617.2 (n = 478), B.1.1.306 (n = 116), B.1.36.29 (n = 100), B.1.1.7 (n = 75), B.1.617.3 (n = 51) were found to be the predominant lineages (Figure 1 and Figure S1).",PMC8307577
B.1.617.3,"Lineages B.1.617.1 (n = 779), B.1.617.2 (n = 478), B.1.1.306 (n = 116), B.1.36.29 (n = 100), B.1.1.7 (n = 75), B.1.617.3 (n = 51) were found to be the predominant lineages (Figure 1 and Figure S1).",PMC8307577
B.1.1.306,"Lineages B.1.617.1 (n = 779), B.1.617.2 (n = 478), B.1.1.306 (n = 116), B.1.36.29 (n = 100), B.1.1.7 (n = 75), B.1.617.3 (n = 51) were found to be the predominant lineages (Figure 1 and Figure S1).",PMC8307577
B.1.617,"Among the new B.1.617 lineages, B.1.617.1 included the majority of the strains from eastern part of Maharashtra while B.1.617.2 also included sequences from major cities like Pune, Thane and Mumbai in the western part of the state.",PMC8307577
P.3,"In addition to the three global VOCs, the global variants of interest (VOIs) such as GH/452R.V1/ B.1.427/B.1.429 (epsilon), GR/P.2 (zeta), G/484K.V3/B.1.525 (eta), GR/P.3 (theta) and GH/B.1.526 (iota) have been identified by the WHO [6].",PMC8307577
B.1.525,"In addition to the three global VOCs, the global variants of interest (VOIs) such as GH/452R.V1/ B.1.427/B.1.429 (epsilon), GR/P.2 (zeta), G/484K.V3/B.1.525 (eta), GR/P.3 (theta) and GH/B.1.526 (iota) have been identified by the WHO [6].",PMC8307577
B.1.526,"In addition to the three global VOCs, the global variants of interest (VOIs) such as GH/452R.V1/ B.1.427/B.1.429 (epsilon), GR/P.2 (zeta), G/484K.V3/B.1.525 (eta), GR/P.3 (theta) and GH/B.1.526 (iota) have been identified by the WHO [6].",PMC8307577
P.2,"In addition to the three global VOCs, the global variants of interest (VOIs) such as GH/452R.V1/ B.1.427/B.1.429 (epsilon), GR/P.2 (zeta), G/484K.V3/B.1.525 (eta), GR/P.3 (theta) and GH/B.1.526 (iota) have been identified by the WHO [6].",PMC8307577
B.1.427,"In addition to the three global VOCs, the global variants of interest (VOIs) such as GH/452R.V1/ B.1.427/B.1.429 (epsilon), GR/P.2 (zeta), G/484K.V3/B.1.525 (eta), GR/P.3 (theta) and GH/B.1.526 (iota) have been identified by the WHO [6].",PMC8307577
B.1.1,"In addition, in India during the period from November 2020 to May 2021, there were other lineages, such as B.1, B.1.1, B.1.36, B.1.351, B.1.618 and B.1.1.216, that were not common in the state of Maharashtra.",PMC8307577
B.1.618,"In addition, in India during the period from November 2020 to May 2021, there were other lineages, such as B.1, B.1.1, B.1.36, B.1.351, B.1.618 and B.1.1.216, that were not common in the state of Maharashtra.",PMC8307577
B.1.36,"In addition, in India during the period from November 2020 to May 2021, there were other lineages, such as B.1, B.1.1, B.1.36, B.1.351, B.1.618 and B.1.1.216, that were not common in the state of Maharashtra.",PMC8307577
B.1,"In addition, in India during the period from November 2020 to May 2021, there were other lineages, such as B.1, B.1.1, B.1.36, B.1.351, B.1.618 and B.1.1.216, that were not common in the state of Maharashtra.",PMC8307577
B.1.1.216,"In addition, in India during the period from November 2020 to May 2021, there were other lineages, such as B.1, B.1.1, B.1.36, B.1.351, B.1.618 and B.1.1.216, that were not common in the state of Maharashtra.",PMC8307577
B.4,"Our earlier studies [9,20] that were based on genome sequences from India from January to August/September 2020 had demonstrated that the dominant lineages were B.1.113, B.1.1.32, B.1.1.8, B.1.80, B.4 and B.6.",PMC8307577
B.1.80,"Our earlier studies [9,20] that were based on genome sequences from India from January to August/September 2020 had demonstrated that the dominant lineages were B.1.113, B.1.1.32, B.1.1.8, B.1.80, B.4 and B.6.",PMC8307577
B.1.1.8,"Our earlier studies [9,20] that were based on genome sequences from India from January to August/September 2020 had demonstrated that the dominant lineages were B.1.113, B.1.1.32, B.1.1.8, B.1.80, B.4 and B.6.",PMC8307577
B.1.113,"Our earlier studies [9,20] that were based on genome sequences from India from January to August/September 2020 had demonstrated that the dominant lineages were B.1.113, B.1.1.32, B.1.1.8, B.1.80, B.4 and B.6.",PMC8307577
B.1.1.32,"Our earlier studies [9,20] that were based on genome sequences from India from January to August/September 2020 had demonstrated that the dominant lineages were B.1.113, B.1.1.32, B.1.1.8, B.1.80, B.4 and B.6.",PMC8307577
B.1.429,"L452R has been noted earlier in lineages B.1.427 and B.1.429 while the E484K mutation is common to the two VOCs beta and gamma and two VUIs, zeta and eta.",PMC8307577
A.23.1,"P681H is one of the mutations in the VIC alpha, while P681R is one of the mutations in the lineage A.23.1, which is identified as a “variant under monitoring” (https://www.ecdc.europa.eu/en/COVID-19/variants-concern, Accessed on 14 June 2021).",PMC8307577
B.1.1.7,"Specifically, the B.1.1.7 lineage (Alpha variant, or variant V1/20I Nextstrain clade; 17 amino-acid substitutions) emerged in southeast England in November 2020 and rapidly spread towards fixation.",PMC8282437
B.1.351,"The B.1.351 lineage (Beta variant, V2/20H Nextstrain clade; 17 amino-acid substitutions) was initially reported in South Africa in December 2020.",PMC8282437
P.1,"Additionally, the P.1 lineage (Gamma variant, V3/20 J Nextstrain clade; 17 amino-acid substitutions) was reported in Brazil in January 2021 (Abdool Karim and de Oliveira, 2021).",PMC8282437
B.1.620,"Most importantly, besides the aforementioned VOCs, the substitution E484K has been reported to emerge independently in several other SARS-CoV-2 lineages worldwide, such as in variants/lineages P.2 (20B), Eta (21D), Iota (21F) and B.1.620 (20A/S:126A) (CoVariants, 2021).",PMC8282437
P.2,"Most importantly, besides the aforementioned VOCs, the substitution E484K has been reported to emerge independently in several other SARS-CoV-2 lineages worldwide, such as in variants/lineages P.2 (20B), Eta (21D), Iota (21F) and B.1.620 (20A/S:126A) (CoVariants, 2021).",PMC8282437
B.1.526,"with the Iota variant (lineage B.1.526), which have been reported to rapidly spread in New York (Annavajhala et al., 2021).",PMC8282437
B.1.1.318,"The B.1.1.318 lineage, now also listed under the Iota variant (European Centre for Disease Prevention and Control (ECDC), 2021b), which was reported by Public Health England and designated as variant under monitoring is also characterized by only the 484K phenotype in the absence of 501Y substitution (Public Health England, 2021).",PMC8282437
B.1.621,"It should be also noted that, besides Beta and Gamma variants, both aforementioned MOCs are also present in strains belonging to the B.1.621 lineage (Nextstrain clade 21H).",PMC8282437
B.1.1,"of samplesVariantFluorescence channelFAMHEXTexas RedCy5HumanNegativeN/A20N/A––––Positive (A)Obtained in September 2020, before the emergence of the targeting mutations20WT++––ViroBOAR Spike 1.0 RT-PCR Kit (SARS-CoV-2) & Roche LightCycler 480 II instrument4WT++––21Alpha (B.1.177)+––+1Beta (B.1.351)––++Positive (B)NGS (Illumina MiSeq)16WT (B.1.177)++––2WT (B.1.258)++––29Alpha (B.1.1.7)+––+12Beta (B.1.351)––++1Other (B.1.1.318)–++–VeterinaryNegativeN/A3 cats, 3 minksN/A––––PositiveNGS (Ion Torrent GeneStudio S5)2 catsWT (B.1.1)++––NGS (Illumina MiSeq)3 minksWT (B.1.1.305)++––N/A: not applicable; WT: wild type; NGS: next-generation sequencing..",PMC8282437
B.1.1.305,"of samplesVariantFluorescence channelFAMHEXTexas RedCy5HumanNegativeN/A20N/A––––Positive (A)Obtained in September 2020, before the emergence of the targeting mutations20WT++––ViroBOAR Spike 1.0 RT-PCR Kit (SARS-CoV-2) & Roche LightCycler 480 II instrument4WT++––21Alpha (B.1.177)+––+1Beta (B.1.351)––++Positive (B)NGS (Illumina MiSeq)16WT (B.1.177)++––2WT (B.1.258)++––29Alpha (B.1.1.7)+––+12Beta (B.1.351)––++1Other (B.1.1.318)–++–VeterinaryNegativeN/A3 cats, 3 minksN/A––––PositiveNGS (Ion Torrent GeneStudio S5)2 catsWT (B.1.1)++––NGS (Illumina MiSeq)3 minksWT (B.1.1.305)++––N/A: not applicable; WT: wild type; NGS: next-generation sequencing..",PMC8282437
B.1.258,"of samplesVariantFluorescence channelFAMHEXTexas RedCy5HumanNegativeN/A20N/A––––Positive (A)Obtained in September 2020, before the emergence of the targeting mutations20WT++––ViroBOAR Spike 1.0 RT-PCR Kit (SARS-CoV-2) & Roche LightCycler 480 II instrument4WT++––21Alpha (B.1.177)+––+1Beta (B.1.351)––++Positive (B)NGS (Illumina MiSeq)16WT (B.1.177)++––2WT (B.1.258)++––29Alpha (B.1.1.7)+––+12Beta (B.1.351)––++1Other (B.1.1.318)–++–VeterinaryNegativeN/A3 cats, 3 minksN/A––––PositiveNGS (Ion Torrent GeneStudio S5)2 catsWT (B.1.1)++––NGS (Illumina MiSeq)3 minksWT (B.1.1.305)++––N/A: not applicable; WT: wild type; NGS: next-generation sequencing..",PMC8282437
B.1.177,"of samplesVariantFluorescence channelFAMHEXTexas RedCy5HumanNegativeN/A20N/A––––Positive (A)Obtained in September 2020, before the emergence of the targeting mutations20WT++––ViroBOAR Spike 1.0 RT-PCR Kit (SARS-CoV-2) & Roche LightCycler 480 II instrument4WT++––21Alpha (B.1.177)+––+1Beta (B.1.351)––++Positive (B)NGS (Illumina MiSeq)16WT (B.1.177)++––2WT (B.1.258)++––29Alpha (B.1.1.7)+––+12Beta (B.1.351)––++1Other (B.1.1.318)–++–VeterinaryNegativeN/A3 cats, 3 minksN/A––––PositiveNGS (Ion Torrent GeneStudio S5)2 catsWT (B.1.1)++––NGS (Illumina MiSeq)3 minksWT (B.1.1.305)++––N/A: not applicable; WT: wild type; NGS: next-generation sequencing..",PMC8282437
B.1.285,"The viral strains from Northern Greece were characterized by whole genome sequencing using the NGS technology (Illumina MiSeq) and were classified as follows: 29 as Alpha variant (B.1.1.7), 12 as Beta variant (B.1.351) and 18 as WT strains (B.1.285 & B.1.177).",PMC8282437
B.1.1.33,"Our analysis, based on 333 genomes, revealed that the first variants detected in the state of Paraná in March 2020 were the B.1.1.33 and B.1.1.28 variants.",PPR370835
B.1.1.28,"Our analysis, based on 333 genomes, revealed that the first variants detected in the state of Paraná in March 2020 were the B.1.1.33 and B.1.1.28 variants.",PPR370835
P.2,"The variants B.1.1.28 and B.1.1.33 were predominant throughout 2020 until the introduction of the variant P.2 in August 2020 and a variant of concern (VOC), P.1, in January 2021.",PPR370835
P.1,"The variants B.1.1.28 and B.1.1.33 were predominant throughout 2020 until the introduction of the variant P.2 in August 2020 and a variant of concern (VOC), P.1, in January 2021.",PPR370835
N.10,"We also report the identification of the S:W152C mutation in one genome from Paraná, classified as the N.10 variant.",PPR370835
B.1.1.7,"We also highlight the identification of 2 high-quality genomes of the variant B.1.1.7, first identified in the United Kingdom, and one high-quality genome of the N.10 variant, recently identified in the Brazilian state of Maranhão (32).",PPR370835
B.1.429,"The S:W152C mutation occurs in the N-terminal domain (NTD) of the S protein and was previously described in another VOI, named B.1.429 (CAL.20C) (Table S1).",PPR370835
B.1.617,"Of note, there was no evidence for the circulation of the B.1.617 variant (first observed in India) or the B.1.351 variant (first observed in South Africa) in Paraná.",PPR370835
B.1.351,"Of note, there was no evidence for the circulation of the B.1.617 variant (first observed in India) or the B.1.351 variant (first observed in South Africa) in Paraná.",PPR370835
B.1.5,"The 5 distinct mink farm sequence clusters (A-E) were derived from 4 lineages B.1.8 (Cluster A), B.11 (Cluster B and D), B.1.22 (Cluster C) and B.1.5 (Cluster E) which have been dominantly circulating in the general human population in the Netherlands according to the Pango-lineage descriptions
5
(version on 1st of April 2021)..",PPR369613
B.1.8,"The 5 distinct mink farm sequence clusters (A-E) were derived from 4 lineages B.1.8 (Cluster A), B.11 (Cluster B and D), B.1.22 (Cluster C) and B.1.5 (Cluster E) which have been dominantly circulating in the general human population in the Netherlands according to the Pango-lineage descriptions
5
(version on 1st of April 2021)..",PPR369613
B.11,"The 5 distinct mink farm sequence clusters (A-E) were derived from 4 lineages B.1.8 (Cluster A), B.11 (Cluster B and D), B.1.22 (Cluster C) and B.1.5 (Cluster E) which have been dominantly circulating in the general human population in the Netherlands according to the Pango-lineage descriptions
5
(version on 1st of April 2021)..",PPR369613
B.1.22,"The 5 distinct mink farm sequence clusters (A-E) were derived from 4 lineages B.1.8 (Cluster A), B.11 (Cluster B and D), B.1.22 (Cluster C) and B.1.5 (Cluster E) which have been dominantly circulating in the general human population in the Netherlands according to the Pango-lineage descriptions
5
(version on 1st of April 2021)..",PPR369613
B.1.1.298,"In comparison, the Cluster V variant, found in farmed minks in Denmark, is derived from a Danish specific lineage B.1.1.298 (https://cov-lineages.org/pango_lineages.html).",PPR369613
B.1.1.7,"According to the data of a phylogenetic analysis, this
strain forms a distinct phylogenetic cluster (lineage B.1.1.7) [84].",PMC8526184
B.1.351,"It is necessary to note the emergence of
convergent mutations common to the P1, B.1.1.7, and B.1.351 lineages
(Table 1).",PMC8526184
A.1,"Six lineages derived from lineage A (A.1–A.6) and two
descendant sublineages of A.1 (A.1.1 and A.3) are identified.",PMC8526184
A.3,"Six lineages derived from lineage A (A.1–A.6) and two
descendant sublineages of A.1 (A.1.1 and A.3) are identified.",PMC8526184
B.1,"Also, there are
16 lineages derived from lineage B. Lineage B.1, comprising 70 sublineages as
of April 2020, is predominant.",PMC8526184
B.1.1,"A phylogenetic analysis of SARS-CoV-2 isolates from
Russia showed that most samples correspond to the B.1, B.1.1, and B.1* lineages
(PANGOLIN nomenclature) or to the G, GR, and GH clades (GISAID nomenclature),
which are widespread in Europe [106].",PMC8526184
B.1.351,"cases 26 V1, 21 V2 and 95 P. participants were mainly young, healthy menAl Kaabi et al., 2021;NCT04510207Data are as of early June 2021.Table 2Vaccine effectiveness (VE) from observational studiesVaccinePlatformLocation# dosesOutcomeVE (%)95% CICommentsReferencePfizer BioNTechmRNAIsrael12documented infection symptomatic COVID-19 hospitalization severe disease documented infection symptomatic COVID-19 hospitalizationsevere disease465774629294879240–5150–6356–8639–8088–9587–9855–10075–100nationwide mass vaccination program; widespread circulation of the alpha (B.1.1.7) variantDagan et al., 2021Pfizer BioNTechAstraZenecamRNA adenovirus vectoredScotland1hospitalization859476–9173–9928–34 days after vaccination; widespread circulation of the alpha (B.1.1.7) variantVasileiou et al., 2021Pfizer BioNTechAstraZenecamRNAadenovirus vectoredEngland121symptomatic COVID-19symptomatic COVID-19symptomatic COVID-1960–7085–9060–75test negative design; odds ratios at different intervals; widespread circulation of the alpha (B.1.1.7) variantBernal et al., 2021bPfizer BioNTech and ModernamRNAUSART-PCR confirmed infection in fully immunizedin partially immunized908068–9759–90Thompson et al., 2021Pfizer BioNTechmRNAQatar2test negative design:any documented infection with B.1.1.7 B.1.351 severe critical or fatal disease cohort study:B.1.1.7 B.1.35189.57597.48772.185.9–92.370.5–78.992.2–99.581.8–90.766.4–77.8N = 16,354; widespread circulation of the alpha and beta (B.1.1.7 and B.1.351) variants(Abu-Raddad et al., 2021)Data are as of early June 2021..

Primary and secondary outcomes from interim reports of phase 3 clinical trials of SARS-CoV-2 vaccines.",PMC8279572
B.1.1.7,"cases 26 V1, 21 V2 and 95 P. participants were mainly young, healthy menAl Kaabi et al., 2021;NCT04510207Data are as of early June 2021.Table 2Vaccine effectiveness (VE) from observational studiesVaccinePlatformLocation# dosesOutcomeVE (%)95% CICommentsReferencePfizer BioNTechmRNAIsrael12documented infection symptomatic COVID-19 hospitalization severe disease documented infection symptomatic COVID-19 hospitalizationsevere disease465774629294879240–5150–6356–8639–8088–9587–9855–10075–100nationwide mass vaccination program; widespread circulation of the alpha (B.1.1.7) variantDagan et al., 2021Pfizer BioNTechAstraZenecamRNA adenovirus vectoredScotland1hospitalization859476–9173–9928–34 days after vaccination; widespread circulation of the alpha (B.1.1.7) variantVasileiou et al., 2021Pfizer BioNTechAstraZenecamRNAadenovirus vectoredEngland121symptomatic COVID-19symptomatic COVID-19symptomatic COVID-1960–7085–9060–75test negative design; odds ratios at different intervals; widespread circulation of the alpha (B.1.1.7) variantBernal et al., 2021bPfizer BioNTech and ModernamRNAUSART-PCR confirmed infection in fully immunizedin partially immunized908068–9759–90Thompson et al., 2021Pfizer BioNTechmRNAQatar2test negative design:any documented infection with B.1.1.7 B.1.351 severe critical or fatal disease cohort study:B.1.1.7 B.1.35189.57597.48772.185.9–92.370.5–78.992.2–99.581.8–90.766.4–77.8N = 16,354; widespread circulation of the alpha and beta (B.1.1.7 and B.1.351) variants(Abu-Raddad et al., 2021)Data are as of early June 2021..

Primary and secondary outcomes from interim reports of phase 3 clinical trials of SARS-CoV-2 vaccines.",PMC8279572
P.3,"As of early June 2021, four VOCs (alpha, beta, gamma, and delta, corresponding to B.1.1.7, B.1.351, P.1, and B.1.617.2, respectively) and six VOIs (epsilon, zeta, eta, theta, iota, and kappa, corresponding to B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.617.1, respectively) have been defined..",PMC8279572
B.1.525,"As of early June 2021, four VOCs (alpha, beta, gamma, and delta, corresponding to B.1.1.7, B.1.351, P.1, and B.1.617.2, respectively) and six VOIs (epsilon, zeta, eta, theta, iota, and kappa, corresponding to B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.617.1, respectively) have been defined..",PMC8279572
B.1.617.1,"As of early June 2021, four VOCs (alpha, beta, gamma, and delta, corresponding to B.1.1.7, B.1.351, P.1, and B.1.617.2, respectively) and six VOIs (epsilon, zeta, eta, theta, iota, and kappa, corresponding to B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.617.1, respectively) have been defined..",PMC8279572
P.1,"As of early June 2021, four VOCs (alpha, beta, gamma, and delta, corresponding to B.1.1.7, B.1.351, P.1, and B.1.617.2, respectively) and six VOIs (epsilon, zeta, eta, theta, iota, and kappa, corresponding to B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.617.1, respectively) have been defined..",PMC8279572
B.1.617.2,"As of early June 2021, four VOCs (alpha, beta, gamma, and delta, corresponding to B.1.1.7, B.1.351, P.1, and B.1.617.2, respectively) and six VOIs (epsilon, zeta, eta, theta, iota, and kappa, corresponding to B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.617.1, respectively) have been defined..",PMC8279572
B.1.526,"As of early June 2021, four VOCs (alpha, beta, gamma, and delta, corresponding to B.1.1.7, B.1.351, P.1, and B.1.617.2, respectively) and six VOIs (epsilon, zeta, eta, theta, iota, and kappa, corresponding to B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.617.1, respectively) have been defined..",PMC8279572
P.2,"As of early June 2021, four VOCs (alpha, beta, gamma, and delta, corresponding to B.1.1.7, B.1.351, P.1, and B.1.617.2, respectively) and six VOIs (epsilon, zeta, eta, theta, iota, and kappa, corresponding to B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.617.1, respectively) have been defined..",PMC8279572
B.1.427,"As of early June 2021, four VOCs (alpha, beta, gamma, and delta, corresponding to B.1.1.7, B.1.351, P.1, and B.1.617.2, respectively) and six VOIs (epsilon, zeta, eta, theta, iota, and kappa, corresponding to B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.617.1, respectively) have been defined..",PMC8279572
B.1.351,The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model.,PMC8245475
B.1.1.7,"Whereas variant B.1.1.7 might still be efficiently neutralized by vaccination-elicited antibodies despite the RBD mutations12–14, variant B.1.351 showed a remarkable resistance to sera from vaccinated as well as from convalescent individuals15–18.",PMC8245475
B.1.617.2,"Building on a two-strain, semi-mechanistic model that synthesizes mortality and genomic data, we find evidence that altered epidemiological properties of B.1.617.2 (Delta) variant play an important role in this resurgence in India.",PPR363646
P.1,"In many other parts of the world, winter of 2020 brought resurgent transmission, with new SARS-CoV-2 variants being identified in the UK (Alpha/B.1.1.7), Brazil (Gamma/P.1) and in South Africa (Beta/B.1.351) (34), concurrent with a globally changing pandemic trajectory (35).",PPR363646
B.1.351,"In many other parts of the world, winter of 2020 brought resurgent transmission, with new SARS-CoV-2 variants being identified in the UK (Alpha/B.1.1.7), Brazil (Gamma/P.1) and in South Africa (Beta/B.1.351) (34), concurrent with a globally changing pandemic trajectory (35).",PPR363646
B.1.1.7,"In many other parts of the world, winter of 2020 brought resurgent transmission, with new SARS-CoV-2 variants being identified in the UK (Alpha/B.1.1.7), Brazil (Gamma/P.1) and in South Africa (Beta/B.1.351) (34), concurrent with a globally changing pandemic trajectory (35).",PPR363646
B.1.617,"The B.1.617(.1/2/3) lineage was first detected in December 2020 in India and rapidly became a dominant lineage, particularly in Maharashtra (38).",PPR363646
B.1.617.1,"Between January and February 2021, the B.1.617 lineage, including Delta (B.1.617.2) and Kappa (B.1.617.1), was detected in about 60% of the 361 sequenced cases sampled in Maharashtra (39), and the B.1.617.2 sub-lineage was marked as a VOC in early-May by WHO (40).",PPR363646
B.1.36,"For instance, the B.1.36 lineage accounted for 43.7% of cases (November 22, 2020, to January 22, 2021) in Bengaluru, Karnataka (41).",PPR363646
B.1.618,"Another newly detected lineage, B.1.618, was reported to be increasingly circulating in the eastern state of West Bengal (43)..",PPR363646
B.10,"Table 1Comparison of corresponding nomenclature of SARS-CoV-2Corresponding nomenclature/clade/lineageNotable variantshCoV-19/ Wuhan/WIV04/2019B.1 clades: D614GB.1.351 lineageB.1.1.7 Lineage and B.1.1.207Andrew Rambaut, et alA.1-A.6B.3-B.7 B.9, B.10 B.13-B.16B.2`B.1Nextstrain.org/ncov19B19A20A20C20B20EGISAIDSL and OVGGHGRGV.",PMC8237041
A.6,"Further six lineages, A.1 to A.6 were recognized from lineage A and two descendant sublineages, A.1.1 and A.3 were recognized from A.1.",PMC8237041
A.1,"Further six lineages, A.1 to A.6 were recognized from lineage A and two descendant sublineages, A.1.1 and A.3 were recognized from A.1.",PMC8237041
A.3,"Further six lineages, A.1 to A.6 were recognized from lineage A and two descendant sublineages, A.1.1 and A.3 were recognized from A.1.",PMC8237041
B.1,"So far, lineage B.1 is the major recognized lineage and it additionally subclassified into more than 70 sublineages [18].According to Nextstrain.org/ncov: Total 11 major clades were distinguished on the basis of analysis of clades.nextstrain.org.",PMC8237041
B.1.1.7,"Variants from this lineage are associated with multiple amino acid changes in the spike protein, including a deletion at 69/70, mutation in ORF8, P681H, N501Y and E484K mutation.A.N501Y: The N501Y (substitution of Asparagine to Tyrosine at 501 amino acid position) mutation is of major concern of B.1.1.7 lineage, as it is present in Receptor Binding Motif of Receptor Binding Domain (RBD) in Spike glycoprotein.",PMC8237041
B.1.351,E484K mutation is also deemed to be responsible for the reduced efficacy of both vaccine and convalescent sera [33].Lineage B.1.351 or 501.2 variant: It is also known as 20C/501Y.V2 or South African Covid Variant and was first detected in South Africa during mid-December 2020.,PMC8237041
B.1.258,Transmission and virulence of this variant is unclear [37].Lineage B.1.258∆: It has been identified within B.1.258 clade in Czech Republic and Slovakia during September-December 2020.,PMC8237041
B.1.1.28,"This variant belongs to B.1.1.28 lineage and contains 17 non-synonymous mutations, 11 in S protein viz L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F; 3 in ORF1ab viz S1188L, K1795Q, and E5665D; one in ORF8 namely E92K, and one P80K in N protein; 1 deletion namely SGF 3675-3677del in ORF1ab; and 4 synonymous mutations.",PMC8237041
B.1.429,"Functional effect of this variant regarding antigenicity and transmissibility of SARS-CoV-2 is uncertain [42].CAL.20C: It arises from lineage B.1.429 and was first identified in Europe and Los Angeles of United states in the year 2020, then it rapidly escalated in California during January 2021.",PMC8237041
B.1.617,"However, most of the commercially available PCR protocols are using multiple targets and presumably no significant impact on diagnosis [48].Faster transmissibility in the population: D614G [49], B.1.1.7 [31], and B.1.617 [45] variant of SARS-CoV-2 has been associated with faster transmissibility compared to 614D variant (wild type).",PMC8237041
B.1.168,"Lineage B.1.617 and Lineage B.1.168 are responsible for recent quick surge of SARS-CoV-2 cases in India.
.

Genomics evaluate the particular virology in real time.",PMC8237041
B.1.351,The emergence of the B.1.1.7 and B.1.351 variants has raised concerns of reduced vaccine efficacy and increased re-infection rates.,PMC8239026
B.1.1.7,The emergence of the B.1.1.7 and B.1.351 variants has raised concerns of reduced vaccine efficacy and increased re-infection rates.,PMC8239026
B.1.463,"Anti-S1 IgG antibody and total anti-S1 Ig levels induced by two doses of BNT162b2 vaccine were clearly higher than the anti-S1 IgG levels measured from the convalescent-phase patient sera, geometric means being 107 and 86 vs. 20 and 23, respectively..

To analyze the neutralization capacity of the vaccinees’ sera, we isolated for microneutralization tests four virus variants circulating in Finland: D614G variants FIN-25 (spring 2020) representing B.1 lineage and SR121 (autumn 2020) representing B.1.463 lineage, a variant of concern 85HEL representing B.1.1.7 lineage and a variant of concern HEL12-102 representing B.1.351 lineage.",PMC8239026
B.1,"Anti-S1 IgG antibody and total anti-S1 Ig levels induced by two doses of BNT162b2 vaccine were clearly higher than the anti-S1 IgG levels measured from the convalescent-phase patient sera, geometric means being 107 and 86 vs. 20 and 23, respectively..

To analyze the neutralization capacity of the vaccinees’ sera, we isolated for microneutralization tests four virus variants circulating in Finland: D614G variants FIN-25 (spring 2020) representing B.1 lineage and SR121 (autumn 2020) representing B.1.463 lineage, a variant of concern 85HEL representing B.1.1.7 lineage and a variant of concern HEL12-102 representing B.1.351 lineage.",PMC8239026
P.1,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
B.1.617.2,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
B.1.351,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
B.1.1.7,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
B.1.617,"More recently, there was a massive outbreak of B.1.617 in India, a lineage characterized by the combination of L452R and E484Q spike mutations in sublineages B.1.617.1 and B.1.617.3 or L452R and T478K in B.1.617.2 [351,352,390].",PMC8307803
B.1.617.3,"More recently, there was a massive outbreak of B.1.617 in India, a lineage characterized by the combination of L452R and E484Q spike mutations in sublineages B.1.617.1 and B.1.617.3 or L452R and T478K in B.1.617.2 [351,352,390].",PMC8307803
B.1.617.1,"More recently, there was a massive outbreak of B.1.617 in India, a lineage characterized by the combination of L452R and E484Q spike mutations in sublineages B.1.617.1 and B.1.617.3 or L452R and T478K in B.1.617.2 [351,352,390].",PMC8307803
B.1.160,"Furthermore, variants 20A.EU1 (B.1.177) and 20A.EU2 (B.1.160) increased in dominance, the latter one carrying the S477N mutation in RBD that might have resulted from selective pressure exerted by the host nAb response and possibly increases RBD’s affinity for ACE2 [371,417].",PMC8307803
B.1.177,"Furthermore, variants 20A.EU1 (B.1.177) and 20A.EU2 (B.1.160) increased in dominance, the latter one carrying the S477N mutation in RBD that might have resulted from selective pressure exerted by the host nAb response and possibly increases RBD’s affinity for ACE2 [371,417].",PMC8307803
B.1.427,"In the US, two Californian lineages (B.1.427 and B.1.429) gained dominance in the second year of the pandemic, characterized, again, by recurring spike mutations [418].",PMC8307803
B.1.429,"In the US, two Californian lineages (B.1.427 and B.1.429) gained dominance in the second year of the pandemic, characterized, again, by recurring spike mutations [418].",PMC8307803
B.1.526,"In New York, B.1.526 variants were detected frequently carrying either the S477N or E484K mutation (Table 2, Figure 6) [423,424].",PMC8307803
B.1.525,"Since E484K is known to impair nAb efficacy as described for B.1.351 and P.1, these variants pose a possible bias to vaccines. .

More recently, lineage B.1.525 was detected in the UK and in Nigeria and rapidly spread over more than 20 countries in the world.",PMC8307803
P.3,"On the Philippines, variant P.3 was identified, which stems from the same lineage B.1.1.28 as P.1 and harbors N501Y, E484K, and P681H mutations [428].",PMC8307803
B.1.1.28,"On the Philippines, variant P.3 was identified, which stems from the same lineage B.1.1.28 as P.1 and harbors N501Y, E484K, and P681H mutations [428].",PMC8307803
B.1.1.1,"In Peru and Chile, a new sublineage within B.1.1.1 is expanding, designated C.37, with the novel spike deletion Δ246–252 [429].",PMC8307803
C.37,"In Peru and Chile, a new sublineage within B.1.1.1 is expanding, designated C.37, with the novel spike deletion Δ246–252 [429].",PMC8307803
A.23.1,Phylogenetic analyses of these sequences revealed the emergence of lineage A.23.1 from lineage A.23.,PMC8318884
B.1.351,"These VOCs include lineage B.1.1.7, first identified in the UK5, B.1.351 in South Africa6 and lineage P.1 (B.1.1.28.1) in Brazil7..

SARS-CoV-2 infection was first detected in Uganda in March 2020, initially among international travellers until passenger flights were stopped in late March 2020.",PMC8318884
P.1,"These VOCs include lineage B.1.1.7, first identified in the UK5, B.1.351 in South Africa6 and lineage P.1 (B.1.1.28.1) in Brazil7..

SARS-CoV-2 infection was first detected in Uganda in March 2020, initially among international travellers until passenger flights were stopped in late March 2020.",PMC8318884
B.1.1.7,"These VOCs include lineage B.1.1.7, first identified in the UK5, B.1.351 in South Africa6 and lineage P.1 (B.1.1.28.1) in Brazil7..

SARS-CoV-2 infection was first detected in Uganda in March 2020, initially among international travellers until passenger flights were stopped in late March 2020.",PMC8318884
B.1,"In the period from June to August 2020, the lineage B.1 and B.1.393 strains were abundant, similar to patterns observed in Kenya10 (Fig.",PMC8318884
B.1.393,"In the period from June to August 2020, the lineage B.1 and B.1.393 strains were abundant, similar to patterns observed in Kenya10 (Fig.",PMC8318884
A.23,"Lineage A.23 strains were first observed in two prison outbreaks in Amuru and Kitgum, Uganda in August 2020; by September–November, A.23 was the major lineage circulating throughout the country (Fig.",PMC8318884
B.1.351,All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain.,PMC8216847
P.1,"Recently, lineages of viral variants have emerged in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (Davies et al., 2020; Faria et al., 2021; Rambaut et al., 2020; Sabino et al., 2021; Tegally et al., 2020; Volz et al., 2021).",PMC8216847
B.1.1.7,"Recently, lineages of viral variants have emerged in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (Davies et al., 2020; Faria et al., 2021; Rambaut et al., 2020; Sabino et al., 2021; Tegally et al., 2020; Volz et al., 2021).",PMC8216847
B.1.1.1,"The most common were B.1.1.70 and B.1.1.1, discovered in the majority of the samples (65.8%) (Figure 1).",PMC8250835
B.1.1.70,"The most common were B.1.1.70 and B.1.1.1, discovered in the majority of the samples (65.8%) (Figure 1).",PMC8250835
P.1,"that characterize three major variants of concern (VOC) (B.1.1.7, P.1, and B.1.351.",PMC8250835
B.1.1.7,"that characterize three major variants of concern (VOC) (B.1.1.7, P.1, and B.1.351.",PMC8250835
B.1.427,"However, three isolates from this study showed the rare substitution L452R, which turned out to be a characteristic of the newly identified variants B.1.427 and B.1.429.",PMC8250835
B.1.1.7,"To determine whether the neutralization activity of monoclonal antibodies, convalescent sera and vaccine-elicited sera was affected by the top five epidemic SARS-CoV-2 variants in the UK, including D614G+L18F+A222V, D614G+A222V, D614G+S477N, VOC-202012/01(B.1.1.7) and D614G+69-70del+N439K, a pseudovirus-neutralization assay was performed to evaluate the relative neutralization titers against the five SARS-CoV-2 variants and 12 single deconvolution mutants based on the variants.",PMC8247764
B.1.351,"For example, D614G rapidly became the dominant strain (1), cluster 5 was transmitted between humans and mink (2), the 501Y.V1(VOC-202012/01, B.1.1.7) variant spread rapidly in the United Kingdom (3), the 501Y.V2(VOC-202012/01, B.1.351) variant appeared in South Africa (4), the 501Y.V3(P1, B.1.1.28.1) variant appeared in Brazil (5), and the COH.20G/677H variant appeared in the USA (6).",PMC8247764
B.1.177,"Our results therefore indicate that the N501Y, P681H, and S982A mutations might be important antigenic sites of the VOC-202012/01 variant..

L18F and A222V are typical mutations of the B.1.177 lineage.",PMC8247764
B.1.160,"S477N is the representative mutation site of the B.1.160, B.1.127, and B.1.526 lineages (COVID-19 CoV Genetics Browser, https://covidcg.org/).",PMC8247764
B.1.127,"S477N is the representative mutation site of the B.1.160, B.1.127, and B.1.526 lineages (COVID-19 CoV Genetics Browser, https://covidcg.org/).",PMC8247764
B.1.526,"S477N is the representative mutation site of the B.1.160, B.1.127, and B.1.526 lineages (COVID-19 CoV Genetics Browser, https://covidcg.org/).",PMC8247764
B.1.258,"The reason for these differences requires further study..

N439K is the representative mutation of lineage B.1.258, in which it always appears together with the 69-70del mutation.",PMC8247764
B.1.617,"Here, we demonstrate that two recently emerging mutations in the receptor-binding domain of the SARS-CoV-2 spike protein, L452R (in B.1.427/429 and B.1.617) and Y453F (in B.1.1.298), confer escape from HLA-A24-restricted cellular immunity.",PMC8205251
B.1.1.298,"Here, we demonstrate that two recently emerging mutations in the receptor-binding domain of the SARS-CoV-2 spike protein, L452R (in B.1.427/429 and B.1.617) and Y453F (in B.1.1.298), confer escape from HLA-A24-restricted cellular immunity.",PMC8205251
B.1.427,"Here, we demonstrate that two recently emerging mutations in the receptor-binding domain of the SARS-CoV-2 spike protein, L452R (in B.1.427/429 and B.1.617) and Y453F (in B.1.1.298), confer escape from HLA-A24-restricted cellular immunity.",PMC8205251
B.1.351,"Additionally, since fall of 2020, new SARS-CoV-2 variants such as B.1.1.7 (also known as a variant of concern 202012/01 or 20I/501Y.V1), B.1.351 (also known as 20H/501Y.V2), and P.1 (also known as 501Y.V3) lineages have emerged in the UK, South Africa, and Brazil, respectively, and have rapidly spread worldwide (CDC, 2020).",PMC8205251
P.1,"Additionally, since fall of 2020, new SARS-CoV-2 variants such as B.1.1.7 (also known as a variant of concern 202012/01 or 20I/501Y.V1), B.1.351 (also known as 20H/501Y.V2), and P.1 (also known as 501Y.V3) lineages have emerged in the UK, South Africa, and Brazil, respectively, and have rapidly spread worldwide (CDC, 2020).",PMC8205251
B.1.1.7,"Additionally, since fall of 2020, new SARS-CoV-2 variants such as B.1.1.7 (also known as a variant of concern 202012/01 or 20I/501Y.V1), B.1.351 (also known as 20H/501Y.V2), and P.1 (also known as 501Y.V3) lineages have emerged in the UK, South Africa, and Brazil, respectively, and have rapidly spread worldwide (CDC, 2020).",PMC8205251
B.1.429,"The HIV-1-based reporter virus pseudotyped with the parental SARS-CoV-2 S or its derivatives (E, L452R, Y453F, and N501Y; F, D614G, B.1.429 [S13I/W152C/L452R/D614G], and B.1.1.298 [HV69-70del/Y453F/D614G]) was inoculated into HEK293 cells transiently expressing human ACE2 and TMPRSS2 at four different doses (1, 3, 5, and 10 ng p24 antigens).",PMC8205251
B.1.39,"Although the L452R mutant was first detected in the B.1.39 lineage in Denmark on March 17, 2020 (GISAID ID: EPI_ISL_429311) (Table 1), this variant did not spread.",PMC8205251
B.1.1.7,A new variant of SARS-CoV-2 (Lineage B.1.1.7) was identified in the UK in December 2020 which was associated with higher transmissibility of COVID-19.,PMC8179719
B.1.351,"The most recent B.1.1.7, B.1.351 and P.1 variants of SARS-CoV-2, highlight the fact that changes in amino acids in the Spike protein can contribute to enhanced infection and transmission efficiency.",PMC8167830
P.1,"The most recent B.1.1.7, B.1.351 and P.1 variants of SARS-CoV-2, highlight the fact that changes in amino acids in the Spike protein can contribute to enhanced infection and transmission efficiency.",PMC8167830
B.1.1.7,"The most recent B.1.1.7, B.1.351 and P.1 variants of SARS-CoV-2, highlight the fact that changes in amino acids in the Spike protein can contribute to enhanced infection and transmission efficiency.",PMC8167830
B.1.1.28,"The B.1.1.7 (20I/501Y.V1, VOC 202012/01) variant, B.1.351(20H/501Y.V2) variant, and the P.1 variant (B.1.1.28 subclade) have been described following viral genome sequencing.",PMC8167830
B.1.1.7,"Specifically, the B.1.1.7 lineage (UK variant or VOC 202012/1; 17 amino-acid substitutions) emerged in southeast England in November 2020 and is rapidly spreading towards fixation.",PPR350341
B.1.351,The B.1.351 lineage (South African variant or S.501Y.V2; 17 amino-acid substitutions) was initially reported in South Africa in December 2020.,PPR350341
P.1,"Additionally, the P.1/B.1.1.28.1 lineage (Brazilian variant or 501Y.V3; 17 amino-acid substitutions) was reported in Brazil in January 2021 (Abdool Karim and de Oliveira, 2021).",PPR350341
A.27,"Most importantly, besides the aforementioned VOCs, both of these substitutions (N501Y and E484K) have been reported to emerge independently in several other SARS-CoV-2 lineages worldwide, such as in lineages AP.1, A.27 for the substitution N501Y, and lineages R.2, N.10 and P.2 for the substitution E484K.",PPR350341
N.10,"Most importantly, besides the aforementioned VOCs, both of these substitutions (N501Y and E484K) have been reported to emerge independently in several other SARS-CoV-2 lineages worldwide, such as in lineages AP.1, A.27 for the substitution N501Y, and lineages R.2, N.10 and P.2 for the substitution E484K.",PPR350341
R.2,"Most importantly, besides the aforementioned VOCs, both of these substitutions (N501Y and E484K) have been reported to emerge independently in several other SARS-CoV-2 lineages worldwide, such as in lineages AP.1, A.27 for the substitution N501Y, and lineages R.2, N.10 and P.2 for the substitution E484K.",PPR350341
P.2,"Most importantly, besides the aforementioned VOCs, both of these substitutions (N501Y and E484K) have been reported to emerge independently in several other SARS-CoV-2 lineages worldwide, such as in lineages AP.1, A.27 for the substitution N501Y, and lineages R.2, N.10 and P.2 for the substitution E484K.",PPR350341
B.1.526,"with the B.1.526 lineages, which have been reported to rapidly spread in New York (Annavajhala et al., 2021).",PPR350341
B.1.1.318,"The B.1.1.318 lineage, which was recently reported by Public Health England and designated as variant under investigation (VUI) is also characterized by only the 484K phenotype in the absence of 501Y substitution (Public Heaalth Ingland, 2021)..

For the determination of the analytical characteristics of the developed assay, two positive RNA extracts, i.e.",PPR350341
B.1.177,"The viral strains from Northern Greece were characterized by whole genome sequencing using the NGS technology (Illumina MiSeq) and were classified as follows: 29 as UK (B.1.1.7), 12 as South African (B.1.351) and 18 as WT strains (B.1.285 & B.1.177).",PPR350341
B.1.285,"The viral strains from Northern Greece were characterized by whole genome sequencing using the NGS technology (Illumina MiSeq) and were classified as follows: 29 as UK (B.1.1.7), 12 as South African (B.1.351) and 18 as WT strains (B.1.285 & B.1.177).",PPR350341
B.1.1.305,"Specifically, 3 animals infected by a WT strain (B.1.1.305) originating from a heavily infected farm were tested.",PPR350341
B.1.617,"The SARS-CoV-2 B.1.617 lineage emerged in October 2020 in India 
1–6
.",PPR348471
B.1.617.3,"The lineage includes three main subtypes (B1.617.1, B.1617.2 and B.1.617.3), which harbour diverse Spike mutations in the N-terminal domain (NTD) and the receptor binding domain (RBD) which may increase their immune evasion potential.",PPR348471
B.1.617.2,"Here, we isolated infectious B.1.617.2 from a traveller returning from India.",PPR348471
B.1.351,"The B.1.1.7 variant was first identified in the UK, B.1.351 in South Africa and the P.1 lineage in Brazil 
7–10,13–15
.",PPR348471
P.1,"The B.1.1.7 variant was first identified in the UK, B.1.351 in South Africa and the P.1 lineage in Brazil 
7–10,13–15
.",PPR348471
B.1.1.7,"The B.1.1.7 variant was first identified in the UK, B.1.351 in South Africa and the P.1 lineage in Brazil 
7–10,13–15
.",PPR348471
B.1.247,Another variant termed B.1.247/B.1.429 was originally detected in California.,PPR348471
B.1.429,"These NTD modifications include the 69-70 and 144-145 deletions in B.1.1.7, the 241-243 deletion and R246I in B.1.351, W152C in B.1.429, and L18F substitution in a small proportion of B.1.351 and P.1 
10,26,28
..

India is facing a large surge in COVID-19 cases since early 2021.",PPR348471
B.1.617.1,"This lineage is under evolution and has been subdivided into three main sublineages, B.1.617.1, B.1.617.2 and B.1.617.3 
29
 The B.1.617.2 sublineage has been recently classified as a VOC, since it is believed to be more transmissible than the two other sub-lineages.",PPR348471
B.1,"In particular, the Spike protein contained 9 mutations, when compared to the D614G strain (belonging to the basal B.1 lineage) used here as a reference, including five mutations in the NTD (T19R, G142D, Δ156, Δ157, R158G), two in the RBD (L452R, T478K), one mutation close to the furin cleavage site (P681R) and one in the S2 region (D950N) (Fig.",PPR348471
B.1.351,"As of April 2021, three SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351 and P.1) have been detected in over 132 countries.",PPR344049
P.1,"As of April 2021, three SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351 and P.1) have been detected in over 132 countries.",PPR344049
B.1.1.7,"As of April 2021, three SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351 and P.1) have been detected in over 132 countries.",PPR344049
P.5,"Between January 1st to February 25th, 2021, “an increase of 0.1 in the proportion of B.1.1.7 was related with to a 15.3% increase in the cumulative number of deaths during that period” (p.5)..

Challen et al.",PPR344049
B.1.617,"For example, this review did not consider the variant of interest that is emerging in India (B.1.617) or other variants of interest which may warrant future evaluation as these situations evolve.",PPR344049
B.1.351,"Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern (VOCs), including the B.1.1.7, B.1.351 and P.1 lineages.",PPR339189
P.1,"Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern (VOCs), including the B.1.1.7, B.1.351 and P.1 lineages.",PPR339189
B.1.1.7,"Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern (VOCs), including the B.1.1.7, B.1.351 and P.1 lineages.",PPR339189
B.1.351,"Furthermore, niclosamide is effective against the D614G, B.1.1.7 and B.1.351 variants.",PPR316202
B.1.1.7,"Furthermore, niclosamide is effective against the D614G, B.1.1.7 and B.1.351 variants.",PPR316202
B.1.1.7,"Recently, genomes representing the novel SARS-CoV-2 lineage B.1.1.7 have been observed around the world.",PMC8054698
B.1.351,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD.",PPR308676
B.1.427,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD.",PPR308676
P.1,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD.",PPR308676
B.1.1.7,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD.",PPR308676
B.1.429,"SARS-CoV-2 genetic drift has resulted in new emerging variants of concern (VOC) characterized by higher transmissibility, immune evasion and/or disease severity such as B.1.1.7, B.1.351, B.1.429, and P.1 originally identified in the UK, South Africa, California, and Brazil, respectively
3–6
.",PPR308676
B.1.1,"Many of the PANGOLIN lineages, notably the B.1.1 lineage, were brought into Russia repeatedly (Fig.",PPR307522
B.1.1.7,"* includes B.1.1.7 but not B.1.1 or B.1.1.31..

Sequences are ordered by sampling date, split into 14 day bins.",PPR307522
B.1,"There are several nomenclature systems commonly used to classify SARS-CoV-2.7,8,9,10 Six distinct SARS-CoV-2 clades, in addition to the progenitor clade (Wuhan), are classified by the Global Initiative on Sharing All Influenza Data (GISAID): S, L, V, G, GH, and GR.11 These roughly correspond to the virus lineages A, B, B.2, B.1, B.1.",PMC8076962
B.1.1.1,"*, and B.1.1.1, respectively.8 Three clades (G, GH, and GR) contain the 23403A>G (D614G) variant within the gene that encodes the spike glycoprotein.",PMC8076962
B.1.1.7,Mutations of interest (for example those found in B.1.1.7) shown as both nucleotide and amino acid changes.,PMC8290271
B.1,"Notably, the major clade containing D614G (Pango lineage B.1 and its sub-lineages) also contained several other genetically linked mutations, including one in the main polymerase subunit NSP12, P323L, that may also have contributed to its dominance by exerting a fitness advantage.",PMC8290271
A.19,"On the other hand, there are several examples of independent acquisition of D614G (but not P323L), such as the A.19 and A.2.4 lineages, which continue to circulate [34].",PMC8290271
A.2.4,"On the other hand, there are several examples of independent acquisition of D614G (but not P323L), such as the A.19 and A.2.4 lineages, which continue to circulate [34].",PMC8290271
A.23,"One exception is a lineage of viruses identified in Uganda (A.23) that, as of March 2021, continued to contain D614.",PMC8290271
P.3,"A recurrent NTD deletion in the 140–145 region has been found in nine separate chronically infected patients, indicating this may be a signature mutation of these long-term infections [71, 100, 104, 115–118].This mutation is also found in the B.1.1.7 lineage (as well the similar B.1.318, B.1.525, and P.3 lineages, discussed later).",PMC8290271
B.1.318,"A recurrent NTD deletion in the 140–145 region has been found in nine separate chronically infected patients, indicating this may be a signature mutation of these long-term infections [71, 100, 104, 115–118].This mutation is also found in the B.1.1.7 lineage (as well the similar B.1.318, B.1.525, and P.3 lineages, discussed later).",PMC8290271
B.1.525,"A recurrent NTD deletion in the 140–145 region has been found in nine separate chronically infected patients, indicating this may be a signature mutation of these long-term infections [71, 100, 104, 115–118].This mutation is also found in the B.1.1.7 lineage (as well the similar B.1.318, B.1.525, and P.3 lineages, discussed later).",PMC8290271
B.1.351,"In recent months, several independent lineages of viruses containing the spike glycoprotein mutation E484K have been detected worldwide – once in South Africa (B.1.351 or 20B/501Y.V2) and at least twice independently in Brazil (P.1 or 20B/501Y.V3, and P.2) [121–123].",PMC8290271
P.2,"In recent months, several independent lineages of viruses containing the spike glycoprotein mutation E484K have been detected worldwide – once in South Africa (B.1.351 or 20B/501Y.V2) and at least twice independently in Brazil (P.1 or 20B/501Y.V3, and P.2) [121–123].",PMC8290271
P.1,"In recent months, several independent lineages of viruses containing the spike glycoprotein mutation E484K have been detected worldwide – once in South Africa (B.1.351 or 20B/501Y.V2) and at least twice independently in Brazil (P.1 or 20B/501Y.V3, and P.2) [121–123].",PMC8290271
B.1.1.318,"The rapidly expanding list includes the B.1.526 lineage, first isolated in New York [133], the A.23.1(E484K) lineage found in the UK (and related to the A.23 and A.23.1 lineages found in Uganda) [53, 54], the B.1.525 and B.1.1.318 lineages, both seen in multiple countries but linked with travel to West Africa [134], the A.27 lineage, associated with a cluster of cases on the island of Mayotte [135], the B.1.341.1 lineage [136], seen in the UK and related to travel to Antigua, and finally the P.3 lineage described first in the Philippines [137, 138].",PMC8290271
A.27,"The rapidly expanding list includes the B.1.526 lineage, first isolated in New York [133], the A.23.1(E484K) lineage found in the UK (and related to the A.23 and A.23.1 lineages found in Uganda) [53, 54], the B.1.525 and B.1.1.318 lineages, both seen in multiple countries but linked with travel to West Africa [134], the A.27 lineage, associated with a cluster of cases on the island of Mayotte [135], the B.1.341.1 lineage [136], seen in the UK and related to travel to Antigua, and finally the P.3 lineage described first in the Philippines [137, 138].",PMC8290271
B.1.526,"The rapidly expanding list includes the B.1.526 lineage, first isolated in New York [133], the A.23.1(E484K) lineage found in the UK (and related to the A.23 and A.23.1 lineages found in Uganda) [53, 54], the B.1.525 and B.1.1.318 lineages, both seen in multiple countries but linked with travel to West Africa [134], the A.27 lineage, associated with a cluster of cases on the island of Mayotte [135], the B.1.341.1 lineage [136], seen in the UK and related to travel to Antigua, and finally the P.3 lineage described first in the Philippines [137, 138].",PMC8290271
A.23.1,"The rapidly expanding list includes the B.1.526 lineage, first isolated in New York [133], the A.23.1(E484K) lineage found in the UK (and related to the A.23 and A.23.1 lineages found in Uganda) [53, 54], the B.1.525 and B.1.1.318 lineages, both seen in multiple countries but linked with travel to West Africa [134], the A.27 lineage, associated with a cluster of cases on the island of Mayotte [135], the B.1.341.1 lineage [136], seen in the UK and related to travel to Antigua, and finally the P.3 lineage described first in the Philippines [137, 138].",PMC8290271
B.1.258,"The predominant lineage containing N439K (B.1.258) is now mostly found in combination with the NTD deletion Δ69–70, although the significance of this is currently unknown [120]..",PMC8290271
B.1.427,In July 2020 a pair of sister lineages of SARS-CoV-2 (B.1.427 and B.1.429) were first detected in California containing the RBD mutation L452R (as well as a pair of mutations in the NTD).,PMC8290271
B.1.429,In July 2020 a pair of sister lineages of SARS-CoV-2 (B.1.427 and B.1.429) were first detected in California containing the RBD mutation L452R (as well as a pair of mutations in the NTD).,PMC8290271
B.1.177,"There is speculation the main A222V-containing lineage (B.1.177) likely spread widely, particularly in the UK, due to a founder effect from tourists visiting Spain during the summer [141].",PMC8290271
B.1.351,"Clade
20I/501Y.V1 (UK variant B.1.1.7); 20C/501Y.V2 (South African variant B.1.351);
20J/501Y.V3 (Brazil variant P1) are indicated.",PMC8029448
B.1.1.7,"Clade
20I/501Y.V1 (UK variant B.1.1.7); 20C/501Y.V2 (South African variant B.1.351);
20J/501Y.V3 (Brazil variant P1) are indicated.",PMC8029448
P.1,"Presently, B.1.1.7 has a substantial fitness advantage over other circulating
lineages, with an estimated increase in person to person transmission of
50–70%.175 Fortunately, there is little evidence for a
clinically significant decline in antibody neutralization titers in convalescent
sera,176 including sera from individuals previously vaccinated with the
Moderna177 or Pfizer mRNA products.178 Whether
B.1.1.7 causes more severe illness remains controversial, but a preliminary study reports an
estimated 35% (CI 12–64%) higher hazard of death associated with infection by this
strain.179 As the number of infections due to this hyper-transmissible
lineage increases worldwide, so does the likelihood that further mutations will evolve..

Two more variant strains have recently emerged that are also of major concern, one
discovered in South Africa and designated B.1.351 (also 20H/501Y.V2) and the other first
identified in Brazil (P.1, also 20J/501Y.V3).",PMC8029448
B.1.351,"The vaccine candidate demonstrates an 85% protection from moderate and severe infection, including from the B.1.351 variant.",PMC8006140
B.1.1.28,"Perhaps most prominent among these are B.1.1.7 (UK variant), B.1.351 (South African variant), and the P.1 (Brazil, B.1.1.28 branch) lineage [87].",PMC8006140
P.1,"Perhaps most prominent among these are B.1.1.7 (UK variant), B.1.351 (South African variant), and the P.1 (Brazil, B.1.1.28 branch) lineage [87].",PMC8006140
B.1.1.7,"Perhaps most prominent among these are B.1.1.7 (UK variant), B.1.351 (South African variant), and the P.1 (Brazil, B.1.1.28 branch) lineage [87].",PMC8006140
B.1.351,"Such variants of concern (VOC) include isolates of lineage B.1.1.7, first identified in the UK, and B.1.351, first identified in South Africa.",PPR304445
B.1.1.7,"Such variants of concern (VOC) include isolates of lineage B.1.1.7, first identified in the UK, and B.1.351, first identified in South Africa.",PPR304445
P.1,"The third variant of concern, P.1 (formerly B.1.1.28.1) is characterized by K417T, in addition to E484K and N501Y, and accounted for 80% of all viruses sequenced in Brazil on 1 March 2021.",PPR304445
B.1,"In early 2021, E484K had been detected first in lineage B.1.1.7 in the United Kingdom (UK)
5
 and subsequently in lineages A23.1, B.1 and B.1.177, as well as in imported cases of B.1.51 and P.21F1F [2].",PPR304445
B.1.177,"In early 2021, E484K had been detected first in lineage B.1.1.7 in the United Kingdom (UK)
5
 and subsequently in lineages A23.1, B.1 and B.1.177, as well as in imported cases of B.1.51 and P.21F1F [2].",PPR304445
B.1.1.7,"Here, we develop and present an open-source method based on allele specific RT-qPCR (AS RT-qPCR) that detects and quantifies the B.1.1.7 variant, targeting spike protein mutations at three independent genomic loci highly predictive of B.1.1.7 (HV69/70del, Y144del, and A570D).",PPR304175
B.1.351,"However, the emergence of new variants of concern (VOCs) such as B.1.1.7 and B.1.351 suggests that continued vigilance is required to control the COVID-19 pandemic (Mascola, Graham, & Fauci, 2021).",PPR304175
B.1.351,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with the same potency.",PPR303818
B.1.617,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with the same potency.",PPR303818
P.1,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with the same potency.",PPR303818
B.1.1.7,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with the same potency.",PPR303818
B.1.617.2,"The B.1.617.2 (Delta) variant, which was initially identified in India, is becoming a dominant strain in many countries (11, 12) and responsible for the majority of new COVID-19 cases.",PPR303818
B.1.351,The emergence of the B.1.1.7 and B.1.351 variants has raised concerns of reduced vaccine efficacy and increased re-infection rates.,PPR302099
B.1.1.7,The emergence of the B.1.1.7 and B.1.351 variants has raised concerns of reduced vaccine efficacy and increased re-infection rates.,PPR302099
B.1.463,"Anti-S1 IgG antibody and total anti-S1 Ig levels induced by two doses of BNT162b2 vaccine were clearly higher than the anti-S1 IgG levels measured from the convalescent phase patient sera, geometric means being 107 and 86 vs. 20 and 23, respectively..

To analyze the neutralization capacity of the vaccinees’ sera, we isolated for microneutralization tests four virus variants circulating in Finland: D614G variants FIN-25 (spring 2020) representing B.1 lineage and SR121 (autumn 2020) representing B.1.463 lineage, a variant of concern 85HEL representing B.1.1.7 lineage and a variant of concern HEL12-102 representing B.1.351 lineage.",PPR302099
B.1,"Anti-S1 IgG antibody and total anti-S1 Ig levels induced by two doses of BNT162b2 vaccine were clearly higher than the anti-S1 IgG levels measured from the convalescent phase patient sera, geometric means being 107 and 86 vs. 20 and 23, respectively..

To analyze the neutralization capacity of the vaccinees’ sera, we isolated for microneutralization tests four virus variants circulating in Finland: D614G variants FIN-25 (spring 2020) representing B.1 lineage and SR121 (autumn 2020) representing B.1.463 lineage, a variant of concern 85HEL representing B.1.1.7 lineage and a variant of concern HEL12-102 representing B.1.351 lineage.",PPR302099
R.1,"This strains were classified into GR clade (GISAID), 20B clade (Nextstrain) and R.1 lineage (PANGO).",PPR300896
B.1.351,"In fact, several SARS-CoV-2 variants of concern have emerged within the last few months, especially in three major lineages (B.1.1.7, B.1.351, and P.1) [5–7].",PPR300896
P.1,"In fact, several SARS-CoV-2 variants of concern have emerged within the last few months, especially in three major lineages (B.1.1.7, B.1.351, and P.1) [5–7].",PPR300896
B.1.1.7,"In fact, several SARS-CoV-2 variants of concern have emerged within the last few months, especially in three major lineages (B.1.1.7, B.1.351, and P.1) [5–7].",PPR300896
B.1.1.316,"R.1 lineage is the sublineage of B.1.1.316 (github.com/cov-lineages/pangolin)..

To investigate the global distribution of R.1 lineage, we next collected registration data from the EpiCoV of GISAID database [28].",PPR300896
B.1.526,"Recently, the E484K mutation present in another SARS-CoV-2 variant of concern (B.1.526) identified in New York [34, 35].",PPR300896
B.1.1,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.1.5,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.4,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.6,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.1.2,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.2.1,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
A.1,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.1,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
A.2,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
A.3,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.1.36,"The dominant lineages observed was B.1.36 (n = 184), B.1 (n = 143), A (n = 14), B.6 (n = 12), B.1.1 (n = 5), B (n = 3).",PMC7972664
P.1,"Also, one case of Brazil variant known as 20J/501Y.V3 or P.1 lineage was also reported recently.",PMC7972664
B.1.1.7,Here we provide an innovative methodology for the recovery of a near-complete SARS-CoV-2 sequence from a wastewater sample collected from across Canadian municipalities including one that experienced a significant outbreak attributable to the SARS-CoV-2 B.1.1.7 variant of concern.,PPR297482
B.1.351,"By late 2020, several variants of concern carrying numerous mutations had emerged that potentially increase viral infectivity, or reduce the response to neutralizing antibodies and multiple variants are now circulating globally..

As of March 1, 2021, three variants of concern have been identified: the B.1.1.7/501Y.V1 variant, first detected in England from a viral sequence analysis initiated in response to an unexpected rise in COVID-19 cases [21]; the B.1.351/501Y.V2 variant, first detected in South Africa [22], and P.1/501Y.V3, first detected in travelers returning to Japan from Brazil by routine airport screening of international travellers [23],[24].",PPR297482
P.1,"By late 2020, several variants of concern carrying numerous mutations had emerged that potentially increase viral infectivity, or reduce the response to neutralizing antibodies and multiple variants are now circulating globally..

As of March 1, 2021, three variants of concern have been identified: the B.1.1.7/501Y.V1 variant, first detected in England from a viral sequence analysis initiated in response to an unexpected rise in COVID-19 cases [21]; the B.1.351/501Y.V2 variant, first detected in South Africa [22], and P.1/501Y.V3, first detected in travelers returning to Japan from Brazil by routine airport screening of international travellers [23],[24].",PPR297482
B.1.351,"Indeed, several SARS-CoV-2 variants, including the B.1.1.7, B.1.351, and P.1 lineages, harbor frequent mutations within the NTD supersite, suggesting ongoing selective pressure and the importance of NTD-specific neutralizing mAbs for protective immunity and vaccine design..

McCallum et al.",PMC7962585
P.1,"Indeed, several SARS-CoV-2 variants, including the B.1.1.7, B.1.351, and P.1 lineages, harbor frequent mutations within the NTD supersite, suggesting ongoing selective pressure and the importance of NTD-specific neutralizing mAbs for protective immunity and vaccine design..

McCallum et al.",PMC7962585
B.1.1.7,"Indeed, several SARS-CoV-2 variants, including the B.1.1.7, B.1.351, and P.1 lineages, harbor frequent mutations within the NTD supersite, suggesting ongoing selective pressure and the importance of NTD-specific neutralizing mAbs for protective immunity and vaccine design..

McCallum et al.",PMC7962585
B.1.351,"In this review we focus on the main variants of concern, that is, the so‐called UK (B.1.1.7), South African (B.1.351) and Brazilian (P.1) strains..

mutation rate.",PMC8250244
P.1,"In this review we focus on the main variants of concern, that is, the so‐called UK (B.1.1.7), South African (B.1.351) and Brazilian (P.1) strains..

mutation rate.",PMC8250244
B.1.1.7,"In this review we focus on the main variants of concern, that is, the so‐called UK (B.1.1.7), South African (B.1.351) and Brazilian (P.1) strains..

mutation rate.",PMC8250244
C.1.1,"In April 2020, a preliminary work by the London School of Hygiene & Tropical Medicine on 5300 sequences from 62 countries identified two clusters (C1 and C2) further classified in 6 main clades (C1, C.1.1, C2, C2.1, C2.1.1 and C.2.1.2).",PMC8250244
B.1,"29
 showed positive selection of D614G, S477N (clade 20A.EU2), A222V (20A.EU1) and V1176F SNPs, an expansion of B.1 clade, especially strain containing Q57H (B.1.",PMC8250244
B.1.1.33,"Comparison of B.1.1.7, B1.1.28‐derived clades, B.1.1.33 (E484K), B.1.351 and CAL.20C lineages with regard to mutations in Spike, other SARS‐CoV‐2 genes and evidences for reinfection.",PMC8250244
B.1.1.207,"66
, 
67
, 
68
 It has been found both in the UK B.1.1.7 lineage described in details below and in B.1.1.207 lineage in Nigeria,
69
 but per se does not seem to lead to increased virus transmission.",PMC8250244
B.1.346,"36
 In summary, it occurs in lineages B.1.375
75
, 
76
 and B.1.346 reported from USA,
75
 and in lineages B.1.1.7 (described below), B.1.1.298 (described below), B.1.177 (EU1), B.1.160 (EU2) and B.1.258∆
77
 reported from Europe.",PMC8250244
B.1.160,"36
 In summary, it occurs in lineages B.1.375
75
, 
76
 and B.1.346 reported from USA,
75
 and in lineages B.1.1.7 (described below), B.1.1.298 (described below), B.1.177 (EU1), B.1.160 (EU2) and B.1.258∆
77
 reported from Europe.",PMC8250244
B.1.177,"36
 In summary, it occurs in lineages B.1.375
75
, 
76
 and B.1.346 reported from USA,
75
 and in lineages B.1.1.7 (described below), B.1.1.298 (described below), B.1.177 (EU1), B.1.160 (EU2) and B.1.258∆
77
 reported from Europe.",PMC8250244
B.1.1.298,"36
 In summary, it occurs in lineages B.1.375
75
, 
76
 and B.1.346 reported from USA,
75
 and in lineages B.1.1.7 (described below), B.1.1.298 (described below), B.1.177 (EU1), B.1.160 (EU2) and B.1.258∆
77
 reported from Europe.",PMC8250244
A.23.1,It is found in the A.23.1 lineage from Uganda together with F157L and Q613H.,PMC8250244
B.1.429,"78
 L452R is the is the only Spike mutation found in CAL.20A [99] (B.1.232, which also infected gorillas in San Diego zoo) and the most concerning and recently acquired mutation in the CAL.20C (B.1.429) strain which caused a peak in cases in Southern California since November 2020.",PMC8250244
B.1.232,"78
 L452R is the is the only Spike mutation found in CAL.20A [99] (B.1.232, which also infected gorillas in San Diego zoo) and the most concerning and recently acquired mutation in the CAL.20C (B.1.429) strain which caused a peak in cases in Southern California since November 2020.",PMC8250244
A.21,"99
 L452R is also found in A.21, A.2.4, B.1.1.10, B.1.1.130 and C.16, while a single B.1.74 strain harbors the L452Q mutation..


Y453F increases affinity to ACE2 (from −12.39 to −10.27 kcal/mol) and partially escapes detection by monoclonal nAbs CC12.1, CC12.3, COVA2‐04, CV07‐250,
100
, 
101
 etesevimab (also known as LyCoV016, CB6 or JS016)
102
 and casirivimab (REGN10933)
102
, 
103
 but not COVA2‐39 or CV07‐270.",PMC8250244
B.1.1.10,"99
 L452R is also found in A.21, A.2.4, B.1.1.10, B.1.1.130 and C.16, while a single B.1.74 strain harbors the L452Q mutation..


Y453F increases affinity to ACE2 (from −12.39 to −10.27 kcal/mol) and partially escapes detection by monoclonal nAbs CC12.1, CC12.3, COVA2‐04, CV07‐250,
100
, 
101
 etesevimab (also known as LyCoV016, CB6 or JS016)
102
 and casirivimab (REGN10933)
102
, 
103
 but not COVA2‐39 or CV07‐270.",PMC8250244
B.1.1.130,"99
 L452R is also found in A.21, A.2.4, B.1.1.10, B.1.1.130 and C.16, while a single B.1.74 strain harbors the L452Q mutation..


Y453F increases affinity to ACE2 (from −12.39 to −10.27 kcal/mol) and partially escapes detection by monoclonal nAbs CC12.1, CC12.3, COVA2‐04, CV07‐250,
100
, 
101
 etesevimab (also known as LyCoV016, CB6 or JS016)
102
 and casirivimab (REGN10933)
102
, 
103
 but not COVA2‐39 or CV07‐270.",PMC8250244
A.2.4,"99
 L452R is also found in A.21, A.2.4, B.1.1.10, B.1.1.130 and C.16, while a single B.1.74 strain harbors the L452Q mutation..


Y453F increases affinity to ACE2 (from −12.39 to −10.27 kcal/mol) and partially escapes detection by monoclonal nAbs CC12.1, CC12.3, COVA2‐04, CV07‐250,
100
, 
101
 etesevimab (also known as LyCoV016, CB6 or JS016)
102
 and casirivimab (REGN10933)
102
, 
103
 but not COVA2‐39 or CV07‐270.",PMC8250244
C.16,"99
 L452R is also found in A.21, A.2.4, B.1.1.10, B.1.1.130 and C.16, while a single B.1.74 strain harbors the L452Q mutation..


Y453F increases affinity to ACE2 (from −12.39 to −10.27 kcal/mol) and partially escapes detection by monoclonal nAbs CC12.1, CC12.3, COVA2‐04, CV07‐250,
100
, 
101
 etesevimab (also known as LyCoV016, CB6 or JS016)
102
 and casirivimab (REGN10933)
102
, 
103
 but not COVA2‐39 or CV07‐270.",PMC8250244
B.1.74,"99
 L452R is also found in A.21, A.2.4, B.1.1.10, B.1.1.130 and C.16, while a single B.1.74 strain harbors the L452Q mutation..


Y453F increases affinity to ACE2 (from −12.39 to −10.27 kcal/mol) and partially escapes detection by monoclonal nAbs CC12.1, CC12.3, COVA2‐04, CV07‐250,
100
, 
101
 etesevimab (also known as LyCoV016, CB6 or JS016)
102
 and casirivimab (REGN10933)
102
, 
103
 but not COVA2‐39 or CV07‐270.",PMC8250244
B.1.526,"V2 lineage from South Africa together with N501Y and K417N, in the B.1.1.33 (E484K), in several B.1.1.7 subclades (termed B.1.525), in the B.1.1.28‐derived lineages from Brazil and in the B.1.526 lineage from New York
106
 (discussed below and summarised in Table 4).",PMC8250244
B.1.525,"V2 lineage from South Africa together with N501Y and K417N, in the B.1.1.33 (E484K), in several B.1.1.7 subclades (termed B.1.525), in the B.1.1.28‐derived lineages from Brazil and in the B.1.526 lineage from New York
106
 (discussed below and summarised in Table 4).",PMC8250244
B.1.1.28,The original B.1.1.28 lineage emerged in Brazil in February 2020.,PMC8250244
B.1.1.248,"P.1 (also improperly termed B.1.1.28.1 or B.1.1.248 or VOC 202101/02 or known in NextStrain as 20J/501Y.V3) was first reported in January 2021 in four Japanese travellers returning from Manaus, the capital of Amazonas state in northern Brazil.",PMC8250244
B.1.91,"172
 Simultaneous infection by B.1.1.248 (either as major or minor haplotype) and B.1.1.33 or B.1.91, respectively, has been reported.",PMC8250244
B.1.375,"Detecting the ΔHV69/70 deletion alone is not definitive for the B.1.1.7 variant, as this deletion has arisen independently in at least five more lineages (B.1.1.298, B.1.160, B.1.177, B.1.258 and B.1.375), but tracking the frequencies of SGTFs helped the UK to track the B.1.1.7 variant.",PMC8250244
B.1.258,"Detecting the ΔHV69/70 deletion alone is not definitive for the B.1.1.7 variant, as this deletion has arisen independently in at least five more lineages (B.1.1.298, B.1.160, B.1.177, B.1.258 and B.1.375), but tracking the frequencies of SGTFs helped the UK to track the B.1.1.7 variant.",PMC8250244
B.1.427,"Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged around May 2020 and increased from 0% to >50% of sequenced cases from September 1, 2020 to January 29, 2021, exhibiting an 18.6-24% increase in transmissibility relative to wild-type circulating strains.",PPR294221
B.1.351,"Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in the B.1.1.7, B.1.351, and P.1 variants.",PPR294221
P.1,"Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in the B.1.1.7, B.1.351, and P.1 variants.",PPR294221
B.1.1.7,"Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in the B.1.1.7, B.1.351, and P.1 variants.",PPR294221
B.1.429,"A novel variant, subsequently named 20C/L452R according to the NextStrain nomenclature system (Bedford et al., 2021) or B.1.427/B.1.429 according to the Pango system (Rambaut et al., 2020a) (henceforth referred to using the Pango designation to distinguish between the B.1.427 and B.1.429 lineages), was identified in 21.1% (459 of 2,172) of the genomes (Supplementary Table 1).",PPR294221
B.1.426,"Molecular clock analysis of SARS-CoV-2 for estimating the TMRCA (time to most recent common ancestor) and divergence dates for the B.1.426/B.1.427 variant was performed using the Markov chain Monte Carlo (MCMC) method implemented by Bayesian Evolutionary Analysis on Sampling Trees (BEAST) software v.2.63 (Drummond et al., 2012).",PPR294221
B.1.351,"examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California).",PMC7919536
B.1.1.7,"examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California).",PMC7919536
P.1,"examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California).",PMC7919536
B.1.429,"examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California).",PMC7919536
B.1.298,"For example, a substitution in nonstructural protein 12 or NSP12 (P323L), a component of the viral RdRp, is observed in all four human variants as well as the Danish mink strain, B.1.298, that has been linked to various human infections.",PMC7919536
B.1.1.298,"Lineages B.1.351, B.1.1.7, and B.1.1.298 reflect sequences deposited on or before 06 January 2021.",PMC7919536
B.1.351,"Here we performed a comprehensive analysis of SARS-CoV-2-specific CD4+ and CD8+ T cell responses from COVID-19 convalescent subjects recognizing the ancestral strain, compared to variant lineages B.1.1.7, B.1.351, P.1, and CAL.20C as well as recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines.",PPR290585
P.1,"Here we performed a comprehensive analysis of SARS-CoV-2-specific CD4+ and CD8+ T cell responses from COVID-19 convalescent subjects recognizing the ancestral strain, compared to variant lineages B.1.1.7, B.1.351, P.1, and CAL.20C as well as recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines.",PPR290585
B.1.1.7,"Here we performed a comprehensive analysis of SARS-CoV-2-specific CD4+ and CD8+ T cell responses from COVID-19 convalescent subjects recognizing the ancestral strain, compared to variant lineages B.1.1.7, B.1.351, P.1, and CAL.20C as well as recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines.",PPR290585
B.1.427,"Variants of concern include the UK (United Kingdom) variant 501Y.V1 lineage B.1.1.7 (Davies et al., 2020), the SA (South Africa) variant 501Y.V2 lineage B.1.351 (Tegally et al., 2020), the BR (Brazilian) variant 501Y.V3 lineage P.1 (Voloch et al., 2020) and the CA (California) variant CAL.20C lineage B.1.427 (Zhang et al., 2021).",PPR290585
B.1.1,"Earlier studies reported nine different lineages of SARS-CoV-2; A, B, B.1, B.1.1, B.1.1.1, B.1.36, B.2, B.3 and B.6 were circulating from the second wave of infections [7], started from February 27, 2020 [2].",PMC7914017
B.3,"Earlier studies reported nine different lineages of SARS-CoV-2; A, B, B.1, B.1.1, B.1.1.1, B.1.36, B.2, B.3 and B.6 were circulating from the second wave of infections [7], started from February 27, 2020 [2].",PMC7914017
B.1.1.1,"Earlier studies reported nine different lineages of SARS-CoV-2; A, B, B.1, B.1.1, B.1.1.1, B.1.36, B.2, B.3 and B.6 were circulating from the second wave of infections [7], started from February 27, 2020 [2].",PMC7914017
B.6,"Earlier studies reported nine different lineages of SARS-CoV-2; A, B, B.1, B.1.1, B.1.1.1, B.1.36, B.2, B.3 and B.6 were circulating from the second wave of infections [7], started from February 27, 2020 [2].",PMC7914017
B.1.36,"Earlier studies reported nine different lineages of SARS-CoV-2; A, B, B.1, B.1.1, B.1.1.1, B.1.36, B.2, B.3 and B.6 were circulating from the second wave of infections [7], started from February 27, 2020 [2].",PMC7914017
B.1,"Earlier studies reported nine different lineages of SARS-CoV-2; A, B, B.1, B.1.1, B.1.1.1, B.1.36, B.2, B.3 and B.6 were circulating from the second wave of infections [7], started from February 27, 2020 [2].",PMC7914017
B.1.5,"As of the analysis presented here is based on January 7, 2021, there were 24 lineages of SARS-CoV-2 circulating in Malaysia, with the major lineage reported here was B.1.5 (Table 1
, highlighted in bold).",PMC7914017
B.1.160,"Many sequences originating from China and many global exports; including to South East Asia Japan South Korea Australia the USA and Europe represented in this lineageB18UK 40.0%, USA 15.0%, China 13.0%, Spain 3.0%, Singapore 3.0%Base of this lineage also lies in China, with many global exports, two distinct SNPs ‘8782TC‘ and ‘28144CT‘ define this lineageB.19USA 48.0%, UK 20.0%, Denmark 4.0%, France 3.0%, Australia 3.0%A large European lineage that corresponds to the Italian outbreak.B.1.116UK 49.0%, USA 11.0%, Russia 4.0%, Portugal 3.0%, Denmark 3.0%European lineage with 3 clear SNPs ‘28881GA‘, ‘28882GA‘, ‘28883GC‘B.1.1.12UK 84.0%, Belgium 2.0%, Denmark 2.0%, Switzerland 2.0%, Peru 1.0%UK/ Europe lineageB.1.1.2821USA 96.0%, Mexico 2.0%, UK 2.0%USA lineageB.1.1.3121USA 100.0%Gambian lineageB.1.1.632Hong_Kong 69.0%, Australia 15.0%, Singapore 3.0%, South_Korea 3.0%, UK 2.0%Hong Kong lineageB.1.160.32Indonesia 61.0%, Singapore 17.0%, Malaysia 9.0%, Hong_Kong 4.0%, Taiwan 4.0%Indonesian lineageB.1.2461Saudi_Arabia 55.0%, India 15.0%, UK 10.0%, Nigeria 6.0%, Australia 4.0%Saudi Arabian lineage, previously some assigned B.1.160B.1.2472Denmark 24.0%, India 22.0%, UK 20.0%, Saudi_Arabia 13.0%, Australia 4.0%Indian/ Saudi Arabian diversity, now European and Australian diversity too, previously some assigned B.1.160 and B.1.36B.1.2551USA 70.0%, UK 5.0%, Canada 4.0%, Australia 3.0%, Colombia 2.0%North American lineage, with other global diversityB.1.362UK 46.0%, India 25.0%, Denmark 9.0%, Australia 3.0%, Saudi_Arabia 3.0%Global lineage with lots of representation of sequences from India and Saudi Arabia.",PMC7914017
B.1.5.33,"Now includes some sequences that previously had been assigned B.1.113.B.1.36.166UK 40.0%, Thailand 30.0%, Bangladesh 13.0%, Singapore 7.0%, Malaysia 5.0%Bangladesh/UK lineageB.1.597UK 25.0%, USA 20.0%, Spain 12.0%, Switzerland 7.0%, France 3.0%Spanish base, European lineage/ lots of Spanish sequences towards the basal end of the subtree and exports worldwide.B.1.781Netherlands 93.0%, UK 4.0%, USA 1.0%, Malaysia 1.0%Netherlands lineageB.1.981UK 74.0%, USA 16.0%, Australia 4.0%, Canada 1.0%, Chile 1.0%Some reassigned to B.1.5.33, UK lineageLineageNumber of complete and high coverage hCoV-19/Malaysia genomeMost common countriesDescriptionB.121Japan 97.0%, Malaysia 3.0%Japanese lineageB.281UK 78.0%, Australia 6.0%, USA 5.0%, Jordan 2.0%, Canada 1.0%UK lineageB.31UK 61.0%, Germany 9.0%, Belgium 4.0%, Australia 4.0%, Denmark 4.0%A European lineageB.645India 56.0%, Australia 8.0%, Malaysia 6.0%, Singapore 5.0%, USA 5.0%Indian lineageB.6.118Malaysia 91.0%, India 5.0%, Brunei 5.0%Malaysian lineageB.6.212Malaysia 100.0%Malaysian lineageB.6.67Singapore 92.0%, India 7.0%, Malaysia 1.0%, Australia 1.0%Singapore lineageNotes: The analysis presented here was based on January 7, 2021.",PMC7914017
B.1.247,"Our phylogenetic analysis of Spike protein of G614 variant shows Pahang/IIUM91 (a red box) sampled on April 2, 2020, from lineage B.1.247 was closely related to Selangor /IMR_WC55122 sampled on May 10, 2020, from lineage B.1.1.1 (Fig.",PMC7914017
B.1.1.63,"While the G614 variant from Sivagangga cluster occurred in Kedah was reported to emerge in Malaysia in July 2020 [28], [30], the data deposited in the GISAID suggest that the possible virus responsible for spreading from this cluster could be either; IMR-WI109, sampled on July 25, 2020 (a yellow box) from lineage B.1.1.63 or IMR-WI085, sampled on July 27, 2020 (a yellow box) from lineage B.1.1.",PMC7914017
B.5,"In conclusion, increases trend of positive COVID-19 in Malaysia may be contributed by major SARS-CoV-2 lineage B.5 which harbour D614G mutation in Spike protein.",PMC7914017
P.1,The sequence was identical to the P.1 lineage (also known as 20J/501Y.V3) reported in Brazil.,PPR289356
B.1.351,"Afterward, new emerging lineages with spike protein mutations were discovered in United Kingdom (B.1.1.7 lineage, 20I/501Y.V1, also named VOC 202012/01) [8], South Africa (B.1.351 lineage, 20H/501Y.V2) [9] and Brazil (P.1 lineage, 20J/501Y.V3) [10, 11].",PPR289356
B.1.1.7,"Afterward, new emerging lineages with spike protein mutations were discovered in United Kingdom (B.1.1.7 lineage, 20I/501Y.V1, also named VOC 202012/01) [8], South Africa (B.1.351 lineage, 20H/501Y.V2) [9] and Brazil (P.1 lineage, 20J/501Y.V3) [10, 11].",PPR289356
B.1,"The initial SARS-CoV-2 epidemic in South Africa primarily involved the B.1 lineage identified in Italy (Giandhari et al., 2021).",PMC7901273
B.1.106,"The predominant variants in South Africa appear to be changing rapidly: in April, the first region-specific lineage, B.1.106, was detected in nosocomial infections in South Africa.",PMC7901273
B.1.1.54,"The first epidemic peak of SARS-CoV-2 in South Africa occurred from June to September, primarily driven by three lineages: B.1.1.54, B.1.1.56, and C.1 (Tegally et al., 2020b).",PMC7901273
B.1.1.56,"The first epidemic peak of SARS-CoV-2 in South Africa occurred from June to September, primarily driven by three lineages: B.1.1.54, B.1.1.56, and C.1 (Tegally et al., 2020b).",PMC7901273
C.1,"The first epidemic peak of SARS-CoV-2 in South Africa occurred from June to September, primarily driven by three lineages: B.1.1.54, B.1.1.56, and C.1 (Tegally et al., 2020b).",PMC7901273
B.1.351,"In this outbreak, a new 501Y.V2 lineage (also known as B.1.351) was identified; variants of this lineage are genetically distinct from those of the first wave.",PMC7901273
B.1.351,"Among these mutations are amino acid changes N501Y (lineage B.1.1.7, first identified in the UK), and the combination N501Y, E484K, K417N (B.1.351, first identified in South Africa), all located at the interface on the receptor binding domain (RBD).",PPR287242
B.1.1.7,"Among these mutations are amino acid changes N501Y (lineage B.1.1.7, first identified in the UK), and the combination N501Y, E484K, K417N (B.1.351, first identified in South Africa), all located at the interface on the receptor binding domain (RBD).",PPR287242
P.2,"In December 2020, new variants of concern have been identified in the UK (B.1.1.7; [4]), South Africa (B.1.351; [5]) and Brazil (P.1 and P.2, both descendants from B.1.1.28; [6, 7]).",PPR287242
P.1,"In December 2020, new variants of concern have been identified in the UK (B.1.1.7; [4]), South Africa (B.1.351; [5]) and Brazil (P.1 and P.2, both descendants from B.1.1.28; [6, 7]).",PPR287242
B.1.1.7,"Finally, the end of the year data revealed the presence of known variants of concern including B.1.1.7, which has acquired additional Spike mutations.",PPR286396
B.1.375,"The rest carry the H69/V70 deletion together with a handful of other mutations, matching the B.1.375 lineage (Fig 4B).",PPR286396
A.2,"One isolate (the oldest studied one, collected on March 16, 2020) belonged to lineage A.2 (bearing a D in position 614 in the spike).",PMC7895374
B.1.5,"The other 6 isolates belonged to lineage B: two B.1, two B1.1, one B.1.117 and one B.1.5, all with the mutation D614G (Figs 2 and 3).",PMC7895374
B.1.117,"The other 6 isolates belonged to lineage B: two B.1, two B1.1, one B.1.117 and one B.1.5, all with the mutation D614G (Figs 2 and 3).",PMC7895374
B.1,"The other 6 isolates belonged to lineage B: two B.1, two B1.1, one B.1.117 and one B.1.5, all with the mutation D614G (Figs 2 and 3).",PMC7895374
B.1.351,SARS-CoV-2 B.1.1.7 and B.1.351 variants emerged respectively in United Kingdom and South Africa and spread in many countries.,PPR282216
B.1.1.7,SARS-CoV-2 B.1.1.7 and B.1.351 variants emerged respectively in United Kingdom and South Africa and spread in many countries.,PPR282216
P.2,"The B.1.1.7 variant emerged in the UK, the B.1.351 variant (also termed 501Y.V2) in South Africa and the P.1 and P.2 lineages in Brazil
2,3,5,9-12
.",PPR282216
P.1,"The B.1.1.7 variant emerged in the UK, the B.1.351 variant (also termed 501Y.V2) in South Africa and the P.1 and P.2 lineages in Brazil
2,3,5,9-12
.",PPR282216
B.1.117,Their nasal swabs similarly neutralized the D614G and B.1.117 strains and were inactive against B.1.351.,PPR282216
B.1.1.351,The B.1.1.351 strain (CNR 202100078) originated from a patient in Creteil (France).,PPR282216
A.23,Here we show a recent shift in the local epidemic with a newly emerging lineage A.23 evolving into A.23.1 which is now dominating the Uganda cases and has spread to 26 other countries.,PPR282435
A.23.1,Here we show a recent shift in the local epidemic with a newly emerging lineage A.23 evolving into A.23.1 which is now dominating the Uganda cases and has spread to 26 other countries.,PPR282435
B.1.351,"These VOC include lineage B.1.1.7 first identified in the UK (5), B.1.351 in South Africa (6) and lineage P.1 (B.1.1.28.1) in Brazil (7)..

SARS-CoV-2 infection was first detected in Uganda in March 2020, initially among international travellers until passenger flights were stopped in late March 2020.",PPR282435
P.1,"These VOC include lineage B.1.1.7 first identified in the UK (5), B.1.351 in South Africa (6) and lineage P.1 (B.1.1.28.1) in Brazil (7)..

SARS-CoV-2 infection was first detected in Uganda in March 2020, initially among international travellers until passenger flights were stopped in late March 2020.",PPR282435
B.1.1.7,"These VOC include lineage B.1.1.7 first identified in the UK (5), B.1.351 in South Africa (6) and lineage P.1 (B.1.1.28.1) in Brazil (7)..

SARS-CoV-2 infection was first detected in Uganda in March 2020, initially among international travellers until passenger flights were stopped in late March 2020.",PPR282435
B.1,"In the period of June to August 2020 lineage B.1 and B.1.393 strains were abundant, similar to patterns observed in Kenya (10) (Figure 1, panel b) although lineage A viruses did not decline as seen in US and Europe.",PPR282435
B.1.393,"In the period of June to August 2020 lineage B.1 and B.1.393 strains were abundant, similar to patterns observed in Kenya (10) (Figure 1, panel b) although lineage A viruses did not decline as seen in US and Europe.",PPR282435
B.1.3,"Analysis of the resulting 104 SARS-CoV-2 genome sequences revealed that B.1 and B.1.3 lineages were the most prevalent during the early months of the pandemic in the Bronx; however, several other lineages were also present at low frequencies (Fig.",PPR280560
B.1,"Analysis of the resulting 104 SARS-CoV-2 genome sequences revealed that B.1 and B.1.3 lineages were the most prevalent during the early months of the pandemic in the Bronx; however, several other lineages were also present at low frequencies (Fig.",PPR280560
B.1.1,"Although B.1.3 plateaued after the first wave, B.1 continued to be sampled, and a new lineage, B.1.1, arose in late August.",PPR280560
B.1.1.7,"We did not observe the B.1.1.7 variant strain, first identified in the United Kingdom in the fall of 2020 which also contains the N501Y variant and similarly the P681H, in our samples.",PPR280560
B.1,"All five lineages originated from lineage B.1 (containing D614G in the spike [S] protein), which has been predominant in Europe, Australia, and multiple states of United States (eFigure 2-3)..

Molecular characterization identified mutations across multiple regions of the viral genome (Figure 2B).",PPR278777
B.1.1,"Interestingly, the two samples were from two distinct SARS-CoV-2 lineages; the first sample belonged to PANGOLIN A.3 lineage, whereas the second belonged to PANGOLIN B.1.1 lineage, suggesting that the patient was reinfected by a different virus within a two-week period.",PPR278777
A.3,"Interestingly, the two samples were from two distinct SARS-CoV-2 lineages; the first sample belonged to PANGOLIN A.3 lineage, whereas the second belonged to PANGOLIN B.1.1 lineage, suggesting that the patient was reinfected by a different virus within a two-week period.",PPR278777
B.1.1.7,"The N501Y strain (B.1.1.7 lineage) was detected first in the United Kingdom
10
 and then appeared in other countries
9
 including the United States
11
.",PPR278777
B.1,"Bat CoV RaTG13, Bat CoVs ZC45, BtKY72 and BGR2008 have also been tested and did not bind hACE2..

N439K is a prevalent RBM mutation (the second most common mutation in the RBD through the end of 2020) which was first sampled in March 2020 in Scotland from lineage B.1 (Rambaut et al., 2020) on the background of D614G.",PMC7843029
B.1.258,"N439K lineages i and ii have recently received the lineage designations B.1.141 and B.1.258, respectively (Rambaut et al., 2020).",PMC7843029
B.1.141,"N439K lineages i and ii have recently received the lineage designations B.1.141 and B.1.258, respectively (Rambaut et al., 2020).",PMC7843029
B.1.1.7,"Globally, G, GH, and GR are constantly increasing, while S, L, and V strains are gradually disappearing [22,23]..

More recently, a distinct phylogenetic cluster derived from the SARS-CoV-2 GR clade, named lineage B.1.1.7, has spread rapidly starting from early December 2020 in UK locations.",PMC7865767
P.1,"Five main variants of concern (VOCs) have emerged since the beginning of the pandemic and have attracted the most widespread attention: alpha (B.1.1.7) in the United Kingdom, beta (B.1.351) in South Africa, gamma (P.1) in Brazil, delta (B.1.617.2) in India, and omicron (B.1.1.529) in Botswana and South Africa (22–27).",PMC8841511
B.1.617.2,"Five main variants of concern (VOCs) have emerged since the beginning of the pandemic and have attracted the most widespread attention: alpha (B.1.1.7) in the United Kingdom, beta (B.1.351) in South Africa, gamma (P.1) in Brazil, delta (B.1.617.2) in India, and omicron (B.1.1.529) in Botswana and South Africa (22–27).",PMC8841511
B.1.1.529,"Five main variants of concern (VOCs) have emerged since the beginning of the pandemic and have attracted the most widespread attention: alpha (B.1.1.7) in the United Kingdom, beta (B.1.351) in South Africa, gamma (P.1) in Brazil, delta (B.1.617.2) in India, and omicron (B.1.1.529) in Botswana and South Africa (22–27).",PMC8841511
B.1.351,"Five main variants of concern (VOCs) have emerged since the beginning of the pandemic and have attracted the most widespread attention: alpha (B.1.1.7) in the United Kingdom, beta (B.1.351) in South Africa, gamma (P.1) in Brazil, delta (B.1.617.2) in India, and omicron (B.1.1.529) in Botswana and South Africa (22–27).",PMC8841511
B.1.1.7,"Five main variants of concern (VOCs) have emerged since the beginning of the pandemic and have attracted the most widespread attention: alpha (B.1.1.7) in the United Kingdom, beta (B.1.351) in South Africa, gamma (P.1) in Brazil, delta (B.1.617.2) in India, and omicron (B.1.1.529) in Botswana and South Africa (22–27).",PMC8841511
B.1,"As well as the ancestor B.1 strain, the alpha variant could produce a high viral load, leading to a low Ct value in RT-qPCR-based diagnosis (47) while being ~50% more transmissible (33, 38, 39, 98).",PMC8841511
P.1,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
B.1.617.2,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
B.1.1.529,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
B.1.351,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
B.1.1.7,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
A.1,"The first samples sequenced in March and April 2020 were similar to strains at the root of the pandemic (lineage A and sublineages) and are classified as A.1, A.3 etc., collectively designated as Pango lineage “other” in Figures 1A,C.",PMC8829001
A.3,"The first samples sequenced in March and April 2020 were similar to strains at the root of the pandemic (lineage A and sublineages) and are classified as A.1, A.3 etc., collectively designated as Pango lineage “other” in Figures 1A,C.",PMC8829001
B.1,The large European lineage B.1 was detected in six samples in April 2020.,PMC8829001
B.1.526,"The former VOC, B.1.526 (Iota), which is a lineage predominantly circulating in New York, was detected from March to June 2021 in 29 samples.",PMC8829001
B.1.617.3,"noCountry of origin(a)LineageWHO labelNext strain cladeMutations/substitutions in spike proteinSeverity (compared to parental strain)RBMS1S21UK-Sept-2020B.1.1.7Alpha201/501Y.V1S494P*E484K*N501YΔ69Δ70Δ144A570DD614GP681HT716IS982AD1118H K1191N*No change2South Africa-May-2020B.1.351Beta20H/501Y.V2E484KN501YΔ241Δ242 Δ 243 D80A,D215GK417ND614GA701V1.5 times higher3Brazil-Nov-2020P.1Gamma20J/501Y.V3E484KN501YL18F T20N P26SD138YR190S K417TD614G H655YT1027I2.6 times higher4India Oct-2020B.1.617.2,B.1.617.3,B.1.617.1Delta+Kappa21A/G/478K.V1E484QL452RT478KT19R G142D R158G Δ156Δ157V382LD614G P681RD950NN/A5USA-Mar-2020B1.427/B.1.429Epsilon21C/GH/452R.V1L452R S13I W152CD614G14–18% higher6Brazil-Apr-2020P.2Zeta20B/S484K/GR/484K.V2E484K D614GF565L* V1176FN/A7Nigeria-Dec-2020B.1.525Eta21D/G/484K.V3E484KA67VΔ69Δ70Δ144D614GQ677HF888LN/A8USA-Nov-2020B.1.526Lota21F/GH/53G.V1S477N*E484K*L452RL5F* D80G T95IF157SD253GΔ144D614GA701V*T791I*T859N* D950HElevated9Philippines-Jan-2021P.3Theta21E/GR/1092K.V1E484KN501YD614GP681HE1092KH1101YV1176FN/A10Peru-Aug-2020C.37Lambda20D/GR/452Q.V1L452QF490SG75VT76I, Δ 246-252 D614GT859NN/A11Uganda-Oct-2020A.23.1––F157LR102I*V367F Q613HP681RN/A12Columbia-Jan-2021B.1.621E484KN501YN/A13France-Jan-2021B.1.616–20CV483AH66DD215G H655YG669SQ949RN1187DN/A14FranceHMN.19B Henn Mondor19BL452RN501YN/AThe table provides a detailed description of country of origin, lineage and clade.",PMC8633907
B.1.1.7,"The major mutations in the spike protein of B.1.1.7 were deletions 69–70, 144 in N terminal domain (NTD) and substitutions N501Y, A570D, D614G, P681H, T716I, S982A, D1118H in RBD and S1/S2 region of S protein (table 2, figure 1).",PMC8633907
B.1.617.2,"B.1.617.1 possesses E484Q mutation, while B.1.617.2 lacks E484Q but contains D157,158 and T478K not present in the other two variants.",PMC8633907
B.1.113,"Pangolin lineages B.1.1.8 and B.1.113 identified within GR and GH clades, respectively, were noted to be indigenous evolutions.",PMC8184080
B.1.1.8,"Pangolin lineages B.1.1.8 and B.1.113 identified within GR and GH clades, respectively, were noted to be indigenous evolutions.",PMC8184080
B.1.1,"As per the Pangolin nomenclature, majority of the Indian sequences belonged to sub-lineages B.1.1.32, B.6, B.1, B.1.1, B.1.113 and B.1.1.8 (Fig.",PMC8184080
B.6,"As per the Pangolin nomenclature, majority of the Indian sequences belonged to sub-lineages B.1.1.32, B.6, B.1, B.1.1, B.1.113 and B.1.1.8 (Fig.",PMC8184080
B.1,"As per the Pangolin nomenclature, majority of the Indian sequences belonged to sub-lineages B.1.1.32, B.6, B.1, B.1.1, B.1.113 and B.1.1.8 (Fig.",PMC8184080
B.1.1.32,"As per the Pangolin nomenclature, majority of the Indian sequences belonged to sub-lineages B.1.1.32, B.6, B.1, B.1.1, B.1.113 and B.1.1.8 (Fig.",PMC8184080
A.9,"As per the Pangolin lineage summaries (https://cov-lineages.org/lineages.html), some of the lineages most likely to have evolved in India are B.1.113 (n=372), B.1.1.8 (n=193), A.7 (n=23) and A.9 (n=6).",PMC8184080
A.7,"As per the Pangolin lineage summaries (https://cov-lineages.org/lineages.html), some of the lineages most likely to have evolved in India are B.1.113 (n=372), B.1.1.8 (n=193), A.7 (n=23) and A.9 (n=6).",PMC8184080
B.1.36,"2 (available from https://www.ijmr.org.in/articles/2021/153/1/images/IndianJMedRes_2021_153_1_166_311942_sm14.pdf)) of the most likely transmission events (https://nextstrain.org/ncov/asia?c=clade_membership&f_country=India&f_region=Asia) revealed that the dominant clade B.6 (GISAID O) that emerged from 19A was introduced into India from China, Europe, South-East Asia and Middle-East while B.1 (G) and B.1.36 (GH) that emerged from 20A had their origins from Europe, Middle-East and Africa.",PMC8184080
B.4,"The other sub-group (B.4) involved mainly Karnataka, Maharashtra, Ladakh, Telangana and Gujarat.",PMC8184080
V.2,Variants with minor allele frequency less than 0.005 as per GnomAD v.2 were filtered and those located in genes known to be associated with cataract development as per Cat-Map database were given a priority for further evaluation.,PMC7705438
C.14,"We identified one previously reported (c.2729 C>T), five novel missense (c.3029 A>G, c.1738-1739 del ins TT, c.1163 G>A, c.3058 C>T, c.329 G>A) and two novel nonsense (c.1213 delT fs*, c.14 C>A fs*) mutations.",PMC7705438
V.1,"All variants were reclassified according to ACMG/AMP guidelines (both applying the TP53 rule specifications (v.1) provided by the ClinGen TP53 Expert Panel, and automatically using PathoMan)..",PMC7705438
C.38,"Results: We found 8 mutations in this patient in 2018 when he found the cancer and the mutation sites were APC c.3189 delT (50.81%), TP53 c.339 delC (55.46%), KRAS c.38 G>A (39.38%), EYS c.157 T>G (0.38%), KIT c.147 C>T (0.31%), PHACTR1 c.760 C>G (0.20%), CSMD3 c.837 T>G (0.08%) and SLITRK4 c.329 A>C (0.05%).",PMC7705438
A.1,"The SARS-CoV-2 lineage was determined using Pangolin software (https://pangolin.cog-uk.io/), which placed the individual’s viral genomes in lineage A.1, which consists of genomes originating from the primary outbreak in Washington state (Rambaut et al., 2020).",PMC7640888
V.1,"The virus neutralization titer is displayed as the reciprocal value of the highest dilution of serum/plasma that still inhibited virus replication at which no cytopathic effect was observed..

Clinical Samples - Viral RNA was extracted from patient nasopharyngeal swabs using Trizol (Invitrogen) for use with the ARTIC nCoV-2019 sequencing protocol V.1 (Protocols.io; https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w).",PMC7640888
B.1,"Strains sequenced in this study could be assigned to the two major clades that occurred so far during this pandemic, namely A and B.1, according to the Pangolin lineage.",PMC7692263
B.1.1,"In contrast, the B.1 lineage is comprised of sequences associated with the large Italian outbreak in February 2020 and represents, to date (current as of date 21 July 2020), together with its sublineage B.1.1, the worldwide prevalent virus clade [19].",PMC7692263
B.1,"Strains sequenced in this study can be assigned to the two major clades that occurred so far during this pandemic, namely A and B.1 according to the Pangolin lineage.",PPR218521
B.1.1,"In contrast, the B.1 lineage comprises sequences associated with the large Italian outbreak in February 2020 and represents to date (date 21.07.2020), together with its sublineage B.1.1, the worldwide prevalent virus clade [19].",PPR218521
